g-cover_10.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 4, 2018

 

GENPACT LIMITED

(Exact Name of Registrant as Specified in Charter)

 

Bermuda

(State or Other Jurisdiction

of Incorporation)

001-33626

(Commission

File Number)

98-0533350

(IRS Employer

Identification No.)

Canon’s Court, 22 Victoria Street

Hamilton HM 12, Bermuda

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (441) 295-2244

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule  405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 

 


 

Item 8.01Other Events.

 

As previously disclosed, in March 2017, Genpact Limited (the “Company”) and its wholly-owned subsidiary, Genpact Luxembourg S.à r.l. (the “Issuer”), entered into an Indenture with Wells Fargo Bank, National Association, as trustee, pursuant to which the Issuer issued $350.0 million aggregate principal amount of its 3.700% Senior Notes due 2022 (the “Original Notes”). The Original Notes were sold in a transaction exempt from registration under the Securities Act of 1933, as amended, and are guaranteed on a senior unsecured basis by the Company.

 

In connection with the anticipated filing of a Registration Statement on Form S-4 relating to an offer to exchange the Original Notes for notes with terms identical to those of the Original Notes (except that such notes will not be subject to restrictions on transfer or the payment of additional interest), the Company is filing this Current Report on Form 8-K to include the condensed consolidating financial information of the Company and the Issuer specified by Rule 3-10 of Regulation S-X in the Company’s consolidated financial statements, and the notes thereto, originally filed on March 1, 2018 as part of the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, and in the Company’s unaudited consolidated financial statements, and the notes thereto, originally filed on May 10, 2018 as part of the Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2018.

 

The consolidated financial statements, and the notes thereto, are set forth in Exhibit 99.1 to this Current Report on Form 8-K and replace and supersede those financial statements referenced in Part II, Item 8, and Part IV, Item 15, of the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

 

The unaudited consolidated financial statements, and the notes thereto, are set forth in Exhibit 99.2 to this Current Report on Form 8-K and replace and supersede those financial statements referenced in Part I, Item 1, of the Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2018.

 

Other than the addition of the condensed consolidating financial information of the Company and the Issuer specified by Rule 3-10 of Regulation S-X, no other changes to the Company’s previously issued financial statements have been made.

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits

The following exhibits are filed with this Current Report on Form 8-K:

 

Exhibit No.

 

Description

23.1

 

Consent of KPMG.

99.1

 

Consolidated Financial Statements and Supplementary Data for the three years ended December 31, 2017.

99.2

 

Unaudited Consolidated Financial Statements and Supplementary Data for the three months ended March 31, 2018.

101.INS

 

XBRL Instance Document.

101.SCH

 

XBRL Taxonomy Extension Schema Document.

101.CAL

 

XBRL Extension Calculation Linkbase Document.

101.DEF

 

XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB

 

XBRL Taxonomy Extension Labels Linkbase Document.

101.PRE

 

XBRL Taxonomy Extension Presentation Linkbase Document.

 


 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

GENPACT LIMITED

 

 

 

Date: June 4, 2018

 

By:

/s/ Heather D. White        

 

 

Name:

Heather D. White

 

 

Title:

Senior Vice President, General Counsel and Secretary

 

 

g-ex231_93.htm

 

 

 

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

The Board of Directors
Genpact Limited:

We consent to the incorporation by reference in the registration statements (No. 333-210729) on Form S-3, (No. 333-217804) on Form S-8, (No. 333-184296) on Form S-8, (No. 333-153113) on Form S-8 and (No. 333-145152) on Form S-8/A of Genpact Limited of our report dated March 1, 2018 (except for Note 31, as to which the date is May 31, 2018), with respect to the consolidated balance sheets of Genpact Limited as of December 31, 2017 and 2016, the related consolidated statements of income, comprehensive income (loss), equity, and cash flows for each of the years in the three-year period ended December 31, 2017, and the related notes (collectively, the “consolidated financial statements”), which report appears in this Current Report on Form 8-K of Genpact Limited dated June 4, 2018.  

 

/s/ KPMG

Gurugram, Haryana, India
June 4, 2018

 

 

 

g-ex991_480.htm

 

Exhibit 99.1

GENPACT LIMITED AND ITS SUBSIDIARIES

Index to Consolidated Financial Statements

 

 

Page No.

Reports of Independent Registered Public Accounting Firm

F-2

Consolidated Balance Sheets as of December 31, 2016 and 2017

F-3

Consolidated Statements of Income for the years ended December 31, 2015, 2016 and 2017

F-4

Consolidated Statements of Comprehensive Income (Loss) for the years ended December 31, 2015, 2016 and 2017

F-5

Consolidated Statements of Equity for the year ended December 31, 2015 and Consolidated Statements of Equity and Redeemable Non-controlling Interest for the years ended December 31, 2016 and 2017

F-6

Consolidated Statements of Cash Flows for the years ended December 31, 2015, 2016 and 2017

F-9

Notes to the Consolidated Financial Statements

F-10

 

 

 


 

Report of Independent Registered Public Accounting Firm

 

To the shareholders and board of directors
Genpact Limited:

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of Genpact Limited and subsidiaries (“Genpact Limited” or the “Company”) as of December 31, 2017 and 2016, the related consolidated statements of income, comprehensive income (loss), equity, and cash flows for each of the years in the three‑year period ended December 31, 2017, and the related notes (collectively, the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of its operations and its cash flows for each of the years in the three‑year period ended December 31, 2017, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the Company’s internal control over financial reporting as of December 31, 2017, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated March 1, 2018 expressed an unqualified opinion on the effectiveness of the Company’s internal control over financial reporting.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

 

/s/ KPMG

We have served as the Company’s auditor since 2004.

Gurugram, Haryana, India
March 1, 2018, except for Note 31 as to which the date is

May 31, 2018

 

 

 

 

F-2


 

GENPACT LIMITED AND ITS SUBSIDIARIES

Consolidated Balance Sheets

(In thousands, except per share data and share count)

 

 

 

Notes

 

 

As of December 31,

2016

 

 

As of December 31,

2017

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

 

4

 

 

$

422,623

 

 

$

504,468

 

Accounts receivable, net

 

 

5

 

 

 

615,265

 

 

 

693,085

 

Prepaid expenses and other current assets

 

 

8

 

 

 

189,149

 

 

 

236,342

 

Total current assets

 

 

 

 

 

$

1,227,037

 

 

$

1,433,895

 

Property, plant and equipment, net

 

 

9

 

 

 

193,218

 

 

 

207,030

 

Deferred tax assets

 

 

25

 

 

 

70,143

 

 

 

76,929

 

Investment in equity affiliates

 

 

 

 

 

 

4,800

 

 

 

886

 

Intangible assets, net

 

 

10

 

 

 

78,946

 

 

 

131,590

 

Goodwill

 

 

10

 

 

 

1,069,408

 

 

 

1,337,122

 

Other assets

 

 

11

 

 

 

242,328

 

 

 

262,169

 

Total assets

 

 

 

 

 

$

2,885,880

 

 

$

3,449,621

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities and equity

 

 

 

 

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

 

 

 

 

Short-term borrowings

 

 

15

 

 

$

160,000

 

 

$

170,000

 

Current portion of long-term debt

 

 

14

 

 

 

39,181

 

 

 

39,226

 

Accounts payable

 

 

 

 

 

 

9,768

 

 

 

15,050

 

Income taxes payable

 

 

25

 

 

 

24,159

 

 

 

30,026

 

Accrued expenses and other current liabilities

 

 

13

 

 

 

498,247

 

 

 

584,482

 

Total current liabilities

 

 

 

 

 

$

731,355

 

 

$

838,784

 

Long-term debt, less current portion

 

 

14

 

 

 

698,152

 

 

 

1,006,687

 

Deferred tax liabilities

 

 

25

 

 

 

2,415

 

 

 

6,747

 

Other liabilities

 

 

16

 

 

 

162,790

 

 

 

168,609

 

Total liabilities

 

 

 

 

 

$

1,594,712

 

 

$

2,020,827

 

Redeemable non-controlling interest

 

 

 

 

 

 

4,520

 

 

 

4,750

 

Shareholders' equity

 

 

 

 

 

 

 

 

 

 

 

 

Preferred shares, $0.01 par value, 250,000,000

   authorized, none issued

 

 

 

 

 

 

 

 

 

 

Common shares, $0.01 par value, 500,000,000 authorized,

   198,794,052 and 192,825,207 issued and outstanding as

   of December 31, 2016 and December 31, 2017, respectively

 

 

 

 

 

 

1,984

 

 

 

1,924

 

Additional paid-in capital

 

 

 

 

 

 

1,384,468

 

 

 

1,421,368

 

Retained earnings

 

 

 

 

 

 

358,121

 

 

 

355,982

 

Accumulated other comprehensive income (loss)

 

 

 

 

 

 

(457,925

)

 

 

(355,230

)

Total equity

 

 

 

 

 

$

1,286,648

 

 

$

1,424,044

 

Commitments and contingencies

 

 

28

 

 

 

 

 

 

 

 

 

Total liabilities, redeemable non-controlling interest

   and equity

 

 

 

 

 

$

2,885,880

 

 

$

3,449,621

 

 

See accompanying notes to the Consolidated Financial Statements.

 

 

F-3


 

GENPACT LIMITED AND ITS SUBSIDIARIES

Consolidated Statements of Income

(In thousands, except per share data and share count)

 

 

 

 

 

 

 

Year ended December 31,

 

 

 

Notes

 

 

2015

 

 

2016

 

 

2017

 

Net revenues

 

 

 

 

 

$

2,461,044

 

 

$

2,570,756

 

 

$

2,736,929

 

Cost of revenue

 

21,27

 

 

 

1,493,547

 

 

 

1,554,707

 

 

 

1,683,704

 

Gross profit

 

 

 

 

 

$

967,497

 

 

$

1,016,049

 

 

$

1,053,225

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative expenses

 

22,27

 

 

 

608,114

 

 

 

653,029

 

 

 

689,847

 

Amortization of acquired intangible assets

 

 

10

 

 

 

28,513

 

 

 

27,183

 

 

 

36,412

 

Other operating (income) expense, net

 

 

23

 

 

 

(3,322

)

 

 

(4,940

)

 

 

(1,661

)

Income from operations

 

 

 

 

 

$

334,192

 

 

$

340,777

 

 

$

328,627

 

Foreign exchange gains (losses), net

 

 

 

 

 

 

5,269

 

 

 

2,630

 

 

 

1,996

 

Interest income (expense), net

 

 

24

 

 

 

(31,267

)

 

 

(16,184

)

 

 

(31,735

)

Other income (expense), net

 

 

 

 

 

 

4,360

 

 

 

10,120

 

 

 

26,238

 

Income before equity-method investment

   activity, net and income tax expense

 

 

 

 

 

$

312,554

 

 

$

337,343

 

 

$

325,126

 

Equity-method investment activity, net

 

 

 

 

 

 

(10,800

)

 

 

(7,698

)

 

 

(4,543

)

Income before income tax expense

 

 

 

 

 

$

301,754

 

 

$

329,645

 

 

$

320,583

 

Income tax expense

 

 

25

 

 

 

61,937

 

 

 

62,098

 

 

 

59,742

 

Net income

 

 

 

 

 

$

239,817

 

 

$

267,547

 

 

$

260,841

 

Net loss attributable to redeemable non-controlling

   interest

 

 

 

 

 

 

 

 

 

2,137

 

 

 

2,270

 

Net income attributable to Genpact Limited

   shareholders

 

 

 

 

 

$

239,817

 

 

$

269,684

 

 

$

263,111

 

Net income available to Genpact Limited common

   shareholders

 

 

20

 

 

$

239,817

 

 

$

269,684

 

 

$

263,111

 

Earnings per common share attributable to Genpact

   Limited common shareholders

 

 

20

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

 

 

 

$

1.11

 

 

$

1.30

 

 

$

1.36

 

Diluted

 

 

 

 

 

$

1.09

 

 

$

1.28

 

 

$

1.34

 

Weighted average number of common shares used in

   computing earnings per common share attributable

   to Genpact Limited common shareholders

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

 

 

 

 

216,606,542

 

 

 

206,861,536

 

 

 

193,864,755

 

Diluted

 

 

 

 

 

 

219,145,044

 

 

 

210,126,023

 

 

 

197,049,552

 

See accompanying notes to the Consolidated Financial Statements.

F-4


 

GENPACT LIMITED AND ITS SUBSIDIARIES

Consolidated Statements of Comprehensive Income (Loss)

(In thousands)

 

 

 

Year ended December 31,

 

 

 

2015

 

 

2016

 

 

2017

 

 

 

Genpact

Limited

Shareholders

 

 

Redeemable

Non-controlling

interest

 

 

Genpact

Limited

Shareholders

 

 

Redeemable

Non-controlling

interest

 

 

Genpact

Limited

Shareholders

 

 

Redeemable

Non-controlling

interest

 

Net income (loss)

 

$

239,817

 

 

$

 

 

$

269,684

 

 

$

(2,137

)

 

$

263,111

 

 

$

(2,270

)

Other comprehensive

   income (loss):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Currency translation

   adjustments

 

 

(64,504

)

 

 

 

 

 

(46,340

)

 

 

104

 

 

 

93,871

 

 

 

(341

)

Net income (loss) on cash

   flow hedging

   derivatives, net of

   taxes (Note 7)

 

 

22,880

 

 

 

 

 

 

43,742

 

 

 

 

 

 

12,611

 

 

 

 

Retirement benefits, net

   of taxes

 

 

2,823

 

 

 

 

 

 

(4,042

)

 

 

 

 

 

(3,787

)

 

 

 

Other comprehensive

   income (loss)

 

$

(38,801

)

 

$

 

 

$

(6,640

)

 

$

104

 

 

$

102,695

 

 

$

(341

)

Comprehensive income

   (loss)

 

$

201,016

 

 

$

 

 

$

263,044

 

 

$

(2,033

)

 

$

365,806

 

 

$

(2,611

)

 

See accompanying notes to the Consolidated Financial Statements.

F-5


 

GENPACT LIMITED AND ITS SUBSIDIARIES

Consolidated Statements of Equity

(In thousands, except share count)

 

 

 

Genpact Limited Shareholders

 

 

 

 

 

 

 

Common shares

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

No. of

Shares

 

 

Amount

 

 

Additional

Paid-in Capital

 

 

Retained

Earnings

 

 

Accumulated Other

Comprehensive

Income (Loss)

 

 

Total

Equity

 

Balance as of January 1, 2015

 

 

218,684,205

 

 

$

2,184

 

 

$

1,296,730

 

 

$

398,706

 

 

$

(412,484

)

 

$

1,285,136

 

Issuance of common shares on

   exercise of options (Note 18)

 

 

1,428,605

 

 

 

14

 

 

 

13,550

 

 

 

 

 

 

 

13,564

 

Issuance of common shares

   under the employee stock

   purchase plan (Note 18)

 

 

121,485

 

 

 

1

 

 

 

2,523

 

 

 

 

 

 

 

 

 

2,524

 

Net settlement on vesting of

   restricted share units

   (Note 18)

 

 

259,776

 

 

 

3

 

 

 

(2,309

)

 

 

 

 

 

 

 

 

(2,306

)

Net settlement on vesting of

   performance units (Note 18)

 

 

846,114

 

 

 

8

 

 

 

(8

)

 

 

 

 

 

 

 

 

-

 

Stock repurchased and retired

   (Note 19)

 

 

(9,867,873

)

 

 

(99

)

 

 

 

 

 

(226,818

)

 

 

 

 

 

(226,917

)

Expenses related to stock

   purchase (Note 19)

 

 

 

 

 

 

 

 

(197

)

 

 

 

 

 

(197

)

Excess tax benefit on stock-

   based compensation

   (Note 25)

 

 

 

 

 

 

 

6,560

 

 

 

 

 

 

 

 

6,560

 

Stock-based compensation

   expense (Note 18)

 

 

 

 

 

 

24,976

 

 

 

 

 

 

 

24,976

 

Comprehensive income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income

 

 

 

 

 

 

 

 

239,817

 

 

 

 

 

239,817

 

Other comprehensive income (loss)

 

 

 

 

 

 

 

 

 

 

(38,801

)

 

 

(38,801

)

Balance as of December 31,

   2015

 

 

211,472,312

 

 

$

2,111

 

 

$

1,342,022

 

 

$

411,508

 

 

$

(451,285

)

 

$

1,304,356

 

See accompanying notes to the Consolidated Financial Statements.

F-6


 

GENPACT LIMITED AND ITS SUBSIDIARIES

Consolidated Statements of Equity and Redeemable Non-controlling Interest

(In thousands, except share count)

 

 

 

Genpact Limited Shareholders

 

 

 

 

 

 

 

 

 

 

Common shares

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

No. of

Shares

 

 

Amount

 

 

Additional

Paid-in Capital

 

 

Retained

Earnings

 

 

Accumulated

Other

Comprehensive

Income (Loss)

 

 

Total

Equity

 

Redeemable non-controlling interest

 

Balance as of January 1,

   2016

 

 

211,472,312

 

 

$

2,111

 

 

$

1,342,022

 

 

$

411,508

 

 

$

(451,285

)

 

$

1,304,356

 

$

 

Issuance of common shares on

   exercise of options (Note 18)

 

 

994,155

 

 

 

10

 

 

 

14,886

 

 

 

 

 

 

 

14,896

 

 

 

Issuance of common shares

   under the employee stock

   purchase plan (Note 18)

 

 

146,685

 

 

 

1

 

 

 

3,331

 

 

 

 

 

 

 

 

 

3,332

 

 

 

Net settlement on vesting of

   restricted share units

   (Note 18)

 

 

121,682

 

 

 

1

 

 

 

(884

)

 

 

 

 

 

 

 

 

(883

)

 

 

Stock repurchased and retired

   (Note 19)

 

 

(13,940,782

)

 

 

(139

)

 

 

 

 

 

(345,061

)

 

 

 

 

 

(345,200

)

 

 

Deferred tax assets recognized

   on early adoption of ASU

   2016-09 (Note 25)

 

 

 

 

 

 

 

 

 

 

 

24,912

 

 

 

 

 

 

24,912

 

 

 

Expenses related to stock

   purchase (Note 19)

 

 

 

 

 

 

 

 

(279

)

 

 

 

 

 

(279

)

 

 

Stock-based compensation

   expense (Note 18)

 

 

 

 

 

 

25,113

 

 

 

 

 

 

 

25,113

 

 

 

Acquisition of redeemable

   non-controlling interest

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3,910

 

Change in fair value of

   redeemable non-controlling

   interest

 

 

 

 

 

 

 

 

 

 

 

(2,643

)

 

 

 

 

 

(2,643

)

 

2,643

 

Comprehensive income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss)

 

 

 

 

 

 

 

 

269,684

 

 

 

 

 

269,684

 

 

(2,137

)

Other comprehensive income (loss)

 

 

 

 

 

 

 

 

 

 

(6,640

)

 

 

(6,640

)

 

104

 

Balance as of

   December 31, 2016

 

 

198,794,052

 

 

$

1,984

 

 

$

1,384,468

 

 

$

358,121

 

 

$

(457,925

)

 

$

1,286,648

 

$

4,520

 

See accompanying notes to the Consolidated Financial Statements.

 

F-7


 

GENPACT LIMITED AND ITS SUBSIDIARIES

Consolidated Statements of Equity and Redeemable Non-controlling Interest

(In thousands, except share count)

 

 

Genpact Limited Shareholders

 

 

 

 

 

 

 

 

 

 

Common shares

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

No. of

Shares

 

 

Amount

 

 

Additional

Paid-in Capital

 

 

Retained

Earnings

 

 

Accumulated

Other

Comprehensive

Income (Loss)

 

 

 

 

 

Total

Equity

 

 

Redeemable

non-controlling

interest

 

Balance as of January 1, 2017

$

198,794,052

 

 

$

1,984

 

 

$

1,384,468

 

 

$

358,121

 

 

$

(457,925

)

 

 

 

 

$

1,286,648

 

 

$

4,520

 

Issuance of common shares on

   exercise of options (Note 18)

 

743,045

 

 

 

7

 

 

 

10,765

 

 

 

 

 

 

 

 

 

 

 

10,772

 

 

 

Issuance of common shares under

   the employee stock purchase

   plan (Note 18)

 

190,435

 

 

 

2

 

 

 

4,754

 

 

 

 

 

 

 

 

 

 

 

 

4,756

 

 

 

 

Net settlement on vesting of

   restricted share units (Note 18)

 

103,220

 

 

 

1

 

 

 

(358

)

 

 

 

 

 

 

 

 

 

 

 

(357

)

 

 

 

Net settlement on vesting of

   performance units (Note 18)

 

731,701

 

 

 

7

 

 

 

(9,946

)

 

 

 

 

 

 

 

 

 

 

 

(9,939

)

 

 

 

Stock repurchased and retired

   (Note 19)

 

(7,737,246

)

 

 

(77

)

 

 

(4,000

)

 

 

(215,707

)

 

 

 

 

 

 

 

 

(219,784

)

 

 

 

Expenses related to stock

   purchase (Note 19)

 

 

 

 

 

 

 

 

 

 

(16

)

 

 

 

 

 

 

 

 

(16

)

 

 

 

Stock-based compensation

   expense (Note 18)

 

 

 

 

 

 

 

35,685

 

 

 

 

 

 

 

 

 

 

 

 

35,685

 

 

 

Change in fair value of

   redeemable non-controlling

   interest

 

 

 

 

 

 

 

 

 

 

(2,841

)

 

 

 

 

 

 

 

 

(2,841

)

 

 

2,841

 

Comprehensive income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income

 

 

 

 

 

 

 

 

 

 

263,111

 

 

 

 

 

 

 

 

 

263,111

 

 

 

(2,270

)

Other comprehensive income

 

 

 

 

 

 

 

 

 

 

 

 

 

102,695

 

 

 

 

 

 

102,695

 

 

 

(341

)

Dividend (Note 19)

 

 

 

 

 

 

 

 

 

 

(46,686

)

 

 

 

 

 

 

 

 

(46,686

)

 

 

 

Balance as of December 31,

   2017

 

192,825,207

 

 

 

1,924

 

 

 

1,421,368

 

 

 

355,982

 

 

 

(355,230

)

 

 

 

 

 

1,424,044

 

 

 

4,750

 

See accompanying notes to the Consolidated Financial Statements.

 

 

F-8


 

GENPACT LIMITED AND ITS SUBSIDIARIES

Consolidated Statements of Cash Flows

(In thousands)

 

 

 

 

Year ended December 31,

 

 

 

 

2015

 

 

2016

 

 

2017

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating activities

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income attributable to Genpact Limited shareholders

 

 

$

239,817

 

 

$

269,684

 

 

$

263,111

 

Net loss attributable to redeemable non-controlling interest

 

 

 

 

 

 

(2,137

)

 

 

(2,270

)

Net income

 

 

$

239,817

 

 

$

267,547

 

 

$

260,841

 

Adjustments to reconcile net income to net cash provided by (used for) operating

    activities:

 

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

 

54,286

 

 

 

54,553

 

 

 

58,503

 

Amortization of debt issuance costs (including loss on extinguishment of debt)

 

 

 

13,546

 

 

 

1,531

 

 

 

1,884

 

Amortization of acquired intangible assets

 

 

 

28,513

 

 

 

27,183

 

 

 

36,412

 

Write-down of intangible assets and property, plant and equipment

 

 

 

10,714

 

 

 

11,195

 

 

 

9,311

 

Reserve for doubtful receivables

 

 

 

2,449

 

 

 

7,282

 

 

 

9,819

 

Unrealized (gain) loss on revaluation of foreign currency asset/liability

 

 

 

(4,999

)

 

 

1,717

 

 

 

(11,830

)

Equity-method investment activity, net

 

 

 

10,800

 

 

 

7,698

 

 

 

4,543

 

Excess tax benefit on stock-based compensation

 

 

 

(6,560

)

 

 

 

 

 

 

Stock-based compensation expense

 

 

 

24,976

 

 

 

25,113

 

 

 

35,685

 

Deferred income taxes

 

 

 

(18,713

)

 

 

30,454

 

 

 

(10,391

)

Loss (gain) on divestiture

 

 

 

 

 

 

(5,214

)

 

 

5,668

 

Others, net

 

 

 

(238

)

 

 

(41

)

 

 

(4,785

)

Change in operating assets and liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

Increase in accounts receivable

 

 

 

(78,923

)

 

 

(48,612

)

 

 

(57,267

)

Increase in prepaid expenses, other current assets and other assets

 

 

 

(32,602

)

 

 

(62,852

)

 

 

(28,381

)

Decrease in accounts payable

 

 

 

(3,988

)

 

 

(463

)

 

 

(2,155

)

Increase in accrued expenses, other current liabilities and other liabilities

 

 

 

69,606

 

 

 

27,977

 

 

 

46,581

 

Increase in income taxes payable

 

 

 

18,757

 

 

 

704

 

 

 

4,640

 

Net cash provided by operating activities

 

 

$

327,441

 

 

$

345,772

 

 

$

359,078

 

Investing activities

 

 

 

 

 

 

 

 

 

 

 

 

 

Purchase of property, plant and equipment

 

 

 

(62,173

)

 

 

(81,926

)

 

 

(57,231

)

Payment for internally generated intangible assets

 

 

 

 

 

 

(6,846

)

 

 

(16,441

)

Proceeds from sale of property, plant and equipment

 

 

 

1,486

 

 

 

547

 

 

 

1,738

 

Investment in equity affiliates

 

 

 

(18,423

)

 

 

(9,620

)

 

 

(496

)

Payment for business acquisitions, net of cash acquired

 

 

 

(21,363

)

 

 

(45,162

)

 

 

(284,822

)

Proceeds from divestiture of business, net of cash divested

 

 

 

 

 

 

17,242

 

 

 

(4,738

)

Net cash used for investing activities

 

 

$

(100,473

)

 

$

(125,765

)

 

$

(361,990

)

Financing activities

 

 

 

 

 

 

 

 

 

 

 

 

 

Repayment of capital lease obligations

 

 

 

(2,035

)

 

 

(1,793

)

 

 

(2,708

)

Payment of debt issuance cost

 

 

 

(6,584

)

 

 

 

 

 

(2,630

)

Proceeds from long-term debt

 

 

 

800,000

 

 

 

 

 

 

350,000

 

Repayment of long-term debt

 

 

 

(684,875

)

 

 

(40,000

)

 

 

(40,000

)

Proceeds from short-term borrowings

 

 

 

1,451,500

 

 

 

200,000

 

 

 

295,000

 

Repayment of short-term borrowings

 

 

 

(1,565,000

)

 

 

(61,500

)

 

 

(285,000

)

Proceeds from issuance of  common shares under stock-based compensation plans

 

 

 

16,088

 

 

 

18,228

 

 

 

15,528

 

Payment for net settlement of stock-based awards

 

 

 

(7,194

)

 

 

(769

)

 

 

(10,296

)

Payment of earn-out/deferred consideration

 

 

 

(230

)

 

 

(1,485

)

 

 

(6,219

)

Dividend paid

 

 

 

 

 

 

 

 

 

(46,686

)

Payment for stock purchased and retired

 

 

 

(226,917

)

 

 

(345,200

)

 

 

(219,784

)

Payment for expenses related to stock purchase

 

 

 

(197

)

 

 

(279

)

 

 

(16

)

Excess tax benefit on stock-based compensation

 

 

 

6,560

 

 

 

 

 

 

 

Net cash (used for) provided by financing activities

 

 

$

(218,884

)

 

$

(232,798

)

 

$

47,189

 

Effect of exchange rate changes

 

 

 

(18,965

)

 

 

(15,493

)

 

 

37,568

 

Net increase (decrease) in cash and cash equivalents

 

 

 

8,084

 

 

 

(12,791

)

 

 

44,277

 

Cash and cash equivalents at the beginning of the period

 

 

 

461,788

 

 

 

450,907

 

 

 

422,623

 

Cash and cash equivalents at the end of the period

 

 

$

450,907

 

 

$

422,623

 

 

$

504,468

 

Supplementary information

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash paid during the period for interest

 

 

$

20,950

 

 

$

17,860

 

 

$

27,853

 

Cash paid during the period for income taxes

 

 

$

72,102

 

 

$

46,731

 

 

$

66,238

 

Property, plant and equipment acquired under capital lease obligations

 

 

$

1,656

 

 

$

2,206

 

 

$

2,318

 

 

See accompanying notes to the Consolidated Financial Statements.

F-9


 

GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

1. Organization

   The Company is a global professional services firm that drives digitally-led innovation and runs digitally-enabled intelligent operations for its clients, guided by its experience running thousands of processes for hundreds of Fortune Global 500 clients.  The Company has over 78,000 employees serving clients in key industry verticals from more than 20 countries.

 

 

2. Summary of significant accounting policies

(a) Basis of preparation and principles of consolidation

The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP). The accompanying consolidated financial statements reflect all adjustments that management considers necessary for a fair presentation of the results of operations for these periods.

The accompanying financial statements have been prepared on a consolidated basis and reflect the financial statements of Genpact Limited, a Bermuda company, and all of its subsidiaries that are more than 50% owned and controlled. When the Company does not have a controlling interest in an entity but exerts significant influence over the entity, the Company applies the equity method of accounting. All intercompany transactions and balances are eliminated in consolidation.

Non-controlling interest in subsidiaries that is redeemable outside of the Company’s control for cash or other assets is reflected in the mezzanine section between liabilities and equity in the consolidated balance sheets at the redeemable value, which approximates fair value. Redeemable non-controlling interest is adjusted to its fair value at each balance sheet date. Any resulting increases or decreases in the estimated redemption amount are affected by corresponding charges to additional paid-in capital. The share of non-controlling interest in subsidiary earnings is reflected in net loss (income) attributable to redeemable non-controlling interest in the consolidated statements of income.

(b) Use of estimates

The preparation of consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements.

 

 

F-10


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

2. Summary of significant accounting policies (Continued)

Significant items subject to such estimates and assumptions include the useful lives of property, plant and equipment, intangibles and goodwill, revenue recognition, reserves for doubtful receivables, valuation allowances for deferred tax assets, the valuation of derivative financial instruments, measurements of stock-based compensation, assets and obligations related to employee benefits, and income tax uncertainties and other contingencies. Management believes that the estimates used in the preparation of the consolidated financial statements are reasonable. Although these estimates are based upon management’s best knowledge of current events and actions, actual results could differ from these estimates. Any changes in estimates are adjusted prospectively in the Company’s consolidated financial statements.

(c) Revenue recognition

The Company derives its revenue primarily from business process outsourcing and information technology services, which are provided on a time-and-material, transaction or fixed-price basis. The Company recognizes revenue when persuasive evidence of an arrangement exists, the sales price is fixed or determinable, services have been rendered and collectability is reasonably assured. Revenues from services rendered under time-and-materials and transaction-based contracts are recognized as the services are provided. The Company’s fixed-price contracts include contracts for application development, maintenance and support services. Revenues from these contracts are recognized ratably over the term of the agreement. The Company accrues for revenue and unbilled receivables for the services rendered between the last billing date and the balance sheet date.

Customer contracts can also include incentive payments received for discrete benefits delivered to clients. Revenues relating to such incentive payments are recorded when the contingency is satisfied and the Company concludes the amounts are earned.

Revenue from fixed-price contracts for the development of software and related services is recognized in accordance with the percentage-of-completion method. Guidance has been drawn from Financial Accounting Standards Board (“FASB”) guidance on Software—Revenue Recognition to account for revenue from fixed-price arrangements for software development and related services in conformity with FASB guidance on Revenue Recognition—Construction—Type and Production-Type Contracts. The input (effort or cost expended) method has been used to measure progress towards completion as there is a direct relationship between input and productivity. Provisions for estimated losses, if any, on uncompleted contracts are recorded in the period in which such losses become probable based on the current contract estimates.

The Company has deferred the revenue and costs attributable to certain process transition activities with respect to its customers where such activities do not represent the culmination of a separate earnings process. Such revenue and costs are subsequently recognized ratably over the period in which the related services are performed. Further, the deferred costs are limited to the amount of the deferred revenues.

Revenues are reported net of value-added tax, business tax and applicable discounts and allowances. Reimbursements of out-of-pocket expenses received from clients have been included as part of revenues.

The Company enters into multiple-element revenue arrangements in which a client may purchase a combination of its services. Revenue from multiple-element arrangements is recognized, for each element, based on (1) the attainment of the delivery criterion; (2) its fair value, which is determined using the selling price hierarchy of vendor-specific objective evidence (“VSOE”) of fair value, third-party evidence or best estimated selling price, as applicable, and (3) its allocated selling price, which is based on the relative sales price method.

F-11


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

2. Summary of significant accounting policies (Continued)

(d) Accounts receivable

Accounts receivable are recorded at the invoiced or to be invoiced amount and do not bear interest. Amounts collected on trade accounts receivable are included in net cash provided by operating activities in the consolidated statements of cash flows. The Company maintains an allowance for doubtful accounts for estimated losses inherent in its accounts receivable portfolio. In establishing the required allowance, management considers historical losses adjusted to take into account current market conditions and clients’ financial conditions, the amount of receivables in dispute, and the current receivables’ aging and current payment patterns. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company does not have any off-balance-sheet credit exposure related to its clients.

(e) Cash and cash equivalents

Cash and cash equivalents consist of cash and bank balances and all highly liquid investments purchased with an original maturity of three months or less.

(f) Short-term investments

All liquid investments with an original maturity greater than 90 days but less than one year are considered to be short-term investments. Marketable short-term investments are classified and accounted for as available-for-sale investments. Available-for-sale investments are reported at fair value with changes in unrealized gains and losses recorded as a separate component of other comprehensive income (loss) until realized. Realized gains and losses on investments are determined based on the specific identification method and are included in “Other income (expense), net.” The Company does not hold these investments for speculative or trading purposes.

(g) Property, plant and equipment, net

Property, plant and equipment are stated at cost less accumulated depreciation and amortization. Expenditures for replacements and improvements are capitalized, whereas the costs of maintenance and repairs are charged to earnings as incurred. The Company depreciates and amortizes all property, plant and equipment using the straight-line method over the following estimated economic useful lives of the assets:

 

 

 

Years

Buildings

 

40

Furniture and fixtures

 

4

Computer equipment and servers

 

4

Plant, machinery and equipment

 

4

Computer software

 

4-7

Leasehold improvements

 

Lesser of lease

period or 10 Years

Vehicles

 

3-4

 

The Company capitalizes certain computer software incurred in connection with developing or obtaining computer software for internal use when both the preliminary project stage is completed and it is probable that the software will be used as intended. Capitalized software costs include only (i) external direct costs of materials and services utilized in developing or obtaining computer software, (ii) compensation and related benefits for employees who are directly associated with the software project, and (iii) interest costs incurred while developing internal-use computer software.

 

F-12


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

2. Summary of significant accounting policies (Continued)

Capitalized software costs are included in property, plant and equipment on the Company’s balance sheet and amortized on a straight-line basis when placed into service over the estimated useful lives of the software. 

Advances paid towards the acquisition of property, plant and equipment outstanding as of each balance sheet date and the cost of property, plant and equipment not put to use before such date are disclosed under “Capital work in progress.

(h) Business combinations, goodwill and other intangible assets

The Company accounts for its business combinations using the acquisition method of accounting in accordance with ASC 805, Business Combinations, by recognizing the identifiable tangible and intangible assets acquired and liabilities assumed, and any non-controlling interest in the acquired business, measured at their acquisition date fair values. Contingent consideration is included within the acquisition cost and is recognized at its fair value on the acquisition date. A liability resulting from contingent consideration is remeasured to fair value as of each reporting date until the contingency is resolved. Changes in fair value are recognized in earnings. All assets and liabilities of the acquired businesses, including goodwill, are assigned to reporting units. Acquisition-related costs are expensed as incurred under Selling, General and Administrative Expenses.

Goodwill represents the cost of acquired businesses in excess of the fair value of identifiable tangible and intangible net assets purchased. Goodwill is not amortized but is tested for impairment at least on an annual basis on December 31, based on a number of factors, including operating results, business plans and future cash flows. The Company performs an assessment of qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Based on the assessment of events or circumstances, the Company performs a quantitative assessment of goodwill impairment if it determines that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, based on the quantitative impairment analysis, the carrying value of the goodwill of a reporting unit exceeds the fair value of such goodwill, an impairment loss is recognized in an amount equal to the excess. In addition, the Company performs a qualitative assessment of goodwill impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. See Note 10 for information and related disclosures.

Intangible assets including technology acquired / developed individually or with a group of other assets or in a business combination are carried at cost less accumulated amortization based on their estimated useful lives as follows:

 

Customer-related intangible assets

 

1-14 years

Marketing-related intangible assets

 

1-10 years

Technology-related intangible assets

 

2-8 years

Other intangible assets

 

3-5 years

 

Intangible assets are amortized over their estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are consumed or otherwise realized.

In business combinations, where the fair value of identifiable tangible and intangible net assets purchased exceeds the cost of the acquired business, the Company recognizes the resulting gain under “Other operating (income) expense, net” in the Consolidated Statements of Income.

F-13


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

2. Summary of significant accounting policies (Continued)

The Company also capitalizes certain software and technology development costs incurred in connection with developing or obtaining software or technology for sale/lease to customers when the initial design phase is completed and commercial and technological feasibility has been established. Any development cost incurred before technological feasibility is established is expensed as incurred as research and development costs. Technological feasibility is established upon completion of a detailed design program or, in its absence, completion of a working model. Capitalized software and technology costs include only (i) external direct costs of materials and services utilized in developing or obtaining software and technology and (ii) compensation and related benefits for employees who are directly associated with the project.

Costs incurred in connection with developing or obtaining software or technology for sale/lease to customers which are under development and not put to use are disclosed under “intangible under development.”

Capitalized software and technology costs are included in intangible assets under technology-related intangible assets on the Company’s balance sheet and amortized on a straight-line basis when placed into service over the estimated useful lives of the software and technology.

 

(i) Impairment of long-lived assets

Long-lived assets, including certain intangible assets, to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Such assets are required to be tested for impairment if the carrying amount of the assets is higher than the future undiscounted net cash flows expected to be generated from the assets. The impairment amount to be recognized is measured as the amount by which the carrying value of the assets exceeds their fair value. The Company determines fair value by using a discounted cash flow approach.

(j) Foreign currency

The Company’s consolidated financial statements are reported in U.S. dollars, the Company’s functional currency. The functional currency for the Company’s subsidiaries organized in Europe, other than the United Kingdom, the Czech Republic, Luxembourg and one subsidiary in Poland, is the euro, and the functional currencies of the Company’s subsidiaries organized in Brazil, China, Colombia, Guatemala, India, Israel, Japan, Morocco, South Africa, the Philippines, the United Kingdom, Poland, the Czech Republic, Hong Kong, Singapore, Australia, Canada and United Arab Emirates are their respective local currencies. The functional currency of all other Company subsidiaries is the U.S. dollar. The translation of the functional currencies of the Company’s subsidiaries into U.S. dollars is performed for balance sheet accounts using the exchange rates in effect as of the balance sheet date and for revenues and expense accounts using a monthly average exchange rate prevailing during the respective period. The gains or losses resulting from such translation are reported as currency translation adjustments under other comprehensive income (loss), net, under accumulated other comprehensive income (loss) as a separate component of equity.

Monetary assets and liabilities of each subsidiary denominated in currencies other than the subsidiary’s functional currency are translated into their respective functional currency at the rates of exchange prevailing on the balance sheet date. Transactions of each subsidiary in currencies other than the subsidiary’s functional currency are translated into the respective functional currencies at the average monthly exchange rate prevailing during the period of the transaction. The gains or losses resulting from foreign currency transactions are included in the consolidated statements of income.

F-14


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

2. Summary of significant accounting policies (Continued)

(k) Derivative instruments and hedging activities

In the normal course of business, the Company uses derivative financial instruments to manage fluctuations in foreign currency exchange rates and interest rate fluctuation. The Company purchases forward foreign exchange contracts to mitigate the risk of changes in foreign exchange rates on intercompany transactions and forecasted transactions denominated in foreign currencies and interest rate swaps to mitigate interest rate fluctuation risk on its indebtedness.

The Company recognizes derivative instruments and hedging activities as either assets or liabilities in its consolidated balance sheets and measures them at fair value. Gains and losses resulting from changes in fair value are accounted for depending on the use of the derivative and whether it is designated and qualifies for hedge accounting. Changes in the fair values of derivatives designated as cash flow hedges are deferred and recorded as a component of other comprehensive income (loss) reported under accumulated other comprehensive income (loss) until the hedged transactions occur and are then recognized in the consolidated statements of income along with the underlying hedged item and disclosed as part of “Total net revenues,” “Cost of revenue,” “Selling, general and administrative expenses,” and “Interest expense,” as applicable. Changes in the fair value of derivatives not designated as hedging instruments and the ineffective portion of derivatives designated as cash flow hedges are recognized in the consolidated statements of income and are included in foreign exchange gains (losses), net, and other income (expense), net, respectively.

With respect to derivatives designated as hedges, the Company formally documents all relationships between hedging instruments and hedged items, as well as its risk management objectives and strategy for undertaking various hedge transactions. The Company also formally assesses, both at the inception of the hedge and on a quarterly basis, whether each derivative is highly effective in offsetting changes in fair values or cash flows of the hedged item. If it is determined that a derivative or portion thereof is not highly effective as a hedge, or if a derivative ceases to be a highly effective hedge, the Company will prospectively discontinue hedge accounting with respect to that derivative.

In all situations in which hedge accounting is discontinued and the derivative is retained, the Company continues to carry the derivative at its fair value on the balance sheet and recognizes any subsequent change in its fair value in the consolidated statements of income. When it is probable that a forecasted transaction will not occur, the Company discontinues hedge accounting and recognizes immediately, in foreign exchange gains (losses), net in the consolidated statements of income, the gains and losses attributable to such derivative that were accumulated in other comprehensive income (loss).

 

(l) Income taxes

The Company accounts for income taxes using the asset and liability method of accounting for income taxes. Under this method, income tax expense is recognized for the amount of taxes payable or refundable for the current year. In addition, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their tax bases and all operating loss and tax credit carry forwards, if any. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates or tax status is recognized in the statement of income in the period that includes the enactment date or the filing or approval date of the tax status change. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized.

F-15


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

2. Summary of significant accounting policies (Continued)

The Company applies a two-step approach for recognizing and measuring the benefit of tax positions. The first step is to evaluate the tax position for recognition by determining, based on the technical merits, that the position will more likely than not be sustained upon examination. The second step is to measure the tax benefit as the largest amount of the tax benefit that is greater than 50 percent likely of being realized upon settlement. The Company includes interest and penalties related to unrecognized tax benefits within income tax expense.

(m) Employee benefit plans

Contributions to defined contribution plans are charged to consolidated statements of income in the period in which services are rendered by the covered employees. Current service costs for defined benefit plans are accrued in the period to which they relate. The liability in respect of defined benefit plans is calculated annually by the Company using the projected unit credit method. Prior service cost, if any, resulting from an amendment to a plan is recognized and amortized over the remaining period of service of the covered employees. The Company recognizes its liabilities for compensated absences dependent on whether the obligation is attributable to employee services already rendered, relates to rights that vest or accumulate and payment is probable and estimable.

The Company records annual amounts relating to its defined benefit plans based on calculations that incorporate various actuarial and other assumptions, including discount rates, mortality, assumed rates of return, compensation increases and turnover rates. The Company reviews its assumptions on an annual basis or quarterly basis and makes modifications to the assumptions based on current rates and trends when it is appropriate to do so. The effect of modifications to those assumptions is recorded in other comprehensive income (loss) and amortized to net periodic cost over future periods using the corridor method. The Company believes that the assumptions utilized in recording its obligations under its plans are reasonable based on its experience and market conditions.

(n) Stock-based compensation

The Company recognizes and measures compensation expense for all stock-based awards based on the grant date fair value. For option awards, grant date fair value is determined under the option-pricing model (Black-Scholes-Merton) and for awards other than option awards, grant date fair value is determined on the basis of the fair market value of a Company common share on the date of grant of such awards. The Company recognizes compensation expense for stock-based awards net of estimated forfeitures. Stock-based compensation recognized in the consolidated statements of income for the years ended December 31, 2015, 2016 and 2017 is based on awards ultimately expected to vest. As a result, the expense has been reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from such estimates.

(o) Accelerated Share Repurchase

The Company entered into an accelerated share repurchase (“ASR”) agreement with a third-party financial institution to repurchase shares of the Company’s common stock. Under the ASR agreement, the Company paid a specified amount to the financial institution and received an initial delivery of shares. Upon an interim delivery and settlement of the ASR agreement, the financial institution delivered additional shares, with the final number of shares delivered determined with reference to the volume-weighted average price of the Company’s common stock over the term of the agreement, less an agreed-upon discount. The transactions are accounted for as equity transactions. All repurchased shares are retired. When the shares are received, there is an immediate reduction in the weighted-average common shares calculation for basic and diluted earnings per share.

 

F-16


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

2. Summary of significant accounting policies (Continued)

(p)  Government incentives

The Company recognizes incentives in the consolidated statement of income to match them with the expenditures for which they are intended to compensate. Incentives are recognized in the income statement when there is reasonable assurance that the Company will comply with the conditions for their receipt and a reasonable expectation that the funds will be received. In certain circumstances, the receipt of an incentive may not be subject to any condition or requirement to incur further costs, in which case the incentive is recognized in the income statement for the period in which it becomes receivable. In the event that it becomes likely that the Company will be required to repay an incentive that has already been recognized, the Company makes a provision for the estimated liability.

(q) Financial instruments and concentration of credit risk

Financial instruments that potentially subject the Company to concentration of credit risk are reflected principally in cash and cash equivalents, derivative financial instruments and accounts receivable. The Company places its cash and cash equivalents and derivative financial instruments with corporations and banks with high investment grade ratings, limits the amount of credit exposure with any one corporation or bank and conducts ongoing evaluations of the creditworthiness of the corporations and banks with which it does business. To reduce its credit risk on accounts receivable, the Company conducts ongoing credit evaluations of its clients. GE accounted for 15% and 11% of the Company’s receivables as of December 31, 2016 and 2017, respectively. GE accounted for 19%, 14% and 10% of the Company’s revenues in the years ended December 31, 2015, 2016 and 2017, respectively.

(r) Earnings (loss) per share

Basic earnings per share is computed using the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed using the weighted average number of common and dilutive common equivalent shares outstanding during the period. For the purposes of calculating diluted earnings per share, the treasury stock method is used for stock-based awards except where the results would be anti-dilutive.

(s) Commitments and contingencies

Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated. Legal costs incurred in connection with such liabilities are expensed as incurred.

(t) Recently issued accounting pronouncements

The authoritative bodies release standards and guidance which are assessed by management for impact on the company’s consolidated financial statements.

The following recently released accounting standard has been adopted by the Company:

In March 2016, the FASB issued ASU 2016-09, Compensation—Stock Compensation (Topic 718): Improvement to Employee Share-Based Payment Accounting. The new standard contains several amendments that will simplify the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, statutory tax withholding requirements, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The changes in the new standard eliminate the requirement for excess tax benefits to be recognized in additional paid-in capital and tax deficiencies recognized either in income tax expense or in additional paid-in capital. In the quarter ended December 31, 2016, the Company elected to early adopt ASU 2016-09 effective January 1, 2016 and applied ASU 2016-09 using a modified retrospective approach. The treatment of forfeitures has not changed as the Company is electing to continue its current process of estimating the number of forfeitures. With the early adoption of ASU 2016-09, the Company has elected to present the cash flow statement on a prospective transition method and no prior periods have been adjusted.

F-17


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

2. Summary of significant accounting policies (Continued)

In addition, the following recently released accounting standards have been adopted by the Company. Adoption of these standards did not have a material impact on the Company’s consolidated results of operations, cash flows, financial position or disclosures:

Effective January 1, 2016, the Company adopted FASB ASU 2015-01 (Topic 225): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items (“ASU 2015-01”). Such items are defined as transactions or events that are both unusual in nature and infrequent in occurrence, and, currently, are required to be presented separately in the income statement, net of income tax, after income from continuing operations. The changes eliminate the concept of an extraordinary item and, therefore, the presentation of such items will no longer be required. Notwithstanding this change, the Company will still be required to present and disclose a transaction or event that is both unusual in nature and infrequent in occurrence in the notes to the consolidated financial statements.

Effective January 1, 2016, the Company adopted FASB ASU 2015-16 (Topic 805), Business Combinations (“ASU 2015-16”), which eliminates the requirement for an acquirer in a business combination to account for measurement-period adjustments retrospectively. The guidance requires that the acquirer shall recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined.

Effective January 1, 2016, the Company adopted FASB ASU 2015-02. In February 2015, the FASB issued ASU No. 2015-02, Amendment to the Consolidation Analysis, which specifies changes to the analysis that an entity must perform to determine whether it should consolidate certain types of legal entities. These changes (i) modify the evaluation of whether limited partnerships and similar legal entities are variable interest entities or voting interest entities, (ii) eliminate the presumption that a general partner should consolidate a limited partnership, (iii) affect the consolidation analysis of reporting entities that are involved with variable interest entities, particularly those that have fee arrangements and related party relationships, and (iv) provide a scope exception from consolidation guidance for reporting entities with interests in legal entities that are required to comply with or operate in accordance with requirements that are similar to those in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds.

 

Effective January 1, 2017, the Company adopted FASB ASU 2016-06, Derivatives and Hedging (Topic 815). The amendments in this update clarify the requirements for assessing whether contingent call (put) options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts. An entity performing the assessment under the amendments in this update is required to assess the embedded call (put) options solely in accordance with a four-step decision sequence.

 

F-18


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

2. Summary of significant accounting policies (Continued)

The following recently released accounting standards have not yet been adopted by the Company:

 

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which will replace most existing revenue recognition guidance in U.S. GAAP. The core principle of the ASU is that an entity should recognize revenue for the transfer of goods or services equal to the amount that it expects to be entitled to receive for those goods or services. The ASU requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments. Subsequently, the FASB issued ASU No. 2017-13, in September 2017, ASU No. 2016-08, “Principal versus Agent Considerations (Reporting Gross versus Net),” in March 2016, ASU No. 2016-10, “Identifying performance obligations and licensing,” in April 2016, and ASU 2016-20 “Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers” in December 2016, which amend and clarify ASU 2014-09. These ASUs will be effective for the Company beginning January 1, 2018, including interim periods in the fiscal year 2018, and allow for both retrospective and prospective adoption. The Company has performed an assessment of the impact of the ASU and developed a transition plan, including necessary changes to policies, processes, and internal controls as well as system enhancements to generate the information necessary for the new disclosures. The implementation plan is on schedule for adoption on January 1, 2018 and the Company will apply the cumulative effect method as its transition approach. The Company expects revenue recognition across the portfolio of services to remain largely unchanged, however there will be an impact on the timing of recognition of certain contract costs, which will now be amortized over the contract period rather than expensed as incurred. Based on the analysis completed to date, the Company does not currently expect that the ASU will have a material impact on consolidated revenue in its Consolidated Financial Statements.

 

In February 2016, the FASB issued ASU No. 2016-02, “Leases.” The core principle of the ASU is that a lessee should recognize the assets and liabilities that arise from its leases other than those that meet the definition of a short-term lease. The ASU requires extensive qualitative and quantitative disclosures, including with respect to significant judgments made by management. Subsequently, the FASB issued ASU No. 2017-13, in September 2017 and ASU No. 2018-01, in January 2018, which amends and clarifies ASU 2016-02. The ASU will be effective for the Company beginning January 1, 2019, including interim periods in the fiscal year 2019. Early adoption is permitted. The Company is in the process of determining the method of adoption and assessing the impact of this ASU on its consolidated results of operations, cash flows, financial position and disclosures.

In October 2016, the FASB issued ASU 2016-16, “Intra-Entity Transfers of Assets Other Than Inventory.” The new guidance eliminates the exception for deferment of tax recognition until the transferred asset is sold to a third party or otherwise recovered through use for all intra-entity sales of assets other than inventory. The ASU is effective for the Company beginning January 1, 2018, including interim periods in the fiscal year 2018. Early adoption is permitted. The Company does not expect the adoption of this update to have a material impact on its consolidated results of operations, cash flows, financial position or disclosures.

In January 2017, the FASB issued ASU 2017-01, “Business Combinations (Topic 805): Clarifying the Definition of a Business.” The new guidance revises the definition of a business. The definition of a business affects many areas of accounting (e.g., acquisitions, disposals, goodwill impairment, consolidation). The ASU is effective for the Company beginning January 1, 2018, including interim periods in the fiscal year 2018. Early adoption is permitted. The Company adopted this ASU on the effective date and will apply the guidance prospectively. The Company does not expect the adoption of this update to have a material impact on its consolidated results of operations, cash flows, financial position or disclosures.

 

F-19


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

2. Summary of significant accounting policies (Continued)

In March 2017, the FASB issued ASU 2017-07, “Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost.” The ASU requires entities to (1) disaggregate the current-service-cost component from the other components of net benefit cost (the “other components”) and present it with other current compensation costs for related employees in the income statement and (2) present the other components elsewhere in the income statement and outside of income from operations if that subtotal is presented. In addition, the ASU requires entities to disclose the income statement lines that contain the other components if they are not presented on appropriately described separate lines. The ASU is effective for the Company beginning January 1, 2018, including interim periods in the fiscal year 2018. The Company adopted this ASU on the effective date and does not expect the adoption of this update to have a material impact on its consolidated results of operations, cash flows, financial position or disclosures.

 

In August 2017, the FASB issued ASU 2017-12, “Derivatives and Hedging.” The amendment expands an entity’s ability to hedge accounting to nonfinancial and financial risk components and requires changes in fair value of hedging instruments to be presented in the same income statement line as the hedged item. The ASU also amends the presentation and disclosure requirements for the effect of hedge accounting. The ASU must be adopted using a modified retrospective approach with a cumulative effect adjustment recorded to the opening balance of retained earnings as of the initial application date. The ASU is effective for the Company beginning January 1, 2019, including interim periods in the fiscal year 2019. Early adoption is permitted. The Company is in the process of assessing the impact of this ASU on its consolidated results of operations, cash flows, financial position and disclosures.

 

In February 2018, the FASB issued ASU 2018-02, “Income Statement—Reporting Comprehensive Income.” The amendments allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act. The amendments in this Update also require certain disclosures about stranded tax effects. The ASU should be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Cuts and Jobs Act was recognized. The ASU is effective for the Company beginning January 1, 2019, including interim periods in the fiscal year 2019. Early adoption is permitted. The Company is in the process of assessing the impact of this ASU on its consolidated results of operations, cash flows, financial position and disclosures. There was no adoption of the provision of ASU 2018-02 in the Financial Statements for the year ended December 31, 2017.

 

(v) Reclassification

 

Certain reclassifications have been made in the consolidated financial statements of prior periods to conform to the classification used in the current period. The impact of such reclassifications on the consolidated financial statements is not material.

 

 

 

3. Business acquisitions

 

A. Certain acquisitions         

 

(a) TandemSeven, Inc.

 

On September 5, 2017, the Company acquired 100% of the outstanding equity interest in TandemSeven, Inc. (“TandemSeven”), a Massachusetts corporation, for estimated total purchase consideration of $35,720, subject to adjustment for closing date working capital and indebtedness. This amount includes cash consideration of $31,866, net of cash acquired of $3,854, and a preliminary adjustment for working capital and indebtedness. In addition, the Company is evaluating certain tax positions, which, when determined, may result in the recognition of additional assets and liabilities as of the acquisition date. The measurement period will not exceed one year from the acquisition date. TandemSeven’s focus on improving the design of customer experiences complements the Company’s existing capabilities aimed at transforming clients’ processes end-to-end.

F-20


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

3. Business acquisitions (Continued)

In connection with the acquisition of TandemSeven, the Company recorded $2,000 in customer-related intangibles, $1,700 in marketing-related intangibles and $800 in technology-related intangible assets, which have a weighted average amortization period of two years. Goodwill arising from the acquisition amounted to $25,298, which has been allocated to the Company’s India reporting unit and is deductible for tax purposes. The goodwill represents primarily the acquired design expertise, operating synergies and other benefits expected to result from combining the acquired operations with those of the Company.

 

Acquisition-related costs of $932 have been included in selling, general and administrative expenses as incurred. In connection with the transaction, the Company also acquired certain assets with a value of $7,388 and assumed certain liabilities amounting to $1,206 and recognized a net deferred tax liability of $260. The results of operations of the acquired business and the fair value of the acquired assets and assumed liabilities are included in the Company’s consolidated financial statements with effect from the date of the acquisition.

 

(b) BrightClaim LLC and associated companies

 

On May 3, 2017, the Company acquired 100% of the outstanding equity interest in each of BrightClaim LLC, a Delaware limited liability company, BrightServe LLC, a Georgia limited liability company, National Vendor LLC, a Delaware limited liability company, and BrightClaim Blocker, Inc., a Delaware corporation (collectively referred to as “BrightClaim”) for total purchase consideration of $56,461, subject to adjustment for closing date working capital, indebtedness and certain transaction expenses incurred by BrightClaim in connection with closing. This amount includes cash consideration of $52,395, net of cash acquired of $4,002, and an adjustment for working capital and net debt. The total consideration paid by the Company to the sellers is $56,496. During the quarter ended September 30, 2017, the Company recorded certain measurement period adjustments resulting in a receivable of $35, which is outstanding as of December 31, 2017.  These measurement period adjustments did not have a significant impact on the Company’s consolidated statements of income, balance sheets or cash flows. This acquisition enhances the Company’s breadth and depth of service offerings for clients in the insurance industry.

 

In connection with the acquisition of BrightClaim, the Company recorded $8,000 in customer-related intangibles, $3,200 in marketing-related intangibles, $2,200 in technology-related intangibles and $200 in other intangibles, which have a weighted average amortization period of four years. Goodwill arising from the acquisition amounted to $42,638, which has been allocated to the Company’s India reporting unit and is partially deductible for tax purposes. The goodwill represents primarily the capabilities, operating synergies and other benefits expected to result from combining the acquired operations with those of the Company.

Acquisition-related costs of $1,563 have been included in selling, general and administrative expenses as incurred. In connection with the transaction, the Company also acquired certain assets with a value of $10,367, assumed certain liabilities amounting to $7,415, and recognized a net deferred tax liability of $2,728. The results of operations of the acquired business and the fair value of the acquired assets and assumed liabilities are included in the Company’s consolidated financial statements with effect from the date of the acquisition.

 

F-21


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

3. Business acquisitions (Continued)

(c) RAGE Frameworks, Inc.

 

On April 13, 2017, the Company acquired 100% of the outstanding equity interest in RAGE Frameworks, Inc. (“RAGE”), a Delaware corporation, for estimated total consideration of $125,089, subject to adjustment for closing date working capital and indebtedness. This amount includes cash consideration of $124,149, net of cash acquired of $1,605, and a preliminary adjustment for working capital and indebtedness. During the quarter ending December 31, 2017, the Company recorded certain measurement period adjustments. These measurement period adjustments did not have a significant impact on the Company’s consolidated statements of income, balance sheets or cash flows. This acquisition enhances the Company’s digital and artificial intelligence capabilities by adding knowledge-based automation technology and services.

 

In connection with the acquisition of RAGE, the Company recorded $1,600 in customer-related intangibles, $600 in marketing-related intangibles, $12,400 in technology-related intangible assets and $100 in other intangible assets, which have a weighted average amortization period of seven years. Goodwill arising from the acquisition amounted to $105,114, which has been allocated to the Company’s India reporting unit and is not deductible for tax purposes. The goodwill represents primarily the acquired digital and artificial intelligence capabilities, operating synergies and other benefits expected to result from combining the acquired operations with those of the Company.

Acquisition-related costs of $881 have been included in selling, general and administrative expenses as incurred. In connection with the transaction, the Company also acquired certain assets with a value of $13,836 and assumed certain liabilities amounting to $9,654. The Company also recognized a net deferred tax asset of $1,094.

The results of operations of the acquired business and the fair value of the acquired assets and assumed liabilities are included in the Company’s consolidated financial statements with effect from the date of the acquisition.

(d) Other acquisitions in 2017

In 2017, the Company also completed five individually immaterial business acquisition transactions, namely the acquisition of a supply chain management delivery center in the U.S. from Kraft Foods Group Brands LLC (“U.S. Delivery Center”), the purchase of all of the outstanding equity interest in OnSource, LLC (“OnSource”), the purchase of the IT business of Birlasoft (“Birlasoft”), the purchase of the image processing business of Fiserv Solutions of Australia Pty Ltd. (“Fiserv”) and the purchase of all of the outstanding equity interest in Lease Dimensions, Inc. (“Lease Dimensions”). The aggregate total estimated consideration the Company paid to consummate these acquisitions was $87,586, subject to certain adjustments. This aggregate amount includes the estimated fair value of contingent earn-out consideration, cash consideration of $76,612, net of cash acquired of $254, and preliminary adjustments for closing date working capital, indebtedness, value transfer, seller transaction expenses and certain employee-related liabilities.

 

The U.S. Delivery Center acquisition enhances the Company’s supply chain management capabilities for its clients in the consumer packaged goods industry. The OnSource acquisition brings incremental digital capabilities to the Company’s insurance service offerings. The Birlasoft transaction

F-22


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

3. Business acquisitions (Continued)

 

expands the Company’s end-to-end capabilities for its clients in the healthcare and aviation industries. The Fiserv transaction strengthens the Company’s financial services portfolio and expands its Australia footprint. The Lease Dimensions acquisition enhances the Company’s capabilities in commercial lending and leasing.

During the quarter ending December 31, 2017, the Company recorded certain measurement period adjustments with respect to the Birlasoft and Fiserv transactions. These measurement period adjustments did not have a significant impact on the Company’s consolidated statements of income, balance sheets or cash flows.

The purchase agreement for the acquisition of the U.S. Delivery Center provides for contingent earn-out consideration ranging from $0 to $10,000, payable by the Company to the seller based on the achievement of certain milestones relative to the thresholds specified in the earn-out calculation. The purchase agreement for the Lease Dimensions acquisition provides for contingent earn-out consideration ranging from $0 to $3,000, payable by the Company to the sellers based on the future performance of the business relative to the thresholds specified in the earn-out calculation.

In connection with these transactions, the Company recorded $33,494 in customer-related intangibles, $1,936 in marketing-related intangibles, $2,956 in technology-related intangibles and $100 in other intangibles, which have a weighted average amortization period of five years. Goodwill arising from these acquisitions amounted to $56,521. The goodwill represents primarily the capabilities, operating synergies and other benefits expected to result from combining the acquired operations with those of the Company.

 

The following table sets forth, with respect to each of the five acquisitions, the acquisition date, goodwill reporting unit and the tax deductibility of the goodwill:

 

Acquisition

Acquisition date

Goodwill reporting unit

Tax deductibility of  goodwill

U.S. Delivery Center

October 16, 2017

India

Deductible

OnSource

July 18, 2017

India

Deductible

Birlasoft

July 18, 2017

IT Services

Deductible

Fiserv

May 11, 2017

India

Non-deductible

Lease Dimensions

February 15, 2017

Americas

Non-deductible

 

Acquisition-related costs for these acquisitions, amounting to $2,369 in the aggregate, have been included in selling, general and administrative expenses as incurred. Through these transactions, the Company acquired assets with a value of $10,387, assumed liabilities amounting to $11,239, and recognized a net deferred tax liability of $6,570. The results of operations of the acquired businesses and the fair value of the acquired assets and assumed liabilities are included in the Company’s consolidated financial statements with effect from the respective dates of the acquisitions.

(e) Endeavour Software Technologies Private Limited

 

On April 13, 2016, the Company acquired 100% of the outstanding equity interest in Endeavour Software Technologies Private Limited (“Endeavour”), an Indian private limited company, for total consideration of $14,788. This amount includes the estimated fair value of the contingent earn-out consideration, cash consideration of $10,345, net of cash acquired of $2,373, and an adjustment for working capital and net debt. During the quarter ending March 31, 2017, the Company recorded certain measurement period adjustments. These measurement period adjustments did not have a significant impact on the Company’s consolidated statements of income, balance sheets or cash flows. The purchase agreement between the Company and the sellers of Endeavour provides for contingent earn-out consideration ranging from $0 to $3,500, payable by the Company to the sellers based on future

F-23


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

3. Business acquisitions (Continued)

 

performance relative to the thresholds specified in the earn-out calculation. This acquisition enhances the Company’s digital capabilities by adding critical end-to-end mobility services.

In connection with the transaction, the Company recorded $800 in customer-related intangibles, $900 in marketing-related intangibles and $950 in other intangible assets, which have a weighted average amortization period of three years. Goodwill arising from the acquisition amounted to $8,936, which has been allocated to the Company’s India reporting unit and is not deductible for tax purposes. The goodwill represents primarily the capabilities in end-to-end mobility services, operating synergies and other benefits expected to result from combining the acquired operations with those of the Company. In connection with the transaction, the Company also acquired certain assets with a value of $5,854 and assumed certain liabilities amounting to $1,735. The results of operations of the acquired business and the fair value of the acquired assets and assumed liabilities are included in the Company’s consolidated financial statements with effect from the date of the acquisition.

(f) Strategic Sourcing Excellence Limited

On January 8, 2016, the Company acquired 51% of the outstanding equity interest in Strategic Sourcing Excellence LLC (“SSE”), a Delaware limited liability company. The total consideration paid by the Company to the selling equity holders for the acquired interest in SSE was $14,541. This amount includes the fair value of earn-out consideration, cash consideration of $2,550, and an adjustment for working capital, transaction expenses and indebtedness. During the quarter ending December 31, 2016, the Company recorded certain measurement period adjustments. These measurement period adjustments did not have a significant impact on the Company’s consolidated statements of income, balance sheets or cash flows in any period. The equity purchase agreement between the Company and the selling equity holders of SSE also provides for contingent earn-out consideration of up to $20,000, payable by the Company to the selling equity holders based on the future performance of the acquired business relative to the thresholds specified in the earn-out calculation. Up to $9,800 of the total potential earn-out consideration, representing the selling equity holders’ 49% interest in SSE, is payable only if either the put or call option, each as described below, is exercised.

The equity purchase agreement grants the Company a call option to purchase the remaining 49% equity interest in SSE, which option the Company had the right to exercise between January 1, 2018 and January 31, 2018. Since the Company did not exercise its call option during such period, the selling equity holders have the right to exercise a put option between March 1, 2018 and April 30, 2018 to require the Company to purchase their 49% interest in SSE at a price ranging from $2,450 to $2,950. This acquisition enhances the Company’s sourcing and procurement consulting domain expertise.

Acquisition-related costs of $164 have been included in selling, general and administrative expenses as incurred. Through this transaction, the Company acquired assets with a value of $412 and assumed liabilities amounting to $617. The results of operations of the acquired business, the fair value of the acquired assets and assumed liabilities, and redeemable non-controlling interest are included in the Company’s Consolidated Financial Statements with effect from the date of the acquisition.

In connection with the transaction, the Company recorded $300 in customer-related intangible assets with an amortization period of five years. Goodwill arising from the acquisition amounted to $14,445, which has been allocated to the Company’s India reporting unit and is deductible for tax purposes. The goodwill represents future economic benefits the Company expects to derive from its expanded presence in the sourcing and procurement consulting domains, operating synergies and other anticipated benefits of combining the acquired operations with those of the Company.

 

 

F-24


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

3. Business acquisitions (Continued)

(g) PNMSoft Ltd.

On August 4, 2016, the Company acquired 100% of the outstanding equity interest in PNMSoft Limited (“PNMSoft”), a company incorporated under the laws of Israel. The total purchase consideration paid by the Company to acquire PNMSoft is $35,341. This amount includes the estimated fair value of contingent earn-out consideration, cash consideration of $28,128, net of cash acquired of $2,853, and an adjustment for working capital, transaction expenses and net debt. During the quarter ending December 31, 2016, the Company recorded certain measurement period adjustments. These measurement period adjustments did not have a significant impact on the Company’s consolidated statements of income, balance sheets or cash flows. The purchase agreement between the Company and the sellers of PNMSoft provides for contingent earn-out consideration ranging from $0 to $9,000, payable by the Company to the sellers of PNMSoft based on the performance of the acquired business for a fixed period following closing relative to the thresholds specified in the earn-out calculation. This acquisition enhances the Company’s digital capabilities by adding dynamic workflow solutions and implementation services.

In connection with this acquisition, the Company recorded $1,700 in customer-related intangibles, $1,630 in marketing-related intangibles and $5,110 in other intangible assets, which have a weighted average amortization period of two years. Goodwill arising from the acquisition amounted to $25,101, which has been allocated to the Company’s India reporting unit and is not deductible for tax purposes. The goodwill represents primarily the capabilities, operating synergies and other benefits expected to result from combining the acquired operations with those of the Company.

Acquisition-related costs of $1,273 have been included in selling, general and administrative expenses as incurred. In connection with the transaction, the Company acquired assets with a value of $7,110, assumed liabilities amounting to $4,366 and recognized a net deferred tax liability of $944. The results of operations of the acquired business and the fair value of the acquired assets and assumed liabilities are included in the Company’s consolidated financial statements with effect from the date of the acquisition.

 

B. Divestiture

(a) A portion of IT support business in Europe

 

In November 2017, the Company completed the sale of a portion of its legacy IT support business in Europe (the “Business”). Sale proceeds were $0. During the year ended December 31, 2017, the Business recorded net revenues of $4,546 and a net loss of $9,706.

 

The Company recorded a loss of $5,668 in its consolidated statement of income in connection with the sale of the Business, calculated as follows:

 

Net sale proceeds

 

$

Net assets of the business, including the translation impact thereof

 

 

5,569

Selling expenses

 

 

99

Loss on divestiture included in other income (expense), net

 

$

        5,668

(b) Atyati Technologies Private Limited

 

In September 2016, the Company completed the sale of its cloud-hosted technology platform for the Indian rural banking sector (“Atyati”), which the Company acquired in 2012. Net sale proceeds from the sale of Atyati were $17,155, net of selling expenses of $427 and cash divested of $854. During the year ended December 31, 2016, Atyati recorded net revenues of $14,958 and a net profit of $64.

 

F-25


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

3. Business acquisitions (Continued)

 

The Company recorded a gain of $5,214 in its consolidated statement of income in connection with the sale of Atyati, calculated as follows:

 

Net sale proceeds

 

$

17,155

Net assets of the business, including intangible assets, allocated goodwill and the translation impact thereof

 

 

11,941

Gain on divestiture included in other income (expense), net

 

$

        5,214

 

 

 

4. Cash and cash equivalents

 

 

 

As of December 31,

 

 

 

2016

 

 

2017

 

Cash and other bank balances

 

$

422,623

 

 

$

504,468

 

Total

 

$

422,623

 

 

$

504,468

 

 

 

5. Accounts receivable, net of reserve for doubtful receivables

The following table provides details of the Company’s reserve for doubtful receivables:

 

 

 

Year ended December 31,

 

 

 

2015

 

 

2016

 

 

2017

 

Opening balance as of January 1

 

$15,192

 

 

$

11,530

 

 

$

15,519

 

Additions due to acquisitions

 

 

 

 

 

 

 

 

235

 

Additions charged to cost and expense

 

2449

 

 

 

7,282

 

 

 

9,819

 

Deductions/effect of exchange rate fluctuations

 

 

(6,111

)

 

 

(3,293

)

 

 

(1,913

)

Closing balance

 

$

11,530

 

 

$

15,519

 

 

$

23,660

 

 

Accounts receivable were $630,784 and $716,745, and reserves for doubtful receivables were $15,519 and $23,660, resulting in net accounts receivable balances of $615,265 and $693,085 as of December 31, 2016 and 2017, respectively. In addition, accounts receivable due after one year amounting to $3,272 and $1,624 as of December 31, 2016 and 2017, respectively, are included under other assets in the consolidated balance sheets.

Accounts receivable from related parties were $2,490 and $36 as of December 31, 2016 and 2017, respectively. There are no doubtful receivables in amounts due from related parties.

 

 

F-26


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

6. Fair Value Measurements

The Company measures certain financial assets and liabilities, including derivative instruments, at fair value on a recurring basis. The fair value measurements of these financial assets and liabilities were determined using the following inputs as of December 31, 2016 and 2017:

 

 

 

As of December 31, 2016

 

 

 

 

 

 

 

Fair Value Measurements at Reporting Date Using

 

 

 

 

 

 

 

Quoted Prices in

Active Markets for

Identical Assets

 

 

Significant Other

Observable

Inputs

 

 

Significant Other

Unobservable

Inputs

 

 

 

Total

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Derivative instruments (Notes a, c)

 

$

55,386

 

 

$

 

 

$

55,386

 

 

$

 

Total

 

$

55,386

 

 

$

 

 

$

55,386

 

 

$

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earn-out consideration (Notes b, d)

 

$

22,435

 

 

$

 

 

$

 

 

$

22,435

 

Derivative instruments (Notes b, c)

 

 

17,353

 

 

 

 

 

 

17,353

 

 

 

 

Total

 

$

39,788

 

 

$

 

 

$

17,353

 

 

$

22,435

 

Redeemable non-controlling interest

   (Note e)

 

$

4,520

 

 

$

 

 

$

 

 

$

4,520

 

 

 

 

As of December 31, 2017

 

 

 

 

 

 

 

Fair Value Measurements at Reporting Date Using

 

 

 

 

 

 

 

Quoted Prices in

Active Markets for

Identical Assets

 

 

Significant Other

Observable

Inputs

 

 

Significant Other

Unobservable

Inputs

 

 

 

Total

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Derivative instruments (Notes a, c)

 

$

73,098

 

 

$

 

 

$

73,098

 

 

$

 

Total

 

$

73,098

 

 

$

 

 

$

73,098

 

 

$

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earn-out consideration (Notes b, d)

 

$

24,732

 

 

$

 

 

$

 

 

$

24,732

 

Derivative instruments (Notes b, c)

 

 

18,188

 

 

 

 

 

 

18,188

 

 

 

 

Total

 

$

42,920

 

 

$

 

 

$

18,188

 

 

$

24,732

 

Redeemable non-controlling interest

   (Note e)

 

$

4,750

 

 

$

 

 

$

 

 

$

4,750

 

 

 

(a)

Included in prepaid expenses and other current assets and other assets in the consolidated balance sheets.

(b)

Included in accrued expenses and other current liabilities and other liabilities in the consolidated balance sheets.

(c)

The Company values its derivative instruments based on market observable inputs, including both forward and spot prices for the relevant currencies and interest rate indices for relevant interest rates. The quotes are taken from an independent market database.

(d)

The fair value of earn-out consideration, calculated as the present value of expected future payments to be made to the sellers of acquired businesses, was derived by estimating the future financial performance of the acquired businesses using the earn-out formula and performance targets specified in each purchase agreement and adjusting the result to reflect the Company’s estimate of the likelihood of achievement of such targets. Given the significance of the unobservable inputs, the valuations are classified in level 3 of the fair value hierarchy.

F-27


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

6. Fair Value Measurements (continued)

(e)

The Company’s estimate of the fair value of redeemable non-controlling interest as of December 31, 2017 is based on unobservable inputs considering the assumptions that market participants would make in pricing the obligation. Given the significance of the unobservable inputs, the valuation was classified in level 3 of the fair value hierarchy. Refer to Note 3—Business Acquisitions.

 

The following table provides a roll-forward of the fair value of earn-out consideration categorized as level 3 in the fair value hierarchy for the years ended December 31, 2016 and 2017:

 

 

 

As of December 31

 

 

2016

 

 

2017

 

 

Opening balance

 

$

22,820

 

 

$

22,435

 

 

Earn-out consideration payable in

   connection with acquisitions

 

 

14,550

 

 

 

10,720

 

 

Payments made of earn-out

   consideration

 

 

(1,611

)

 

 

(7,239

)

 

Change in fair value (note a)

 

 

(14,869

)

 

 

(3,695

)

 

Other (note b)

 

 

1,545

 

 

 

2,511

 

 

Ending balance

 

$

22,435

 

 

$

24,732

 

 

 

(a)

Changes in the fair value of earn-out consideration are reported in other operating (income) expense, net in the consolidated statements of income.

 

(b)

Interest expense is included in interest income (expense), net and the impact of changes in foreign exchange is reported in foreign exchange gains (losses), net in the consolidated statements of income. The cumulative translation adjustment is reported as a component of other comprehensive income (loss).

 

7. Derivative financial instruments

The Company is exposed to the risk of rate fluctuations on foreign currency assets and liabilities and on foreign currency denominated forecasted cash flows. The Company has established risk management policies, including the use of derivative financial instruments to hedge foreign currency assets and liabilities and foreign currency denominated forecasted cash flows and interest rate risks. These derivative financial instruments are largely deliverable and non-deliverable forward foreign exchange contracts and interest rate swaps. The Company enters into these contracts with counterparties that are banks or other financial institutions, and the Company considers the risk of non-performance by such counterparties not to be material. The forward foreign exchange contracts and interest rate swaps mature over periods of up to 60 months and the forecasted transactions are expected to occur during the same periods.

F-28


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

7. Derivative financial instruments (Continued)

 

The following table presents the aggregate notional principal amounts of outstanding derivative financial instruments together with the related balance sheet exposure:

 

 

 

Notional principal amounts

(note a)

 

 

Balance sheet exposure asset

(liability)  (note b)

 

 

 

As of

December 31,

2016

 

 

As of

December 31,

2017

 

 

As of

December 31,

2016

 

 

As of

December 31,

2017

 

Foreign exchange forward contracts

   denominated in:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

United States Dollars (sell) Indian Rupees (buy)

 

$

1,108,400

 

 

$

1,289,400

 

 

$

6,669

 

 

$

54,398

 

United States Dollars (sell) Mexican Peso (buy)

 

 

9,120

 

 

 

9,000

 

 

 

(187

)

 

 

(441

)

United States Dollars (sell) Philippines Peso (buy)

 

 

70,050

 

 

 

76,650

 

 

 

(1,036

)

 

 

69

 

Euro (sell) United States Dollars (buy)

 

 

138,613

 

 

 

170,542

 

 

 

9,180

 

 

 

(2,069

)

Pound Sterling (buy) United States Dollars (sell)

 

 

 

 

 

24,041

 

 

 

 

 

 

253

 

Euro (sell) Romanian Leu (buy)

 

 

29,805

 

 

 

35,826

 

 

 

(152

)

 

 

(892

)

Japanese Yen (sell) Chinese Renminbi (buy)

 

 

77,267

 

 

 

60,768

 

 

 

(742

)

 

 

1,918

 

Pound Sterling (sell) United States Dollars (buy)

 

 

104,142

 

 

 

80,871

 

 

 

14,228

 

 

 

(2,478

)

Australian Dollars (sell) United States Dollars

   (buy)

 

 

114,412

 

 

 

136,092

 

 

 

2,328

 

 

 

(5,180

)

Interest rate swaps (floating to fixed)

 

 

456,810

 

 

 

432,117

 

 

 

7,746

 

 

 

9,332

 

 

 

 

 

 

 

 

 

 

 

$

38,034

 

 

$

54,910

 

 

(a)

Notional amounts are key elements of derivative financial instrument agreements but do not represent the amount exchanged by counterparties and do not measure the Company’s exposure to credit, foreign exchange, interest rate or other market risks. However, the amounts exchanged are based on the notional amounts and other provisions of the underlying derivative financial instrument agreements.

(b)

Balance sheet exposure is denominated in U.S. dollars and denotes the mark-to-market impact of the derivative financial instruments on the reporting date.

FASB guidance on derivatives and hedging requires companies to recognize all derivative instruments as either assets or liabilities at fair value in the Balance Sheet. In accordance with the FASB guidance on derivatives and hedging, the Company designates foreign exchange forward contracts and interest rate swaps as cash flow hedges. Foreign exchange forward contracts are entered into to cover the effects of future exchange rate variability on forecasted revenue and purchases of services, and interest rate swaps are entered into to cover interest rate fluctuation risk. In addition to this program, the Company uses derivative instruments that are not accounted for as hedges under the FASB guidance in order to hedge foreign exchange risks related to balance sheet items, such as receivables and intercompany borrowings, that are denominated in currencies other than the Company’s underlying functional currency.

F-29


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

7. Derivative financial instruments (Continued)

 

The fair values of the Company’s derivative instruments and their location in the Company’s financial statements are summarized in the table below:

 

 

 

Cash flow hedges

 

 

Non-designated

 

 

 

As of

December 31, 2016

 

 

As of

December 31, 2017

 

 

As of

December 31, 2016

 

 

As of

December 31, 2017

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Prepaid expenses and other

   current assets

 

$

33,921

 

 

$

43,557

 

 

$

809

 

 

$

4,635

 

Other assets

 

$

20,657

 

 

$

24,906

 

 

$

 

 

$

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accrued expenses and other

   current liabilities

 

$

4,540

 

 

$

10,092

 

 

$

237

 

 

$

254

 

Other liabilities

 

$

12,576

 

 

$

7,842

 

 

$

 

 

$

 

 

Cash flow hedges

For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of the gain (loss) on the derivative instrument is reported as a component of other comprehensive income (loss) and reclassified into earnings in the same period or periods during which the hedged transaction is recognized in the consolidated statements of income. Gains (losses) on the derivatives, representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness, are recognized in earnings as incurred.

In connection with cash flow hedges, the gains (losses) recorded as a component of other comprehensive income (loss), or OCI, and the related tax effects are summarized below:

 

 

 

Year ended December 31,

 

 

 

2015

 

 

2016

 

 

2017

 

 

 

Before-

Tax

amount

 

 

Tax

(Expense)

or

Benefit

 

 

Net of

tax

Amount

 

 

Before-

Tax

amount

 

 

Tax

(Expense)

or

Benefit

 

 

Net of

tax

Amount

 

 

Before-

Tax

amount

 

 

Tax

(Expense)

or

Benefit

 

 

Net of

tax

Amount

 

Opening balance

 

$

(66,786

)

 

$

23,646

 

 

$

(43,140

)

 

$

(30,090

)

 

$

9,830

 

 

$

(20,260

)

 

$

37,461

 

 

$

(13,979

)

 

$

23,482

 

Net gains (losses)

   reclassified into

   statement of  income

   on completion of

   hedged transactions

 

 

(42,106

)

 

 

15,346

 

 

 

(26,760

)

 

 

(6,799

)

 

 

409

 

 

 

(6,390

)

 

 

54,494

 

 

 

(17,725

)

 

 

36,769

 

Changes in fair value of

   effective portion of

   outstanding

   derivatives, net

 

 

(5,410

)

 

 

1,530

 

 

 

(3,880

)

 

 

60,752

 

 

 

(23,400

)

 

 

37,352

 

 

 

67,562

 

 

 

(18,182

)

 

 

49,380

 

Gain (loss) on cash flow

   hedging derivatives,

   net

 

 

36,696

 

 

 

(13,816

)

 

 

22,880

 

 

 

67,551

 

 

 

(23,809

)

 

 

43,742

 

 

 

13,068

 

 

 

(457

)

 

 

12,611

 

Closing balance

 

$

(30,090

)

 

$

9,830

 

 

$

(20,260

)

 

$

37,461

 

 

$

(13,979

)

 

$

23,482

 

 

$

50,529

 

 

$

(14,436

)

 

$

36,093

 

 

 

F-30


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

7. Derivative financial instruments (Continued)

 

The gains or losses recognized in other comprehensive income (loss) and their effects on financial performance are summarized below:

 

Derivatives in Cash Flow Hedging Relationships

Amount of Gain (loss)

recognized in OCI on

Derivatives (Effective

Portion)

 

 

 

Location of Gain

(loss)

reclassified from

OCI into

Statement of

Income

(Effective

Portion)

 

Amount of Gain (loss)

reclassified from OCI into

Statement of Income

(Effective Portion)

 

 

Year ended December 31,

 

 

 

 

 

Year ended December 31,

 

 

2015

 

 

2016

 

 

2017

 

 

 

 

 

2015

 

 

2016

 

 

2017

 

Forward foreign

   exchange contracts

$

(5,410

)

 

$

54,664

 

 

$

66,037

 

 

 

Revenue

 

$

13,667

 

 

$

12,859

 

 

$

5,858

 

Interest rate swaps

$

 

 

$

6,088

 

 

$

1,525

 

 

 

Cost of revenue

 

$

(44,634

)

 

$

(14,223

)

 

$

37,849

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and

administrative

expenses

 

$

(11,139

)

 

$

(3,765

)

 

$

10,849

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

$

 

 

$

(1,670

)

 

$

(62

)

 

$

(5,410

)

 

$

60,752

 

 

$

67,562

 

 

 

 

 

$

(42,106

)

 

$

(6,799

)

 

$

54,494

 

 

Gain (loss) recognized in income on the ineffective portion of derivatives and the amount excluded from effectiveness testing is $0 as of December 31, 2015, 2016 and 2017.

 

Non-designated Hedges

 

Derivatives not designated as

hedging instruments

 

Location of Gain (Loss) recognized in Statement of

Income on Derivatives

 

Amount of Gain (Loss)

recognized in Statement of

Income on Derivatives

 

 

 

 

 

Year ended December 31,

 

 

 

 

 

2015

 

 

2016

 

 

2017

 

Forward foreign exchange contracts (Note a)

 

Foreign exchange gains (losses), net

 

$

6,566

 

 

$

2,921

 

 

$

16,696

 

 

 

 

 

$

6,566

 

 

$

2,921

 

 

$

16,696

 

 

(a)

These forward foreign exchange contracts were entered into to hedge fluctuations in foreign exchange rates for recognized balance sheet items, such as receivables and intercompany borrowings, and were not originally designated as hedges under FASB guidance on derivatives and hedging. Realized gains (losses) and changes in the fair value of these derivatives are recorded in foreign exchange gains (losses), net in the consolidated statements of income.

 

 

F-31


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

8. Prepaid expenses and other current assets

Prepaid expenses and other current assets consist of the following:

 

 

 

As of December 31,

 

 

 

2016

 

 

2017

 

Advance income and non-income taxes

 

$

50,676

 

 

$

51,832

 

Deferred transition costs

 

 

45,252

 

 

 

62,029

 

Derivative instruments

 

 

34,730

 

 

 

48,192

 

Prepaid expenses

 

 

22,222

 

 

 

16,944

 

Customer acquisition cost

 

 

11,126

 

 

 

19,327

 

Employee advances

 

 

6,880

 

 

 

5,014

 

Deposits

 

 

2,688

 

 

 

4,719

 

Advances to suppliers

 

 

10,059

 

 

 

2,705

 

Others

 

 

5,516

 

 

 

25,580

 

 

 

$

189,149

 

 

$

236,342

 

 

 

 

 

F-32


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

9. Property, plant and equipment, net

Property, plant and equipment, net consist of the following:

 

 

 

 

As of December 31,

 

 

 

2016

 

 

2017

 

Land

 

$

9,635

 

 

$

10,209

 

Buildings

 

 

44,487

 

 

 

46,007

 

Furniture and fixtures

 

 

37,421

 

 

 

43,091

 

Computer equipment and servers

 

 

187,119

 

 

 

210,725

 

Plant, machinery and equipment

 

 

84,677

 

 

 

92,981

 

Computer software

 

 

119,648

 

 

 

137,459

 

Leasehold improvements

 

 

92,313

 

 

 

102,072

 

Vehicles

 

 

6,753

 

 

 

6,418

 

Capital work in progress

 

 

18,501

 

 

 

17,069

 

Property, plant and equipment, gross

 

$

600,554

 

 

$

666,031

 

Less: accumulated depreciation, amortization and impairment

 

 

(407,336

)

 

 

(459,001

)

Property, plant and equipment, net

 

$

193,218

 

 

$

207,030

 

 

Depreciation expense on property, plant and equipment for the years ended December 31, 2015, 2016 and 2017 was $47,673, $45,826 and $44,909, respectively. Software amortization for the years ended December 31, 2015, 2016 and 2017 amounted to $9,114, $9,471 and $11,400, respectively.

The depreciation and amortization expenses set forth above include the effect of the reclassification of foreign exchange (gains) losses related to the effective portion of foreign currency derivative contracts, amounting to $2,501, $744 and $(1,727) for the years ended December 31, 2015, 2016 and 2017, respectively.

Property, plant and equipment, net include assets held under capital lease arrangements amounting to $3,183 and $3,302 as of December 31, 2016 and December 31, 2017, respectively. Depreciation expense in respect of these assets was $1,594, $1,564 and $1,682 for the years ended December 31, 2015, 2016 and 2017, respectively.

During the year ended December 31, 2017, the Company tested for recoverability a group of assets, comprised of computer software and a technology-related intangible asset, as a result of a downward revision to the forecasted cash flows to be generated by this group of assets. Based on the results of its testing, the Company determined that the carrying value of the group of assets exceeded the estimated undiscounted cash flows and the Company recorded an $8,000 write-down to reduce the carrying value to its fair value. The Company used the income approach to determine the fair value of the group of assets for the purpose of calculating the charge. This write-down has been recorded in other operating (income) expenses, net in the consolidated statement of income and has been allocated to computer software and technology-related intangible assets, amounting to $5,760 and $2,240, respectively.

 

 

 

F-33


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

10. Goodwill and intangible assets

The following table presents the changes in goodwill for the years ended December 31, 2016 and 2017:

 

 

 

As of December 31,

 

 

 

2016

 

 

2017

 

Opening balance

 

$

1,038,346

 

 

$

1,069,408

 

Goodwill relating to acquisitions consummated during the period

 

 

51,535

 

 

 

229,745

 

Goodwill relating to divestitures during the period

 

 

(2,226

)

 

 

 

Impact of measurement period adjustments

 

 

(59

)

 

 

(106

)

Effect of exchange rate fluctuations

 

 

(18,188

)

 

 

38,075

 

Closing balance

 

$

1,069,408

 

 

$

1,337,122

 

 

Goodwill has been allocated to the following reporting units, which represent different business units of the Company, as follows:

 

 

 

As of December 31,

 

 

 

2016

 

 

2017

 

India

 

$

493,084

 

 

$

735,596

 

China

 

 

58,139

 

 

 

60,171

 

Europe

 

 

36,584

 

 

 

41,775

 

Americas

 

 

48,713

 

 

 

57,021

 

IT services

 

 

432,888

 

 

 

442,559

 

 

 

$

1,069,408

 

 

$

1,337,122

 

 

In the year ended December 31, 2017, in accordance with ASU 2011-08, the Company performed an assessment of qualitative factors to determine whether events or circumstances exist that may lead to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Based on such assessment, as at December 31, 2017, the Company concluded that it is not more likely than not that the fair values of all of the Company’s reporting units are less than their carrying amounts.

 

In the year ended December 31, 2016, in accordance with ASU 2011-08, the Company performed an assessment of qualitative factors to determine whether events or circumstances exist that may lead to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Based on its assessment, the Company concluded that it is not more likely than not that the fair value of any of the Company’s reporting units is less than its carrying amount other than its IT services reporting unit, primarily due to a decline in planned revenues. Accordingly, the Company performed a quantitative assessment of goodwill impairment for its IT services reporting unit. Based on such quantitative assessment, the Company concluded that no impairment is warranted for the year ended December 31, 2016 and that the fair value of its IT services reporting unit substantially exceeded its carrying value as of December 31, 2016.

 

F-34


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

10. Goodwill and intangible assets (Continued)

 

The total amount of the Company’s goodwill deductible for tax purposes is $39,032 and $120,617 as of December 31, 2016 and 2017, respectively.

The Company’s intangible assets acquired either individually or with a group of other assets or in a business combination are as follows:

 

 

 

As of December 31, 2016

 

 

As of December 31, 2017

 

 

 

Gross carrying

amount

 

 

Accumulated

amortization &

Impairment

 

 

Net

 

 

Gross carrying

amount

 

 

Accumulated

amortization &

Impairment

 

 

Net

 

Customer-related

   intangible assets

 

$

312,041

 

 

$

260,018

 

 

$

52,023

 

 

$

369,173

 

 

$

293,029

 

 

$

76,144

 

Marketing-related

   intangible assets

 

 

45,098

 

 

 

30,571

 

 

 

14,527

 

 

 

52,443

 

 

 

39,212

 

 

 

13,231

 

Technology-related

   intangible assets

 

 

26,116

 

 

 

21,026

 

 

 

5,090

 

 

 

54,189

 

 

 

28,278

 

 

 

25,911

 

Other intangible

   assets

 

 

2,875

 

 

 

2,466

 

 

 

409

 

 

 

3,081

 

 

 

2,314

 

 

 

767

 

Intangible assets

   under development

 

 

6,897

 

 

 

 

 

 

6,897

 

 

 

15,537

 

 

 

 

 

 

15,537

 

 

 

$

393,027

 

 

$

314,081

 

 

$

78,946

 

 

$

494,423

 

 

$

362,833

 

 

$

131,590

 

Amortization expenses for intangible assets disclosed in the Consolidated Statements of Income under amortization of acquired intangible assets for the years ended December 31, 2015, 2016 and 2017 were $28,513, $27,183 and $36,412, respectively.

Amortization expenses for technology-related internally developed intangible assets disclosed in the consolidated statements of income under cost of revenue and selling, general and administrative expense for the years ended December 31, 2015, 2016 and 2017 were $0, $0 and $467, respectively.

 

 During the year ended December 31, 2017, the Company tested a customer-related intangible asset for recoverability as a result of the termination of a client contract. Based on the results of such testing, the Company recorded a $1,311 write-down to reduce the amount of the asset’s total carrying value. The Company used the income approach to determine the fair value of the intangible asset for the purpose of calculating the resulting charge. This write-down has been recorded in other operating (income) expenses, net in the consolidated statement of income. During the year ended December 31, 2017, the Company also recorded a write-down to a technology-related intangible asset as described in note 9.

 

During the year ended December 31, 2016, the Company tested an intangible software asset for recoverability as a result of a downward revision to the forecasted cash flows to be generated by the intangible asset. The Company previously recorded a charge to this asset in the third quarter of 2015. Based on the results of its testing, the Company determined that the carrying value of the intangible asset exceeded its estimated undiscounted cash flows by $10,324 and recorded an additional write-down to further reduce the carrying value by this amount. The Company used the income approach to determine the fair value of the intangible asset for the purpose of calculating the charge. This write-down had been recorded in other operating (income) expenses, net in the consolidated statement of income. During the year ended December 31, 2016, the Company also tested a customer-related intangible asset for recoverability as a result of the termination of a client contract. Based on results of such testing, the Company recorded an $871 write-down in the amount of the asset’s total carrying value. The Company used the income approach to determine the fair value of the intangible asset for the purpose of calculating the resulting charge. This write-down had been recorded in other operating (income) expenses, net in the consolidated statement of income.

 

F-35


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

10. Goodwill and intangible assets (Continued)

 

The estimated amortization schedule for the Company’s intangible assets for future periods is set out below:

 

For the year ending December 31:

 

 

 

 

2018

 

$

38,569

 

2019

 

 

27,518

 

2020

 

 

26,831

 

2021

 

 

13,080

 

2022 and beyond

 

 

25,592

 

 

 

$

131,590

 

 

 

11. Other assets

Other assets consist of the following:

 

 

 

As of December 31,

 

 

 

2016

 

 

2017

 

Customer acquisition cost

 

$

30,996

 

 

$

37,017

 

Advance income and non-income taxes

 

 

60,203

 

 

 

63,474

 

Deferred transition costs

 

 

74,462

 

 

 

77,255

 

Deposits

 

 

29,853

 

 

 

32,174

 

Derivative instruments

 

 

20,657

 

 

 

24,906

 

Prepaid expenses

 

 

3,179

 

 

 

2,849

 

Accounts receivable due after one year

 

 

3,272

 

 

 

1,624

 

Others

 

 

19,706

 

 

 

22,870

 

 

 

$

242,328

 

 

$

262,169

 

 

 

12. Leases

The Company has leased vehicles, furniture and fixtures, computer equipment and servers, and plants, machinery and equipment from various lessors under capital lease arrangements which are not material to the consolidated financial statements.

The Company conducts its operations using facilities under non-cancellable operating lease agreements that expire at various dates. Future minimum lease payments under these agreements are as follows:

 

As of December 31:

 

 

 

 

2018

 

$

59,269

 

2019

 

 

54,844

 

2020

 

 

47,788

 

2021

 

 

43,692

 

2022

 

 

38,275

 

2023 and beyond

 

 

122,150

 

Total minimum lease payments

 

$

366,018

 

 

Rental expenses in agreements with rent holidays and scheduled rent increases are recorded on a straight-line basis over the applicable lease term. Rent expenses under cancellable and non-cancellable operating leases were $50,342, $50,827 and $59,484 for the years ended December 31, 2015, 2016 and 2017, respectively.

The rental expenses set out above include the effect of the reclassification of foreign exchange (gains) losses related to the effective portion of foreign currency derivative contracts amounting to $2,037, $598 and $(1,533) for the years ended December 31, 2015, 2016 and 2017, respectively.

F-36


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

 

 

13. Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consist of the following:

 

 

 

As of December 31,

 

 

 

2016

 

 

2017

 

Accrued expenses

 

$

163,400

 

 

$

204,997

 

Accrued employee cost

 

 

179,360

 

 

 

204,506

 

Deferred transition revenue

 

 

50,552

 

 

 

52,233

 

Statutory liabilities

 

 

36,878

 

 

 

36,283

 

Retirement benefits

 

 

17,616

 

 

 

21,074

 

Derivative instruments

 

 

4,777

 

 

 

10,346

 

Advance from customers

 

 

21,969

 

 

 

25,476

 

Earn-out consideration

 

 

6,885

 

 

 

14,928

 

Other liabilities

 

 

15,461

 

 

 

13,093

 

Capital lease obligations

 

 

1,349

 

 

 

1,546

 

 

 

$

498,247

 

 

$

584,482

 

 

 

14. Long-term debt

In June 2015, the Company refinanced its 2012 facility through a new credit facility comprised of an $800,000 term loan and a $350,000 revolving credit facility. Borrowings under the new facility bear interest at a rate equal to, at the election of the Company, either LIBOR plus a margin of 1.50% per annum or a base rate plus a margin of 0.50% per annum, in each case subject to adjustment based on the Company’s debt ratings provided by Standard & Poor’s Rating Services and Moody’s Investors Service, Inc. Based on the Company’s election and current credit rating, the applicable interest rate is equal to LIBOR plus 1.50% per annum. As a result of the June 2015 refinancing, the gross outstanding term loan under the previous facility, which amounted to $663,188 as of June 30, 2015, was extinguished, and the Company expensed $10,050, representing accelerated amortization of the existing unamortized debt issuance costs related to the prior facility. Additionally, the refinancing of the revolving facility resulted in the accelerated amortization of $65 relating to the existing unamortized debt issuance cost. The remaining unamortized costs for the revolving facility, together with the fees paid to the Company’s lenders and third parties in connection with the new term loan and revolving facility, will be amortized over the term of the refinanced facility, which ends on June 30, 2020. For the year ended 2017, the Company was in compliance with the financial covenants.

As of December 31, 2016 and December 31, 2017, the amount outstanding under the Company’s term loan, net of debt amortization expense of $2,667 and $1,848, was $737,333 and $698,152, respectively.  As of December 31, 2016 and December 31, 2017, the term loan bore interest at a rate equal to LIBOR plus a margin of 1.50% per annum based on the Company’s election and then current credit rating. Indebtedness under the refinanced facility is unsecured. The amount outstanding on the term loan as of December 31, 2017 will be repaid through quarterly payments of $10,000, and the balance will be repaid upon the maturity of the term loan on June 30, 2020.

The maturity profile of the term loan, net of debt amortization expense, is as follows:

 

Year ended

 

Amount

 

2018

 

$

39,226

 

2019

 

 

39,272

 

2020

 

 

619,654

 

Total

 

$

698,152

 

 

F-37


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

14. Long-term debt (Continued)

In March 2017, the Company issued $350,000 aggregate principal amount of 3.70% senior notes in a private offering, resulting in cash proceeds of approximately $348,519, net of an underwriting fee of $1,481. In connection with the offering, the Company incurred other debt issuance costs of $1,161. The total debt issuance cost of $2,642 is being amortized over the life of the notes as additional interest expense. As of December 31, 2017, the amount outstanding under the notes, net of debt amortization expense of $2,239, was $347,761, which is payable on April 1, 2022. The Company will pay interest on the notes semi-annually in arrears on April 1 and October 1 of each year, ending on the maturity date of April 1, 2022. The Company, at its option, may redeem the notes at any time in whole or in part, at a redemption price equal to (i) 100% of the principal amount of the notes redeemed, together with accrued and unpaid interest on the redeemed amount, and (ii) if the notes are redeemed prior to March 1, 2022, a specified “make-whole” premium. The notes are subject to certain customary covenants, including limitations on the ability of the Company and certain of its subsidiaries to incur debt secured by liens, engage in certain sale and leaseback transactions and consolidate, merge, convey or transfer their assets. Upon certain change of control transactions, the Company will be required to make an offer to repurchase the notes at a price equal to 101% of the aggregate principal amount of such notes, plus accrued and unpaid interest.  The interest rate payable on the notes is subject to adjustment if the credit rating of the notes is downgraded up to a maximum increase of 2.0%. The Company is required to offer to exchange the notes for registered notes or have one or more shelf registration statements declared effective within 455 days after the issue date of the notes and, if such exchange offer fails to be consummated or such registration statement fails to be effective by June 25, 2018, then the interest payable on the notes will increase by 0.25% per annum during the 90-day period immediately following such date and will further increase by 0.25% per annum at the end of each subsequent 90-day period up to a maximum increase of 0.50%. The notes are senior unsecured obligations of the Company and will rank equally with all other senior unsecured indebtedness of the Company outstanding from time to time.

 

15. Short-term borrowings

The Company has the following borrowing facilities:

 

(a)

Fund-based and non-fund-based credit facilities with banks, which are available for operational requirements in the form of overdrafts, letters of credit, guarantees and short-term loans. As of December 31, 2016 and December 31, 2017, the limits available were $15,382 and $15,064, respectively, of which $10,980 and $7,900 was utilized, constituting non-funded drawdown.

 

(b)

A fund-based and non-fund based revolving credit facility of $350,000, which the Company obtained in June 2015 as described in note 14. This facility replaces the Company’s $250,000 facility initially entered into in August 2012 and subsequently amended in June 2013. As of December 31, 2016 and December 31, 2017, a total of $160,978 and $170,978 respectively, was utilized, of which $160,000 and $170,000, respectively, constituted funded drawdown and $978 and $978, respectively, constituted non-funded drawdown. The revolving facility expires in June 2020. The funded drawdown amount bore interest at a rate equal to LIBOR plus a margin of 1.50% as of December 31, 2016. As of December 31, 2017, the revolving facility bore interest at a rate equal to LIBOR plus a margin of 1.50% per annum. The unutilized amount on the revolving facility bore a commitment fee of 0.25% and 0.25% as of December 31, 2016 and December 31, 2017, respectively. The credit agreement contains certain customary covenants, including a maximum leverage covenant and a minimum interest coverage ratio. During the year ended December 31, 2017, the Company was in compliance with the financial covenants.

 

 

F-38


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

16. Other liabilities

Other liabilities consist of the following:

 

 

 

As of December 31,

 

 

 

2016

 

 

2017

 

Accrued employee cost

 

$

3,976

 

 

$

14,020

 

Deferred transition revenue

 

 

72,560

 

 

 

70,900

 

Retirement benefits

 

 

39,020

 

 

 

40,520

 

Derivative instruments

 

 

12,576

 

 

 

7,842

 

Amount received from GE under

   indemnification arrangement, pending

   adjustment

 

 

3,159

 

 

 

3,359

 

Advance from customers

 

 

2,371

 

 

 

790

 

Earn-out consideration

 

 

15,550

 

 

 

9,804

 

Others

 

 

11,078

 

 

 

18,710

 

Capital lease obligations

 

 

2,500

 

 

 

2,664

 

 

 

$

162,790

 

 

$

168,609

 

 

 

17. Employee benefit plans

The Company has employee benefit plans in the form of certain statutory and other schemes covering its employees.

Defined benefit plans

In accordance with Indian law, the Company provides a defined benefit retirement plan (the “Gratuity Plan”) covering substantially all of its Indian employees. The Gratuity Plan provides a lump-sum payment to vested employees upon retirement or termination of employment in an amount based on each employee’s salary and duration of employment with the Company. The Gratuity Plan benefit cost for the year is calculated on an actuarial basis. The Company contributes the required funding for all ascertained liabilities to the Gratuity Plan. Trustees administer contributions made to the trust, and contributions are invested in specific designated instruments as permitted by Indian law. The Company’s overall investment strategy is to invest predominantly in fixed income funds managed by asset management companies. These funds further invest in debt securities such as money market instruments, government securities and public and private bonds. During the years ended December 31, 2015, 2016 and 2017, all of the plan assets were primarily invested in debt securities.

In addition, in accordance with Mexican law, the Company provides certain termination benefits (the “Mexican Plan”) to all of its Mexican employees based on the age, duration of service and salary of each eligible employee. The full-year benefit cost of the Mexican Plan is calculated on an actuarial basis.

In addition, certain of the Company’s subsidiaries organized or operating in the Philippines and Japan have sponsored defined benefit retirement programs (respectively, the “Philippines Plan” and the “Japan Plan”). The full-year benefit costs of the Japan Plan and the Philippines Plan are calculated on an actuarial basis. Company contributions in respect of these plans are made to insurer-managed funds or to a trust. The trust contributions are further invested in government bonds.

In addition, in accordance with Israeli law, the Company provides certain termination benefits (the “Israeli Plan”) to all of its Israeli employees based on the age, duration of service and salary of each eligible employee. The full-year benefit cost of the Israeli Plan is calculated on an actuarial basis.

Current service costs for defined benefit plans are accrued in the year to which they relate on a monthly basis. Actuarial gains or losses, or prior service costs, if any, resulting from amendments to the plans are recognized and amortized over the remaining period of service of the employees or over the average remaining life expectancies for inactive employees if most of the plan obligations are payable to inactive employees.

F-39


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

17. Employee benefit plans (Continued)

The following table sets forth the funded status of the Company’s defined benefit plans and the amounts recognized in the Company’s financial statements based on actuarial valuations carried out as of December 31, 2016 and 2017.

 

 

As of December 31,

 

 

2016

 

 

2017

 

Change in benefit obligation

 

 

 

 

 

 

 

Projected benefit obligation at the

   beginning of the year

$

35,617

 

 

$

45,283

 

Service cost

 

5,661

 

 

 

7,735

 

Actuarial loss

 

6,749

 

 

 

4,493

 

Interest cost

 

2,585

 

 

 

3,252

 

Liabilities assumed on acquisition

 

693

 

 

 

 

 

Benefits paid

 

(4,967

)

 

 

(5,367

)

Special termination benefit

-

 

 

 

57

 

Effect of exchange rate changes

 

(1,055

)

 

 

2,641

 

Projected benefit obligation at the

   end of the year

$

45,283

 

 

$

58,094

 

Change in fair value of plan

   assets

 

 

 

 

 

 

 

Fair value of plan assets at the

   beginning of  the year

$

28,549

 

 

$

30,871

 

Employer contributions

 

5,776

 

 

 

15,176

 

Actual gain on plan assets

 

1,777

 

 

 

2,746

 

Assets assumed on acquisition

 

170

 

 

 

0

 

Actuarial gain

 

 

 

 

11

 

Benefits paid

 

(4,897

)

 

 

(5,301

)

Effect of exchange rate changes

 

(504

)

 

 

2,057

 

Fair value of plan assets at the end

   of the year

$

30,871

 

 

$

45,560

 

 

Amounts included in other comprehensive income (loss) as of December 31, 2016 and 2017 were as follows:

 

 

As of December 31,

 

 

2016

 

 

2017

 

Net actuarial loss

 

(8,979

)

 

 

(12,228

)

Deferred tax assets

 

2,759

 

 

 

2,221

 

Other comprehensive income, net

 

(6,220

)

 

 

(10,007

)

 

Changes in other comprehensive income (loss) during the year ended December 31, 2017 were as follows:

 

 

2017

 

Net actuarial loss

$

(4,182

)

Amortization of net actuarial loss

 

1,177

 

Deferred income taxes

 

(670

)

One-time cost

 

211

 

Effect of exchange rate changes

 

(323

)

Other comprehensive income (loss), net

$

(3,787

)

 

F-40


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

17. Employee benefit plans (Continued)

 

Net defined benefit plan costs for the years ended December 31, 2015, 2016 and 2017 include the following components:

 

 

Year ended December 31,

 

 

2015

 

 

2016

 

 

2017

 

Service costs

$

5,578

 

 

$

5,661

 

 

$

7,735

 

Interest costs

 

2,629

 

 

 

2,585

 

 

 

3,252

 

Amortization of actuarial loss

 

330

 

 

 

(113

)

 

 

1,177

 

Expected return on plan assets

 

(2,154

)

 

 

(2,043

)

 

 

(2,412

)

One-time cost

 

 

 

 

 

 

 

209

 

Special termination benefits

 

 

 

 

 

 

 

426

 

Net defined benefit plan costs

$

6,383

 

 

$

6,090

 

 

$

10,387

 

 

The amount in other comprehensive loss that is expected to be recognized as a component of net periodic benefit cost over the next fiscal year is $1,353.

The weighted average assumptions used to determine the benefit obligations of the Gratuity Plan as of December 31, 2016 and 2017 are presented below:

 

 

 

As of December 31,

 

 

2016

 

2017

Discount rate

 

7.10% - 7.5%

 

7.40% - 7.60%

Rate of increase in compensation per annum

 

5.20%-11.00%

 

5.20%-11.00%

 

The weighted average assumptions used to determine the Gratuity Plan costs for the years ended December 31, 2015, 2016 and 2017 are presented below:

 

 

 

Year ended December 31,

 

 

 

2015

 

 

2016

 

 

2017

 

Discount rate

 

8.50% - 8.55%

 

 

8.30% - 8.45%

 

 

7.10% - 7.5%

 

Rate of increase in compensation per

   annum

 

5.20% - 11.00%

 

 

5.20% - 11.00%

 

 

5.20% - 11.00%

 

Expected long-term rate of return on plan

   assets per annum

 

8.50%

 

 

7.50%

 

 

7.50%

 

 

The weighted average assumptions used to determine the benefit obligations of the Mexican Plan as of December 31, 2016 and 2017 are presented below:

 

 

 

Year ended December 31,

 

 

 

2016

 

 

2017

 

Discount rate

 

 

6.80

%

 

 

7.60

%

Rate of increase in compensation per annum

 

 

5.50

%

 

 

5.50

%

 

The weighted average assumptions used to determine the costs of the Mexican Plan for the years ended December 31, 2015, 2016 and 2017 are presented below:

 

 

 

Year ended December 31,

 

 

 

2015

 

 

2016

 

 

2017

 

Discount rate

 

 

6.50

%

 

 

6.50

%

 

 

6.80

%

Rate of increase in

   compensation per annum

 

 

5.50

%

 

 

5.50

%

 

 

5.50

%

Expected long-term rate of

   return on plan assets per

   annum

 

 

0.00

%

 

 

0.00

%

 

 

0.00

%

 

F-41


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

17. Employee benefit plans (Continued)

 

The weighted average assumptions used to determine the benefit obligation of the Japan Plan as of December 31, 2016 and 2017 are presented below:

 

 

 

Year ended December 31,

 

 

2016

 

2017

Discount rate

 

0.08% - 1.30%

 

0.113%-0.789%

Rate of increase in compensation

   per annum

 

0.00% - 3.55%

 

0.00% - 3.55%

 

The weighted average assumptions used to determine the costs of the Japan Plan for the years ended December 31, 2015, 2016 and 2017 are presented below:

 

 

 

Year ended December 31,

 

 

2015

 

2016

 

2017

Discount rate

 

0.20% - 1.30%

 

0.24% - 1.30%

 

0.08% - 1.30%

Rate of increase in compensation

   per annum

 

0.00% - 3.55%

 

0.00% - 3.55%

 

0.00% - 3.55%

Expected long-term rate of return

   on plan assets per annum

 

2.69% - 3.44%

 

0.00% - 3.77%

 

0.00% - 3.09%

 

The expected returns on plan assets set forth above are based on the Company’s expectation of the average long-term rate of return expected to prevail over the next 15 to 20 years on the types of investments prescribed by applicable statute.

The Company evaluates these assumptions based on projections of the Company’s long-term growth and prevalent industry standards. Unrecognized actuarial loss is amortized over the average remaining service period of the active employees expected to receive benefits under the plan.

The fair values of the Company’s plan assets as of December 31, 2016 and 2017 by asset category are as follows:

 

 

 

Total

 

 

 

As of December 31, 2017

 

 

 

Fair Value Measurements at Reporting Date Using

 

 

 

 

 

 

 

Quoted Prices in

Active Markets for

Identical Assets

 

 

Significant Other

Observable

Inputs

 

 

Significant Other

Unobservable

Inputs

 

 

 

Total

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

Asset Category

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash

 

$

472

 

 

$

472

 

 

$

 

 

$

 

Fixed income securities (Note a)

 

 

42,328

 

 

 

3,419

 

 

 

38,909

 

 

 

 

Other securities (Note b)

 

 

2,760

 

 

 

2,437

 

 

 

323

 

 

 

 

Total

 

$

45,560

 

 

$

6,328

 

 

$

39,232

 

 

$

 

 

F-42


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

17. Employee benefit plans (Continued)

 

 

 

Total

 

 

 

As of December 31, 2016

 

 

 

Fair Value Measurements at Reporting Date Using

 

 

 

 

 

 

 

Quoted Prices in

Active Markets for

Identical Assets

 

 

Significant Other

Observable

Inputs

 

 

Significant Other

Unobservable

Inputs

 

 

 

Total

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

Asset Category

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash

 

$

4,809

 

 

$

4,809

 

 

$

 

 

$

 

Fixed income securities

   (Note a)

 

 

23,659

 

 

 

3,001

 

 

 

20,658

 

 

 

 

Other securities (Note b)

 

 

2,403

 

 

 

2,191

 

 

 

212

 

 

 

 

Total

 

$

30,871

 

 

$

10,001

 

 

$

20,870

 

 

$

 

 

(a)

Includes investments in funds that invest 100% of their assets in fixed income securities such as money market instruments, government securities and public and private bonds.

(b)

Includes investments in funds that invest primarily in fixed income securities and the remaining portion in equity securities.

The expected benefit plan payments set forth below reflect expected future service:

 

Year ending December 31,

 

 

 

2018

$

8,469

 

2019

 

8,823

 

2020

 

9,330

 

2021

 

9,946

 

2022

 

10,118

 

2023 - 2027

 

48,107

 

 

$

94,793

 

 

The Company’s expected benefit plan payments are based on the same assumptions that were used to measure the Company’s benefit obligations as of December 31, 2017.

Defined contribution plans

During the years ended December 31, 2015, 2016 and 2017, the Company contributed the following amounts to defined contribution plans in various jurisdictions:

 

 

 

Year ended December 31,

 

 

 

2015

 

 

2016

 

 

2017

 

India

 

$

15,915

 

 

$

19,074

 

 

$

22,242

 

U.S.

 

 

8,148

 

 

 

10,379

 

 

 

11,147

 

U.K.

 

 

4,453

 

 

 

6,593

 

 

 

7,823

 

China

 

 

14,511

 

 

 

15,512

 

 

 

15,950

 

Other regions

 

 

4,690

 

 

 

4,684

 

 

 

4,059

 

Total

 

$

47,717

 

 

$

56,242

 

 

$

61,221

 

 

 

18. Stock-based compensation

The Company has issued options under the Genpact Limited 2007 Omnibus Incentive Compensation Plan (the “2007 Omnibus Plan”) and the Genpact Limited 2017 Omnibus Incentive Compensation Plan (the “2017 Omnibus Plan”) to eligible persons, including employees, directors and certain other persons associated with the Company.

F-43


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

 

18. Stock-based compensation (Continued)

Under the 2007 Omnibus Plan, shares underlying options forfeited, expired, terminated or cancelled under any of the Company’s predecessor plans were added to the number of shares otherwise available for grant under the 2007 Omnibus Plan. The 2007 Omnibus Plan was amended and restated on April 11, 2012 to increase the number of common shares authorized for issuance by 5,593,200 shares to 15,000,000 shares.

During the year ended December 31, 2012, the number of common shares authorized for issuance under the 2007 Omnibus Plan was increased by 8,858,823 shares as a result of a one-time adjustment to outstanding unvested share awards in connection with a special dividend payment.

A brief summary of each plan is provided below:

2007 Omnibus Plan

The Company adopted the 2007 Omnibus Plan on July 13, 2007 and amended and restated it on April 11, 2012. The 2007 Omnibus Plan provided for the grant of awards intended to qualify as incentive stock options, non-qualified stock options, share appreciation rights, restricted share awards, restricted share units, performance units, cash incentive awards and other equity-based or equity-related awards. Under the 2007 Omnibus Plan, the Company was authorized to grant awards for the issuance of up to a total of 23,858,823 common shares.

2017 Omnibus Plan

On May 9, 2017, the Company’s shareholders approved the adoption of the Genpact Limited 2017 Omnibus Incentive Compensation Plan (the “2017 Omnibus Plan”), pursuant to which 15,000,000 Company common shares are available for issuance. No grants may be made under the 2007 Omnibus Plan after the date of adoption of the 2017 Omnibus Plan.  Grants that were outstanding under the 2007 Omnibus Plan as of the Company’s adoption of the 2017 Omnibus Plan remain subject to the terms of the 2007 Omnibus Plan.

Stock-based compensation costs relating to the foregoing plans during the years ended December 31, 2015, 2016 and 2017, were $24,684, $24,686 and $35,112, respectively, and have been allocated to cost of revenue and selling, general, and administrative expenses.

Income tax benefits recognized in relation to stock-based compensation charges, excluding excess tax benefits, during the years ended December 31, 2015, 2016 and 2017 were $6,125, $6,446 and $9,600, respectively.

Stock options

All options granted under the 2007 and 2017 Omnibus Plans are exercisable into common shares of the Company, have a contractual period of ten years and vest over four to five years unless specified otherwise in the applicable award agreement. The Company recognizes compensation cost over the vesting period of the option.

F-44


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

18. Stock-based compensation (Continued)

 

Compensation cost is determined at the date of grant by estimating the fair value of an option using the Black-Scholes option-pricing model.

 

The following table shows the significant assumptions used in connection with the determination of the fair value of options granted in 2015, 2016 and 2017:

 

 

 

2015

 

 

2016

 

 

2017

 

Dividend yield

 

 

 

 

 

 

 

 

0.97%

 

Expected life (in months)

 

84

 

 

84

 

 

84

 

Risk-free rate of interest for expected

   life

 

1.99%

 

 

1.42% - 1.56%

 

 

2.25%

 

Volatility

 

34.97%

 

 

25.60% - 27.22%

 

 

24.28%

 

 

Volatility was calculated based on the historical volatility of the Company’s share price during a period equivalent to the estimated term of the option. The Company estimates the expected term of an option using the “simplified method,” which is based on the average of its contractual vesting term. The risk-free interest rate that the Company uses in the option valuation model is based on U.S. Treasury bonds with a term similar to the expected term of the options. The Company did not pay any regular cash dividends in fiscal 2016.  The Company paid a cash dividend of $0.06 per share in each quarter of fiscal 2017.

The Company has issued, and intends to continue to issue, new common shares upon stock option exercises and the vesting of share awards under its equity-based incentive compensation plans.

A summary of stock option activity during the years ended December 31, 2015, 2016 and 2017 is set out below:

 

 

 

Year ended December 31, 2015

 

 

 

Shares arising

out of options

 

 

Weighted

average

exercise price

 

 

Weighted average

remaining

contractual life

(years)

 

 

Aggregate

intrinsic

value

 

Outstanding as of January 1, 2015

 

 

7,371,727

 

 

$

15.44

 

 

 

5.9

 

 

$

 

Granted

 

 

170,000

 

 

 

22.77

 

 

 

 

 

 

 

Forfeited

 

 

(125,000

)

 

 

19.35

 

 

 

 

 

 

 

Expired

 

 

(1,277

)

 

 

14.32

 

 

 

 

 

 

 

Exercised

 

 

(1,428,605

)

 

 

9.49

 

 

 

 

 

 

22,122

 

Outstanding as of December 31, 2015

 

 

5,986,845

 

 

$

16.99

 

 

 

5.8

 

 

$

48,661

 

Vested as of December 31, 2015 and expected

   to vest thereafter (Note a)

 

 

5,754,969

 

 

$

16.76

 

 

 

5.8

 

 

$

47,325

 

Vested and exercisable as of December 31,

   2015

 

 

2,183,846

 

 

$

12.67

 

 

 

2.7

 

 

$

26,892

 

Weighted average grant-date fair value of

   options granted during the period

 

$

9.15

 

 

 

 

 

 

 

 

 

 

 

 

 

 

F-45


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

18. Stock-based compensation (Continued)

 

 

 

Year ended December 31, 2016

 

 

 

Shares arising

out of options

 

 

Weighted

average

exercise price

 

 

Weighted average

remaining

contractual life

(years)

 

 

Aggregate

intrinsic

value

 

Outstanding as of January 1, 2016

 

 

5,986,845

 

 

$

16.99

 

 

 

5.8

 

 

$

 

Granted

 

 

860,000

 

 

 

26.80

 

 

 

 

 

 

 

Forfeited

 

 

(145,000

)

 

 

17.77

 

 

 

 

 

 

 

Expired

 

 

 

 

 

 

 

 

 

 

 

 

Exercised

 

 

(994,155

)

 

 

14.98

 

 

 

 

 

 

9,301

 

Outstanding as of December 31, 2016

 

 

5,707,690

 

 

$

18.65

 

 

 

5.8

 

 

$

34,641

 

Vested as of December 31, 2016 and expected

   to vest thereafter (Note a)

 

 

5,457,701

 

 

$

18.42

 

 

 

5.8

 

 

$

34,150

 

Vested and exercisable as of December 31,

   2016

 

 

2,746,191

 

 

$

15.62

 

 

 

4.0

 

 

$

23,960

 

Weighted average grant-date fair value of

   options granted during the period

 

$

8.50

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 2017

 

 

 

 

Shares arising

out of options

 

 

Weighted

average

exercise price

 

 

Weighted average

remaining

contractual life

(years)

 

 

Aggregate

intrinsic

value

 

Outstanding as of January 1, 2017

 

 

5,707,690

 

 

$

18.65

 

 

 

5.8

 

 

$

 

Granted

 

 

250,000

 

 

 

24.74

 

 

 

 

 

 

 

Forfeited

 

 

(80,000

)

 

 

20.63

 

 

 

 

 

 

 

Expired

 

 

 

 

 

 

 

 

 

 

 

 

Exercised

 

 

(743,045

)

 

 

14.50

 

 

 

 

 

 

12,636

 

Outstanding as of December 31, 2017

 

 

5,134,645

 

 

$

19.52

 

 

 

5.6

 

 

$

62,743

 

Vested as of December 31, 2017 and expected

   to vest thereafter (Note a)

 

 

4,988,875

 

 

$

19.36

 

 

 

5.6

 

 

$

61,779

 

Vested and exercisable as of December 31,

   2017

 

 

2,203,146

 

 

$

16.17

 

 

 

4.1

 

 

$

34,303

 

Weighted average grant-date fair value of

   options granted during the period

 

$

6.62

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(a)

Options expected to vest reflect an estimated forfeiture rate.

Cash received by the Company upon the exercise of stock options amounted to $13,564, $14,896 and $10,772. Cash tax benefits realized by the Company upon the exercise of stock options during the year ended December 31, 2015 and tax benefits from the exercise of stock options during the years ended December 31, 2016 and 2017 were $6,982, $1,548 and $2,016 (including excess tax benefits of $6,560, $1,004, $1,723), respectively.

As of December 31, 2017, the total remaining unrecognized stock-based compensation cost for options expected to vest amounted to $6,479, which will be recognized over the weighted average remaining requisite vesting period of 2.9 years.

Restricted Share Units

The Company has granted restricted share units, or RSUs, under the 2007 and 2017 Omnibus Plans. Each RSU represents the right to receive one common share. The fair value of each RSU is the market price of one common share of the Company on the date of grant. The RSUs granted to date have graded

F-46


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

18. Stock-based compensation (Continued)

vesting schedules of three months to four years. The compensation expense is recognized on a straight-line basis over the vesting term.

 

A summary of RSUs granted during the years ended December 31, 2015, 2016 and 2017 is set out below:

 

 

 

Year ended December 31, 2015

 

 

 

Number of Restricted

Share Units

 

 

Weighted Average

Grant Date Fair Value

 

Outstanding as of January 1,

   2015

 

 

488,418

 

 

$

15.36

 

Granted

 

 

53,546

 

 

 

20.88

 

Vested (Note b)

 

 

(351,338

)

 

 

15.29

 

Forfeited

 

 

(33,236

)

 

 

14.00

 

Outstanding as of

   December 31, 2015

 

 

157,390

 

 

$

17.67

 

Expected to vest (Note a)

 

 

147,226

 

 

 

 

 

 

 

 

Year ended December 31, 2016

 

 

 

Number of Restricted

Share Units

 

 

Weighted Average

Grant Date Fair Value

 

Outstanding as of January 1,

   2016

 

 

157,390

 

 

$

17.67

 

Granted

 

 

95,553

 

 

 

25.49

 

Vested (Note c)

 

 

(133,903

)

 

 

20.66

 

Forfeited

 

 

(1,135

)

 

 

14.18

 

Outstanding as of

   December 31, 2016

 

 

117,905

 

 

$

20.65

 

Expected to vest (Note a)

 

 

107,366

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 2017

 

 

 

Number of Restricted

Share Units

 

 

Weighted Average

Grant Date Fair Value

 

Outstanding as of January 1,

   2017

 

 

117,905

 

 

$

20.65

 

Granted

 

 

1,533,836

 

 

 

26.36

 

Vested (Note d)

 

 

(45,248

)

 

 

18.31

 

Forfeited

 

 

(1,242

)

 

 

25.53

 

Outstanding as of

   December 31, 2017

 

 

1,605,251

 

 

$

26.17

 

Expected to vest (Note a)

 

 

1,371,567

 

 

 

 

 

 

(a)

RSUs expected to vest reflect an estimated forfeiture rate.

(b)

Vested RSUs were net settled by issuing 199,949 shares (net of minimum statutory tax withholding). 53,546 RSUs vested in the year ended December 31, 2015, 53,023 shares in respect of which were issued in 2017 after withholding shares to the extent of minimum statutory withholding taxes.

(c)

Vested RSUs were net settled by issuing 29,719 shares (net of minimum statutory tax withholding). 86,517 RSUs vested in the year ended December 31, 2016. 17,802 common shares underlying 34,035 of such RSUs were issued in 2017 after withholding shares to the extent of minimum statutory withholding taxes. Shares underlying the remaining 52,482 of such RSUs will be issued in 2018 after withholding shares to the extent of minimum statutory withholding taxes.

(d)

Vested RSUs were net settled by issuing 32,395 shares (net of minimum statutory tax withholding).

F-47


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

18. Stock-based compensation (Continued)

92,692 RSUs vested in the year ended December 31, 2014, in respect of which 91,963 shares were issued in 2016 after withholding shares to the extent of minimum statutory withholding taxes.

61,057 RSUs vested in the year ended December 31, 2013, in respect of which 59,827 shares were issued in January 2015 after withholding shares to the extent of minimum statutory withholding taxes.

As of December 31, 2017, the total remaining unrecognized stock-based compensation cost related to RSUs amounted to $26,543, which will be recognized over the weighted average remaining requisite vesting period of 2.9 years.

Performance Units

The Company also grants stock awards in the form of performance units, or PUs, and has granted PU’s under both the 2007 and 2017 Omnibus Plans.

Each PU represents the right to receive one common share at a future date based on the Company’s performance against specified targets. PUs granted to date have vesting schedules of six months to three years. The fair value of each PU is the market price of one common share of the Company on the date of grant and assumes that performance targets will be achieved. PUs granted under the plan are subject to cliff vesting. The compensation expense for such awards is recognized on a straight-line basis over the vesting terms. During the performance period, the Company’s estimate of the number of shares to be issued is adjusted upward or downward based upon the probability of achievement of the performance targets. The ultimate number of shares issued and the related compensation cost recognized is based on a comparison of the final performance metrics to the specified targets.

A summary of PU activity during the years ended December 31, 2015, 2016 and 2017 is set out below:

 

 

 

Year ended December 31, 2015

 

 

 

Number of

Performance Units

 

 

Weighted Average

Grant Date Fair Value

 

 

Maximum Shares

Eligible to Receive

 

Outstanding as of

   January 1, 2015

 

 

1,292,750

 

 

$

16.78

 

 

 

2,648,626

 

Granted

 

 

1,375,650

 

 

 

22.72

 

 

 

2,965,475

 

Vested (Note b)

 

 

(855

)

 

 

16.78

 

 

 

(855

)

Forfeited

 

 

(136,216

)

 

 

17.82

 

 

 

(156,194

)

Adjustment due to

   achievement of

   lower-than-target

   performance (Note c)

 

 

(32,007

)

 

 

20.45

 

 

 

 

 

Adjustment due to

   achievement of

   lower-than-maximum

   performance (Note d)

 

 

 

 

 

 

 

 

 

 

(2,957,730

)

Outstanding as of

   December 31, 2015

 

 

2,499,322

 

 

$

19.95

 

 

 

2,499,322

 

Expected to vest (Note a)

 

 

2,184,906

 

 

 

 

 

 

 

 

 

 

F-48


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

18. Stock-based compensation (Continued)

 

 

 

Year ended December 31, 2016

 

 

 

Number of

Performance Units

 

 

Weighted Average

Grant Date Fair Value

 

 

Maximum Shares

Eligible to Receive

 

Outstanding as of

   January 1, 2016

 

 

2,499,322

 

 

$

19.95

 

 

 

2,499,322

 

Granted

 

 

1,518,374

 

 

 

27.93

 

 

 

3,343,335

 

Vested

 

 

 

 

 

 

 

 

 

Forfeited

 

 

(252,842

)

 

 

21.88

 

 

 

(325,817

)

Adjustment upon final

   determination of

   level of performance

   goal achievement

   (Note e)

 

 

7,274

 

 

 

22.72

 

 

 

 

 

Adjustment upon final

   determination of

   level of performance

   goal achievement

   (Note e)

 

 

 

 

 

 

 

 

 

 

7,274

 

Outstanding as of

   December 31, 2016

 

 

3,772,128

 

 

$

23.04

 

 

 

5,524,114

 

Expected to vest

   (Note a)

 

 

2,226,489

 

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 2017

 

 

 

Number of

Performance Units

 

 

Weighted Average

Grant Date Fair Value

 

 

Maximum Shares

Eligible to Receive

 

Outstanding as of

   January 1, 2017

 

 

3,772,128

 

 

$

23.04

 

 

 

5,524,114

 

Granted

 

 

1,811,292

 

 

 

25.22

 

 

 

3,622,584

 

Vested (Note f)

 

 

(1,136,047)

 

 

 

16.78

 

 

 

(1,136,047)

 

Forfeited (Note g)

 

 

(1,583,913

)

 

 

27.57

 

 

 

(1,627,313

)

Adjustment upon final

   determination of

   level of performance

   goal achievement

   (Note h)

 

 

37,480

 

 

 

25.22

 

 

 

 

 

Adjustment upon final

   determination of level of performance

   goal achievement

   (Note i)

 

 

 

 

 

 

 

 

 

 

(3,482,398)

 

Outstanding as of

   December 31, 2017

 

 

2,900,940

 

 

$

24.40

 

 

 

2,900,940

 

Expected to vest

   (Note a)

 

 

2,657,685

 

 

 

 

 

 

 

 

 

 

(a)

PUs expected to vest are based on the probable achievement of the performance targets after considering an estimated forfeiture rate.

(b)

Vested PUs were net settled upon vesting by issuing 590 shares (net of minimum statutory tax withholding).

 

F-49


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

18. Stock-based compensation (Continued)

(c)

Represents a 5.2% to 6.7% reduction, depending on the targets under the PU award granted, in the number of target shares as a result of achievement of lower-than-target performance for the PUs granted in 2015, partially offset by a 0.8% to 6.6% increase in the number of target shares as a result of achievement of higher-than-target performance for the PUs granted in 2014.

(d)

Represents the difference between the maximum number of shares achievable and the number of shares expected to vest under the PU awards granted in 2015. Also includes the difference between the maximum number of shares achievable and the number of shares eligible to vest under the PU awards granted in 2014 based on the certified level of achievement of the performance goals.

(e)

Represents an adjustment made in March 2016 to the number of shares underlying the PUs granted in 2015 upon certification of the level of achievement of the performance targets for such awards.

(f)

Vested PUs were net settled upon vesting by issuing 731,701 shares (net of minimum statutory tax withholding).

(g)

Includes 1,443,624 target shares underlying PUs granted in 2016 which were forfeited for failure to achieve all of the threshold performance targets under such awards as certified by the compensation committee based on the Company’s audited financial statements for the year ended December 31, 2016.

(h)

Represents a 2.7% increase in the number of target shares as a result of achievement of higher-than-target performance for certain PUs granted in 2017, partially offset by a 12.5% reduction as a result of achievement of lower-than-target performance for certain PUs granted in 2017.

(i)

Represents the difference between the maximum number of shares achievable and the number of shares expected to vest under the PU awards granted in 2017 based on the level of achievement of the performance goals. Also includes the difference between the maximum number of shares achievable and the number of shares eligible to vest under the PU awards granted in 2016, which were forfeited for failure to achieve all of the threshold performance targets under such awards as certified by the compensation committee based on the Company’s audited financial statements for the year ended December 31, 2016.

1,329,270 shares vested in the year ended December 31, 2014 in respect of PUs granted in March 2012. 845,524 shares (net of minimum statutory tax withholding) in respect of such PUs were issued in January 2015.

As of December 31, 2017, the total remaining unrecognized stock-based compensation cost related to PUs amounted to $28,992, which will be recognized over the weighted average remaining requisite vesting period of 2.0 years.

Employee Stock Purchase Plan (ESPP)

On May 1, 2008, the Company adopted the Genpact Limited U.S. Employee Stock Purchase Plan and the Genpact Limited International Employee Stock Purchase Plan (together, the “ESPP”).

The ESPP allows eligible employees to purchase the Company’s common shares through payroll deductions at 90% of the closing price of the Company’s common shares on the last business day of each purchase interval. The dollar amount of common shares purchased under the ESPP must not exceed 15% of the participating employee’s base salary, subject to a cap of $25 per employee per calendar year. With effect from September 1, 2009, the offering periods commence on the first business day in March, June, September and December of each year and end on the last business day of the subsequent May, August, November and February. 4,200,000 common shares have been reserved for issuance in the aggregate over the term of the ESPP.

F-50


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

18. Stock-based compensation (Continued)

During the years ended December 31, 2015, 2016 and 2017, 121,485, 146,685 and 190,435 common shares, respectively, were issued under the ESPP.

The ESPP is considered compensatory under FASB guidance on Compensation-Stock Compensation.

The compensation expense for the ESPP is recognized in accordance with the FASB guidance on Compensation—Stock Compensation. The compensation expense for the ESPP during the years ended

December 31, 2015, 2016 and 2017 was $292, $428 and $573, respectively, and has been allocated to cost of revenue and selling, general, and administrative expenses.

 

 

19. Capital stock

The Company’s authorized capital stock as of December 31, 2016 and 2017 consisted of 500 million common shares with a par value of $0.01 per share, and 250 million preferred shares with a par value of $0.01 per share. There were 198,794,052 and 192,825,207 common shares, and no preferred shares, issued and outstanding as of December 31, 2016 and 2017, respectively.

Holders of common shares are entitled to one vote per share. Upon the liquidation, dissolution or winding up of the Company, common shareholders are entitled to receive a ratable share of the available net assets of the Company after payment of all debts and other liabilities. The common shares have no preemptive, subscription, redemption or conversion rights.

The Company’s board of directors by resolution can establish one or more series of preferred shares having such par value, designations, dividend rates, relative voting rights, conversion or exchange rights, redemption rights, liquidation rights and other relative participation, optional or other rights, qualifications, limitations or restrictions as may be fixed by the board of directors without shareholder approval. Such rights, preferences, powers and limitations as may be established could also have the effect of discouraging an attempt to obtain control of the Company. These preferred shares are of the type commonly known as “blank-check” preferred shares.

Under Bermuda law, the Company may declare and pay dividends from time to time unless there are reasonable grounds for believing that the Company is or would, after the payment, be unable to pay its liabilities as they become due or that the realizable value of its assets would thereby be less than the aggregate of its liabilities, its issued share capital, and its share premium accounts. Under the Company’s bye-laws, each common share is entitled to dividends if, as and when dividends are declared by the Company’s board of directors. There are no restrictions in Bermuda on the Company’s ability to transfer funds (other than funds denominated in Bermuda dollars) in or out of Bermuda or to pay dividends to U.S. residents who are holders of common shares. The Company’s ability to declare and pay cash dividends is restricted by its debt covenants.

F-51


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

19. Capital stock (Continued)

Share Repurchases

As of December 31, 2016, the Company’s board of directors (the “Board”) had authorized the Company to repurchase up to $750,000 in value of the Company’s common shares under its share repurchase program first announced in February 2015. On February 10, 2017 the Board approved up to an additional $500,000 in share repurchases, bringing the total authorization under the Company’s existing program to $1,250,000. The Company’s share repurchase program does not obligate it to acquire any specific number of shares. Under the program, shares may be purchased in privately negotiated and/or open market transactions, including under plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

On March 29, 2017, the Company entered into an accelerated share repurchase (“ASR”) agreement with Morgan Stanley & Co. LLC (the “Dealer”) to repurchase Company common shares for an aggregate purchase price of $200,000. Pursuant to the ASR agreement, as amended in November 2017, the Company paid the aggregate purchase price to the Dealer upfront and received an initial delivery of 6,578,947 common shares on March 30, 2017 and an additional delivery of 350,006 common shares on December 29, 2017. The total value of the 6,928,953 common shares delivered to the Company through December 29, 2017 was $196,000, and the weighted average price per share of the common shares delivered was $28.29. The Company’s purchase of its common shares under the ASR has been recorded as a reduction in retained earnings. The value of the common shares to be purchased under the ASR but not yet delivered to the Company as of December 31, 2017, amounting to $4,000, was recorded in additional paid-in-capital. All repurchased shares have been retired.

The final settlement of the shares repurchased under the ASR was completed in January 2018. The final number of common shares repurchased by the Company under the ASR agreement was based on the volume-weighted average share price of the Company’s common shares during the term of the transaction, less a discount and subject to adjustments pursuant to the terms of the ASR agreement.

The ASR agreement contains customary provisions, including, among other things, with respect to mechanisms to determine the number of shares or the amount of cash that will be delivered at settlement, the required timing of delivery upon settlement, specific circumstances under which adjustments may be made to the repurchase transaction, and specific circumstances under which the repurchase transaction may be canceled prior to the scheduled maturity.

During the years ended December 31, 2017 and December 31, 2016, the Company also purchased 808,293 and 13,940,782 of its common shares, respectively, on the open market at a weighted average price of $24.48 and $24.76  per share, respectively, for an aggregate cash amount of $19,784 and $345,200, respectively. All repurchased shares have been retired.

The Company records repurchases of its common shares on the settlement date of each transaction. Shares purchased and retired are deducted to the extent of their par value from common stock and from retained earnings for the excess over par value. Direct costs incurred to acquire the shares are included in the total cost of the shares purchased. For the year ended December 31, 2015, December 31, 2016 and December 31, 2017, $197, $279 and $16, respectively, was deducted from retained earnings in direct costs related to share repurchases.

Dividend

In February 2017, the Company’s board of directors approved a dividend program under which the Company paid a regular quarterly cash dividend of $0.06 per share to holders of its common shares, representing an annual dividend of $0.24 per share in 2017. On March 28, 2017, June 28, 2017, September 21, 2017, and December 20, 2017 the Company paid dividends of $0.06 per share, amounting to $11,957, $11,558, $11,581 and $11,590 in the aggregate, to shareholders of record as of March 10, 2017, June 12, 2017, September 8, 2017 and December 8, 2017 respectively.

 

F-52


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

20. Earnings per share

The Company calculates earnings per share in accordance with FASB guidance on Earnings per Share. Basic and diluted earnings per common share give effect to the change in the number of common shares outstanding. The calculation of basic earnings per common share was determined by dividing net income available to common shareholders by the weighted average number of common shares outstanding. The potentially dilutive shares, consisting of outstanding options on common shares, restricted share units, common shares to be issued under the ESPP and performance units, have been included in the computation of diluted net earnings per share and number of weighted average shares outstanding, except where the result would be anti-dilutive.

 

The number of stock awards outstanding but not included in the computation of diluted earnings per common share because their effect was anti-dilutive is 2,821,000, 781,215 and 1,007,480 for the years ended December 31, 2015, 2016 and 2017, respectively.

 

 

 

Year ended December 31,

 

 

 

2015

 

 

2016

 

 

2017

 

Net income available to Genpact

   Limited common shareholders

 

$

239,817

 

 

$

269,684

 

 

$

263,111

 

Weighted average number of common

   shares used in computing basic

   earnings per common share

 

 

216,606,542

 

 

 

206,861,536

 

 

 

193,864,755

 

Dilutive effect of stock-based awards

 

 

2,538,502

 

 

 

3,264,487

 

 

 

3,184,797

 

Weighted average number of common

   shares used in computing dilutive

   earnings per common share

 

 

219,145,044

 

 

 

210,126,023

 

 

 

197,049,552

 

Earnings per common share attributable

   to Genpact Limited common

   shareholders

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

1.11

 

 

$

1.30

 

 

$

1.36

 

Diluted

 

$

1.09

 

 

$

1.28

 

 

$

1.34

 

 

 

21. Cost of revenue

Cost of revenue consists of the following:

 

 

 

Year ended December 31,

 

 

 

2015

 

 

2016

 

 

2017

 

Personnel expenses

 

$

1,013,209

 

 

$

1,061,501

 

 

$

1,155,745

 

Operational expenses

 

 

432,535

 

 

 

446,922

 

 

 

481,012

 

Depreciation and amortization

 

 

47,803

 

 

 

46,284

 

 

 

46,947

 

 

 

$

1,493,547

 

 

$

1,554,707

 

 

$

1,683,704

 

 

 

22. Selling, general and administrative expenses

Selling, general and administrative expenses consist of the following:

 

 

 

Year ended December 31,

 

 

 

2015

 

 

2016

 

 

2017

 

Personnel expenses

 

$

430,088

 

 

$

469,956

 

 

$

501,445

 

Operational expenses

 

 

169,042

 

 

 

174,060

 

 

 

178,573

 

Depreciation and amortization

 

 

8,984

 

 

 

9,013

 

 

 

9,829

 

 

 

$

608,114

 

 

$

653,029

 

 

$

689,847

 

 

 

F-53


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

23. Other operating (income) expense, net

 

 

 

Year ended December 31,

 

 

 

2015

 

 

2016

 

 

2017

 

Other operating (income) expense

 

$

(2,515

)

 

$

(1,266

)

 

$

(7,277

)

Provision for impairment of intangible

   assets and property, plant and equipment

 

 

10,714

 

 

 

11,195

 

 

 

9,311

 

Change in fair value of earn-out

   consideration and deferred consideration

   (relating to business acquisitions)

 

 

(11,521

)

 

 

(14,869

)

 

 

(3,695

)

Other operating (income) expense,

   net

 

$

(3,322

)

 

$

(4,940

)

 

$

(1,661

)

 

 

24. Interest income (expense), net

Interest income (expense), net consists of the following:

 

 

 

Year ended December 31,

 

 

 

2015

 

 

2016

 

 

2017

 

Interest income

 

$

8,676

 

 

$

7,247

 

 

$

8,182

 

Interest expense

 

 

(29,828

)

 

 

(23,431

)

 

 

(39,917

)

Loss on extinguishment of debt

 

 

(10,115

)

 

 

-

 

 

 

-

 

Interest income (expense), net

 

$

(31,267

)

 

$

(16,184

)

 

$

(31,735

)

 

 

25. Income taxes

Income tax expense (benefit) for the years ended December 31, 2015, 2016 and 2017 is allocated as follows:

 

 

 

Year ended December 31,

 

 

 

2015

 

 

2016

 

 

2017

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income from continuing operations

 

$

61,937

 

 

$

62,098

 

 

$

59,742

 

Other comprehensive Income:

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gains (losses) on cash flow hedges

 

 

13,816

 

 

 

23,809

 

 

 

457

 

      Retirement benefits

 

 

1,304

 

 

 

(1,885

)

 

 

670

 

Additional paid in capital:

 

 

 

 

 

 

 

 

 

 

 

 

      Excess tax benefit on stock-based compensation

 

 

(6,560

)

 

 

 

 

 

 

Retained earnings:

 

 

 

 

 

 

 

 

 

 

 

 

      Deferred tax assets recognized on early adoption of

   ASU 2016-09

 

 

 

 

 

(24,912

)

 

 

 

 

The components of income before income tax expense from continuing operations are as follows:

 

 

 

Year ended December 31,

 

 

 

2015

 

 

2016

 

 

2017

 

Domestic (U.S.)

 

$

23,122

 

 

$

44,110

 

 

$

8,440

 

Foreign (Non-U.S.)

 

 

278,632

 

 

 

285,535

 

 

 

312,143

 

Income before income taxes

 

$

301,754

 

 

$

329,645

 

 

$

320,583

 

 

F-54


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

25. Income taxes (Continued)

 

Income tax expense (benefit) attributable to income from continuing operations consists of:

 

 

 

Year ended December 31,

 

 

 

2015

 

 

2016

 

 

2017

 

Current taxes:

 

 

 

 

 

 

 

 

 

 

 

 

Domestic (U.S. federal taxes)

 

$

12,142

 

 

$

78

 

 

$

3,380

 

Domestic (U.S. state taxes)

 

 

301

 

 

 

1,069

 

 

 

1,268

 

Foreign (Non-U.S.)

 

 

68,207

 

 

 

30,497

 

 

 

65,485

 

 

 

$

80,650

 

 

$

31,644

 

 

$

70,133

 

Deferred taxes:

 

 

 

 

 

 

 

 

 

 

 

 

Domestic (U.S. federal taxes)

 

$

(5,396

)

 

$

11,379

 

 

$

3,549

 

Domestic (U.S. state taxes)

 

 

344

 

 

 

(459

)

 

 

(2,809

)

Foreign (Non-U.S.)

 

 

(13,661

)

 

 

19,534

 

 

 

(11,131

)

 

 

$

(18,713

)

 

$

30,454

 

 

$

(10,391

)

Total income tax expense (benefit)

 

$

61,937

 

 

$

62,098

 

 

$

59,742

 

 

 

Income tax expense (benefit) attributable to income from continuing operations differed from the amounts computed by applying the U.S. federal statutory income tax rate of 35% to income before income taxes, as a result of the following:

 

 

Year ended December 31,

 

 

 

2015

 

 

2016

 

 

2017

 

Income before income tax expense

 

$

301,754

 

 

$

329,645

 

 

$

320,583

 

Statutory tax rates

 

 

35

%

 

 

35

%

 

 

35

%

Computed expected income tax expense

 

 

105,614

 

 

 

115,376

 

 

 

112,204

 

Increase (decrease) in income taxes

   resulting from:

 

 

 

 

 

 

 

 

 

 

 

 

Foreign tax rate differential

 

 

(16,550

)

 

 

(18,574

)

 

 

(25,224

)

Tax benefit from tax holiday

 

 

(38,039

)

 

 

(32,893

)

 

 

(35,814

)

Non-deductible expenses

 

 

1,884

 

 

 

2,295

 

 

 

1,146

 

Effect of change in tax rates

 

 

1,436

 

 

 

353

 

 

 

2,778

 

Change in valuation allowance

 

 

(33

)

 

 

(4,830

)

 

 

9,041

 

Unrecognized tax benefits

 

 

6,272

 

 

 

(627

)

 

 

1,611

 

Other*

 

 

1,353

 

 

 

998

 

 

 

(6,000

)

Reported income tax expense (benefit)

 

$

61,937

 

 

$

62,098

 

 

$

59,742

 

*During 2017, following the transfer/closure of certain affiliated entities, deferred tax liabilities recorded against the outside basis difference amounting to $9,600 were reversed. It was not more likely than not that the resulting net deferred tax asset would be realized. Therefore, a full valuation allowance was established to offset the reduction in deferred tax liabilities.

 

 

A portion of the profits of the Company’s operations is exempt from income tax in India.  One of the Company’s Indian subsidiaries has sixteen units eligible for a tax holiday as a special economic zone unit in respect of 100% of the export profits it generates for a period of 5 years from commencement, 50% of such profits for the next 5 years (year 6 to year 10 from commencement) and 50% of the profits for an additional period of 5 years (year 11 to year 15 from commencement), subject to the satisfaction of certain capital investment requirements. The tax holidays for the Company’s existing special economic zone units will begin to expire on March 31, 2022 and will have fully expired on March 31, 2029, assuming the Company satisfies the capital investment requirements.

The effect of the Indian tax holiday on basic earnings per share was $0.18, $0.19 and $0.18, respectively, for the years ended December 31, 2015, 2016 and 2017. The effect of the tax holiday on diluted earnings per share was $0.17, $0.18 and $0.18, respectively, for the years ended December 31, 2015, 2016 and 2017.

F-55


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

25. Income taxes (Continued)

The components of the Company’s deferred tax balances as of December 31, 2016 and 2017 are as follows:

 

 

 

As of December 31,

 

 

 

2016

 

 

2017

 

Deferred tax assets

 

 

 

 

 

 

 

 

Net operating loss carryforwards

 

$

52,997

 

 

$

55,500

 

Accrued liabilities and other expenses

 

 

19,840

 

 

 

41,177

 

Provision for doubtful debts

 

 

6,419

 

 

 

10,509

 

Property, plant and equipment

 

 

3,445

 

 

 

1,270

 

Unrealized losses on cash flow hedges,

   Net

 

 

558

 

 

 

275

 

Share-based compensation

 

 

19,054

 

 

 

19,789

 

Retirement benefits

 

 

5,067

 

 

 

5,817

 

Deferred revenue

 

 

44,892

 

 

 

22,948

 

Tax credit carryforwards

 

 

34,509

 

 

 

35,322

 

Other

 

 

8,876

 

 

 

11,571

 

Gross deferred tax assets

 

$

195,657

 

 

$

204,178

 

Less: valuation allowance

 

 

(14,746

)

 

 

(24,549

)

Total deferred tax assets

 

$

180,911

 

 

$

179,629

 

Deferred tax liabilities

 

 

 

 

 

 

 

 

Intangible assets

 

$

13,519

 

 

$

15,954

 

Property, plant and equipment

 

 

2,745

 

 

 

1,131

 

Deferred cost

 

 

41,950

 

 

 

33,816

 

Investments in foreign subsidiaries not

   indefinitely reinvested

 

 

29,546

 

 

 

18,949

 

Unrealized gains on cash flow

   hedges, net

 

 

14,350

 

 

 

14,711

 

Other

 

 

11,073

 

 

 

24,886

 

Total deferred tax liabilities

 

$

113,183

 

 

$

109,447

 

Net deferred tax asset

 

$

67,728

 

 

$

70,182

 

 

 

 

As of December 31,

 

Classified as

 

2016

 

 

2017

 

Deferred tax assets

 

 

 

 

 

 

 

 

Non-current

 

$

70,143

 

 

$

76,929

 

Deferred tax liabilities

 

 

 

 

 

 

 

 

Non-current

 

 

2,415

 

 

 

6,747

 

 

 

$

67,728

 

 

$

70,182

 

 

The change in the total valuation allowance for deferred tax assets as of December 31, 2015, 2016 and 2017 is as follows:

 

 

 

Year ended December 31,

 

 

 

2015

 

 

2016

 

 

2017

 

Opening valuation allowance

 

$

21,094

 

 

$

20,091

 

 

$

14,746

 

Reduction during the year

 

 

(3,499

)

 

 

(7,299

)

 

 

(3,957

)

Addition during the year

 

 

2,496

 

 

 

1,954

 

 

 

13,760

 

Closing valuation allowance

 

$

20,091

 

 

$

14,746

 

 

$

24,549

 

 

 

F-56


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

25. Income taxes (Continued)

 

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the periods in which temporary differences are deductible.

Management considers the scheduled reversal of deferred tax liabilities and projected taxable income in making this assessment. In order to fully realize a deferred tax asset, the Company must generate future taxable income prior to the expiration of the deferred tax asset under applicable law. Based on the level of historical taxable income and projections for future taxable income over the periods during which the Company’s deferred tax assets are deductible, management believes that it is more likely than not that the Company will realize the benefits of these deductible differences, net of the existing valuation allowances as of December 31, 2017. The amount of the Company’s deferred tax assets considered realizable, however, could be reduced in the near term if estimates of future taxable income during the carryforward period are reduced.

In 2016, one of the Company’s subsidiaries filed amended tax returns with respect to prior years, resulting in revised assessments, higher taxable income and the utilization of operating loss carryforwards. The use of operating loss carryforwards resulted in the complete reversal of the subsidiary’s remaining valuation allowance of $3,377.  

On January 1, 2016, the Company elected the early adoption of ASU 2016-09, which was applied using a modified retrospective approach. Accordingly, excess tax benefits relating to the exercise of stock options prior to December 31, 2015 amounting to $24,912 were recorded through retained earnings. For the year ended December 31, 2016 and 2017, the Company has recognized net excess tax benefits of $1,004 and $1,723 in income tax expense attributable to continuing operations.

The Company recorded excess tax benefits of $6,560, $0, and $0 through additional paid-in capital during the years ended December 31, 2015, 2016 and 2017, respectively.

As of December 31, 2017, the Company’s deferred tax assets related to net operating loss carryforwards of $223,415 amounted to $50,495 (excluding state net operating losses). Net operating losses of subsidiaries in the United Kingdom, Singapore, Malaysia, Australia, Brazil, Israel, South Africa, Hong Kong and Luxembourg amounted to $126,612 and can be carried forward for an indefinite period.

F-57


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

25. Income taxes (Continued)

The Company’s remaining tax loss carryforwards expire as set forth in the table below:

 

 

 

 

    US –

Federal

 

 

Europe

 

 

Others

 

Year ending December 31,

 

 

 

 

 

 

 

 

 

 

 

 

2018

 

$

 

 

$

 

 

$

20

 

2019

 

 

 

 

 

 

 

 

72

 

2020

 

 

 

 

 

1,872

 

 

 

62

 

2021

 

 

 

 

 

581

 

 

 

2,084

 

2022

 

 

 

 

 

5,253

 

 

 

60

 

2023

 

 

 

 

 

8,500

 

 

 

953

 

2024

 

 

 

 

 

1,213

 

 

 

7,941

 

2025

 

 

 

 

 

28,222

 

 

 

9,647

 

2026

 

 

9,511

 

 

 

2,263

 

 

 

3,072

 

2027

 

 

9,913

 

 

 

 

 

 

2,053

 

2028

 

 

 

 

 

33

 

 

 

2,451

 

2034

 

 

 

 

 

 

 

 

1,027

 

 

 

$

19,424

 

 

$

47,937

 

 

$

29,442

 

 

In the table above, “Europe” includes net operating losses of subsidiaries in Hungary, Poland, the Netherlands, the Czech Republic, Slovakia, and Portugal, while “Others” includes net operating losses of subsidiaries in Mexico, Japan, China, India and Canada.

 

As of December 31, 2017, the Company had additional deferred tax assets for U.S. state and local tax loss carryforwards amounting to $5,005 with varying expiration periods between 2018 and 2036.      

As of December 31, 2017, the company had a total foreign tax credit carryforward of $33,220, which will expire as set forth in the table below:

 

Year ending December 31,

 

Amount

 

2023

 

$

893

 

2024

 

 

1,202

 

2025

 

 

15,552

 

2026

 

 

8,481

 

2027

 

 

5,362

 

2028

 

 

1,730

 

 

 

$

33,220

 

 

Undistributed earnings of the Company’s foreign (non-Bermuda) subsidiaries which cannot be repatriated in a tax-free manner and for which a deferred tax liability has not been recognized amounted to $36,029 as of December 31, 2017. The Company has not accrued any income, distribution or withholding taxes that would arise if such earnings were repatriated. Due to the Company’s changing corporate structure, the various methods that are available to repatriate earnings, and uncertainty relative to the applicable taxes at the time of repatriation, it is not practicable to determine the amount of tax that would be imposed upon repatriation. If undistributed earnings are repatriated in the future, or are no longer deemed to be indefinitely reinvested, the company will accrue the applicable amount of taxes associated with such earnings at that time.

 

F-58


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

25. Income taxes (Continued)

As of December 31, 2017, $499,532 of the Company’s $504,468, in cash and cash equivalents was held by the Company’s foreign (non-Bermuda) subsidiaries. $243,813 of this cash is held by foreign subsidiaries for which the Company expects to incur and has accrued a deferred tax liability on the repatriation of $17,343 of retained earnings. $122,674 of the Company’s cash and cash equivalents is held by foreign subsidiaries in jurisdictions where no tax is expected to be imposed upon repatriation. The remaining $133,045 in cash and cash equivalents held by certain foreign subsidiaries of the Company is being indefinitely reinvested.

On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cut and Jobs Act (the “Tax Act”). The Tax Act makes broad and complex changes to the U.S. tax code that affect 2017. The Tax Act also establishes new tax laws that will affect 2018 and subsequent years, including a reduction in the U.S. federal corporate income tax rate from 35% to 21%.

On December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118 (“SAB 118”), which provides guidance on accounting for the tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740, Income Taxes. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Tax Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate in the financial statements.

As a result of the reduction in the federal corporate income tax rate, the Company has revalued its net deferred tax assets, excluding tax credits to the extent affected by changes in the law as of December 31, 2017. Based on this revaluation, the Company has recorded a net tax expense of $3,182 to reduce its net deferred tax asset balance, which was recorded as additional income tax expense for the year ended December 31, 2017. Additionally, the Company has claimed 100% depreciation on $7,685 of the investments it made in depreciable property after September 27, 2017. 

The estimation of transition tax on mandatory repatriation introduced under the Tax Act is provisional, which is currently estimated based on information available as of December 31, 2017. The Company has not recorded any tax liability for transition tax as of December 31, 2017 pending detailed workings for the earnings and profit pool of its controlled foreign corporations. The Company will recognize any changes to the provisional amounts as it refines its estimates and interpretations of the application of the Tax Act. The Company expects to complete its analysis of the provisional items during the second half of 2018. The effects of other provisions of the Tax Act are not expected to have a material impact on the Company’s consolidated financial statements for the year ended December 31, 2017.

F-59


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

25. Income taxes (Continued)

The following table summarizes activities related to our unrecognized tax benefits from January 1 to December 31 for each of 2015, 2016 and 2017:

 

 

 

Year Ended December 31,

 

 

 

2015

 

 

2016

 

 

2017

 

Opening balance at January 1

 

$

22,718

 

 

$

26,357

 

 

$

23,467

 

Increase related to prior year tax positions,

   including recorded in acquisition accounting

 

 

2,000

 

 

 

370

 

 

 

2,582

 

Decrease related to prior year tax positions

 

 

 

 

 

(1,506

)

 

 

(1,398

)

Decrease related to divestiture of business

 

 

 

 

 

(345

)

 

 

 

Decrease related to prior year tax position due to

   lapse of applicable statute of limitation

 

 

(820

)

 

 

(2,122

)

 

 

(1,019

)

Increase related to current year tax positions,

   including recorded in acquisition accounting

 

 

3,544

 

 

 

3,225

 

 

 

1,661

 

Decrease related to settlements with tax

   Authorities

 

 

 

 

 

(2,000

)

 

 

 

Effect of exchange rate changes

 

 

(1,085

)

 

 

(512

)

 

 

767

 

Closing balance at December 31

 

$

26,357

 

 

$

23,467

 

 

$

26,060

 

 

 

As of December 31, 2015, 2016 and 2017, the Company had unrecognized tax benefits amounting to $24,935, $22,469 and $24,877, respectively, which, if recognized, would impact the effective tax rate.

As of December 31, 2015, 2016 and 2017, the Company had accrued $4,223, $3,856 and $4,614, respectively, in interest relating to unrecognized tax benefits. During the years ended December 31, 2015, 2016 and 2017, the Company recognized $1,152, $(206) and $(224), respectively, excluding exchange rate differences, in interest on unrecognized tax benefits. As of December 31, 2015, 2016 and 2017, the company had accrued $958, $977 and $1,033, respectively, for penalties.

In the next twelve months and for all tax years that remain open to examinations by U.S. federal and various state, local, and non-U.S. tax authorities, the Company estimates that it is reasonably possible that the total amount of its unrecognized tax benefits will vary. However, the Company does not expect significant changes within the next twelve months other than depending on the progress of tax matters or examinations with various tax authorities, which are difficult to predict.

With exceptions, the Company is no longer subject to U.S. federal, state and local or non-U.S. income tax audits by taxing authorities for years prior to 2013. The Company’s subsidiaries in India and China are open to examination by relevant taxing authorities for tax years beginning on or after April 1, 2009, and January 1, 2007, respectively. The Company regularly reviews the likelihood of additional tax assessments and adjusts its reserves as additional information or events require.

 

 

F-60


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

26. Segment reporting

The Company manages various types of business process and information technology services in an integrated manner for clients in various industries and geographic locations. The Company’s Chief Executive Officer, who has been identified as the Chief Operation Decision Maker (CODM), reviews financial information prepared on a consolidated basis, accompanied by disaggregated information about revenue and adjusted operating income by identified business units. The identified business units are organized for operational reasons and represent either services-based, customer-based, industry-based or geography-based units. There is significant overlap between the manner in which the business units are organized. Additionally, the composition and organization of the business units is fluid and the structure changes regularly in response to growth of the overall business, acquisitions and changes in the reporting structure, clients, services, industries served, and delivery centers.

Based on an overall evaluation of all facts and circumstances, and after combining operating segments with similar economic characteristics that comply with other aggregation criteria specified in the FASB guidance on segment reporting, the Company has determined that it operates as a single reportable segment.

Net revenues by service type are as follows:

 

 

 

Year ended December 31,

 

 

 

2015

 

 

2016

 

 

2017

 

Business process outsourcing

 

$

1,933,095

 

 

$

2,083,450

 

 

$

2,264,335

 

Information technology services

 

 

527,949

 

 

 

487,306

 

 

 

472,594

 

Total net revenues

 

$

2,461,044

 

 

$

2,570,756

 

 

$

2,736,929

 

 

Revenues from clients based on the industry serviced are as follows:

 

 

 

Year ended December 31,

 

 

 

2015

 

 

2016

 

 

2017

 

Banking, financial services and insurance

 

$

1,030,584

 

 

$

1,055,704

 

 

$

1,105,731

 

Manufacturing, including pharmaceuticals

   and medical equipment manufacturing

 

 

878,570

 

 

 

958,779

 

 

 

1,002,973

 

Technology, healthcare and other services

 

 

551,890

 

 

 

556,273

 

 

 

628,225

 

Total net revenues

 

$

2,461,044

 

 

$

2,570,756

 

 

$

2,736,929

 

 

Net revenues from geographic areas based on the location of the Company’s service delivery centers are as follows. A portion of net revenues attributable to India consists of net revenues for services performed by delivery centers in India or at clients’ premises outside of India by business units or personnel normally based in India.

 

 

 

Year ended December 31,

 

 

 

2015

 

 

2016

 

 

2017

 

India

 

$

1,687,699

 

 

$

1,804,113

 

 

$

1,712,783

 

Asia, other than India

 

 

238,529

 

 

 

249,839

 

 

 

286,338

 

North and Latin America

 

 

304,879

 

 

 

282,434

 

 

 

455,059

 

Europe

 

 

229,937

 

 

 

234,370

 

 

 

282,749

 

Total net revenues

 

$

2,461,044

 

 

$

2,570,756

 

 

$

2,736,929

 

 

Revenues from GE comprised 19%, 14% and 10% of the Company’s consolidated total net revenues in 2015, 2016 and 2017, respectively. No other customer accounted for 10% or more of the Company’s consolidated total net revenues during these periods.

F-61


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

26. Segment reporting (Continued)

Property, plant and equipment, net by geographic region are as follows:

 

 

 

As of December 31,

 

 

 

2016

 

 

2017

 

India

 

$

116,417

 

 

$

125,490

 

Asia, other than India

 

 

13,549

 

 

 

15,899

 

North and Latin America

 

 

44,633

 

 

 

38,438

 

Europe

 

 

18,619

 

 

 

27,203

 

Total

 

$

193,218

 

 

$

207,030

 

 

 

27. Related party transactions

The Company has entered into related party transactions with its non-consolidating affiliates. The Company has also entered into related party transactions with a significant shareholder and its affiliates.

The Company’s related party transactions can be categorized as follows:

Revenue from services

In the years ended December 31, 2015, 2016, and 2017, the Company recognized net revenues of $326, $335 and $398, respectively, from a client that is also a significant shareholder of the Company.

In the years ended December 31, 2015, 2016 and 2017, the Company recognized net revenues of $7,826, $8,077 and $5,400, respectively, from a client that was a non-consolidating affiliate of the Company. As of June 30, 2017 this non-consolidating affiliate ceased to be a related party. 

Cost of revenue from services

The Company purchases certain services from its non-consolidating affiliates, mainly relating to training and recruitment, the costs of which are included in cost of revenue. For the years ended December 31, 2015, 2016 and 2017, cost of revenue includes an amount of $2,173, $2,067 and $2,043, respectively, attributable to the cost of such services provided by the Company’s non-consolidating affiliates.

Selling, general and administrative expenses

The Company purchases certain services from its non-consolidating affiliates, mainly relating to training and recruitment, the costs of which are included in selling, general and administrative expenses. For the years ended December 31, 2015, 2016 and 2017, selling, general and administrative expenses include an amount of $384, $291 and $315, respectively, attributable to the cost of such services provided by the Company’s non-consolidating affiliates.

During the years ended December 31, 2015, 2016 and 2017, the Company engaged a significant shareholder of the Company to provide services to the Company at a cost of $421, $58 and $57, respectively. 

Investment in equity affiliates

During the years ended December 31, 2016 and 2017, the Company made investments of $5,884 and $496, respectively, in its non-consolidating affiliates.

During the year ended December 31, 2017, the Company recorded a charge of $ 2,849 related to an investment in one of its non-consolidating affiliates. This charge has been included in equity-method investment activity, net in the Company’s consolidated statement of income.  

 

F-62


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

27. Related party transactions (Continued)

As of December 31, 2016 and 2017, the Company’s investments in its non-consolidating affiliates amounted to $4,800 and $886, respectively.

Others

During the years ended December 31, 2015, 2016 and 2017, the Company entered into transactions with one of its non-consolidating affiliates for certain cost reimbursements amounting to $2,077, $1,162 and $477, respectively.

During the year ended December 31, 2017, the Company entered into transactions with a client that is a significant shareholder of the Company for certain cost reimbursements amounting to $127, of which $127 is receivable as of December 31, 2017.  

During the year ended December 31, 2016, the Company claimed a portion of an equity affiliate’s net operating losses under consortium relief in the United Kingdom amounting to $3,291, which was outstanding and had been included in other liabilities in the company’s consolidated balance sheet as of December 31, 2016.

During the year ended December 31, 2017, the Company made a payment of $3,847 to one of its non-consolidating affiliates under a tax-sharing arrangement in the U.K. This amount represents a portion of the non-consolidated affiliate’s net operating losses surrendered to the Company under the tax sharing arrangement for the years 2015 and 2016. As of June 30, 2017 this non-consolidating affiliate ceased to be a related party.

 

28. Commitments and contingencies

Capital commitments

As of December 31, 2016 and 2017, the Company has committed to spend $5,185 and $8,314, respectively, under agreements to purchase property, plant and equipment. This amount is net of capital advances paid in respect of such purchases.

Bank guarantees

The Company has outstanding bank guarantees amounting to $11,958 and $8,879 as of December 31, 2016 and 2017, respectively. Bank guarantees are generally provided to government agencies and excise and customs authorities for the purposes of maintaining a bonded warehouse. These guarantees may be revoked by the government agencies if they suffer any losses or damages through the breach of any of the covenants contained in the agreements governing such guarantees.

Other commitments

The Company’s business process delivery centers in India are 100% export-oriented units or Software Technology Parks of India (“STPI”) units under the STPI guidelines issued by the Government of India. These units are exempt from customs, central excise duties, and levies on imported and indigenous capital goods, stores, and spares. The Company has undertaken to pay custom duties, service taxes, levies, and liquidated damages payable, if any, in respect of imported and indigenous capital goods, stores, and spares consumed duty free, in the event that certain terms and conditions are not fulfilled.

 

 

F-63


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

29. Quarterly financial data (unaudited)

 

 

 

Three months ended

 

 

Year ended

 

 

 

March 31, 2017

 

 

June 30, 2017

 

 

September 30, 2017

 

 

December 31, 2017

 

 

December 31, 2017

 

Total net revenues

 

$

622,995

 

 

$

670,697

 

 

$

708,824

 

 

$

734,413

 

 

$

2,736,929

 

Gross profit

 

$

239,658

 

 

$

255,404

 

 

$

279,633

 

 

$

278,530

 

 

$

1,053,225

 

Income from operations

 

$

79,096

 

 

$

80,031

 

 

$

97,451

 

 

$

72,049

 

 

$

328,627

 

Income before equity method

   investment activity, net and

   income tax expense

 

$

69,243

 

 

$

84,582

 

 

$

89,742

 

 

$

81,559

 

 

$

325,126

 

Net Income

 

$

52,440

 

 

$

69,102

 

 

$

73,161

 

 

$

66,138

 

 

$

260,841

 

Net (income) loss attributable

   to redeemable non-controlling interest

 

$

898

 

 

$

(156

)

 

$

584

 

 

$

944

 

 

$

2,270

 

Net income attributable to

   Genpact Limited common

   shareholders

 

$

53,338

 

 

$

68,946

 

 

$

73,745

 

 

$

67,082

 

 

$

263,111

 

Earnings per common share

   attributable to Genpact

   Limited common

   shareholders

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

0.27

 

 

$

0.36

 

 

$

0.38

 

 

$

0.35

 

 

$

1.36

 

Diluted

 

$

0.26

 

 

$

0.36

 

 

$

0.38

 

 

$

0.34

 

 

$

1.34

 

Weighted average number of

   common shares used  in

   computing earnings per

   common share attributable to

   Genpact Limited common

   shareholders

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

199,069,528

 

 

 

191,469,593

 

 

 

192,124,366

 

 

 

192,795,534

 

 

 

193,864,755

 

Diluted

 

 

202,655,937

 

 

 

193,732,406

 

 

 

194,947,699

 

 

 

196,862,168

 

 

 

197,049,552

 

 

F-64


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

29. Quarterly financial data (unaudited) (Continued)

 

 

 

Three months ended

 

 

Year ended

 

 

 

March 31, 2016

 

 

June 30, 2016

 

 

September 30, 2016

 

 

December 31, 2016

 

 

December 31, 2016

 

Total net revenues

 

$

609,703

 

 

$

630,523

 

 

$

648,783

 

 

$

681,747

 

 

$

2,570,756

 

Gross profit

 

$

236,855

 

 

$

246,768

 

 

$

256,351

 

 

$

276,075

 

 

$

1,016,049

 

Income from operations

 

$

75,622

 

 

$

79,940

 

 

$

87,124

 

 

$

98,092

 

 

$

340,777

 

Income before equity method investment

   activity, net and income tax expense

 

$

72,664

 

 

$

81,818

 

 

$

87,360

 

 

$

95,502

 

 

$

337,343

 

Net income

 

$

58,505

 

 

$

64,788

 

 

$

68,188

 

 

$

76,066

 

 

$

267,547

 

Net (income) loss attributable to

   redeemable non-controlling interest

 

$

289

 

 

$

882

 

 

$

734

 

 

$

232

 

 

$

2,137

 

Net income attributable to Genpact

   Limited common shareholders

 

$

58,794

 

 

$

65,670

 

 

$

68,922

 

 

$

76,298

 

 

$

269,684

 

Earnings per common share attributable to

   Genpact Limited common shareholders

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

0.28

 

 

$

0.31

 

 

$

0.33

 

 

$

0.38

 

 

$

1.30

 

Diluted

 

$

0.27

 

 

$

0.31

 

 

$

0.33

 

 

$

0.38

 

 

$

1.28

 

Weighted average number of common

   shares used in computing earnings

   per common share attributable to

   Genpact Limited common shareholders

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

210,780,165

 

 

 

210,178,050

 

 

 

206,146,007

 

 

 

200,341,922

 

 

 

206,861,536

 

Diluted

 

 

213,892,964

 

 

 

213,803,134

 

 

 

209,376,683

 

 

 

203,431,310

 

 

 

210,126,023

 

 

 

F-65


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

30. Subsequent Events

Share Repurchase

Pursuant to its share repurchase program, the Company repurchased 757,526 of its common shares between January 1, 2018 and March 1, 2018 on the open market at a weighted average price of $31.67 per share for an aggregate cash amount of $23,993.

The Company repurchased 163,975 of its common shares at a weighted average price of $28.20 per share on January 17, 2018 upon final settlement of the transaction under the Company’s ASR agreement. The Company repurchased 7,092,928 of its common shares in the aggregate under the ASR agreement for an aggregate purchase price of $200,000.

Dividend

 

On February 12, 2018, the Company announced that its Board of Directors has approved a 25% increase in its quarterly cash dividend, representing a planned annual dividend of $0.30 per common share, increased from $0.24 per common share in 2017. The Board of Directors also declared a dividend for the first quarter of 2018 of $0.075 per common share, which will be paid on or about March 21, 2018 to shareholders of record as of the close of business on March 9, 2018. The declaration of any future dividends will be at the discretion of the Board of Directors.

 

 

 

F-66


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

 

31. Guarantor financial information

 

In March 2017, Genpact Luxembourg S.à r.l. (hereinafter referred to as the “Issuer”), a wholly-owned subsidiary of the Company, issued $350,000 aggregate principal amount of 3.70% senior notes in a private offering. See Note 14 for additional information. The issuance is fully and unconditionally guaranteed by the Company. In connection with the anticipated filing of a registration statement relating to an offer to exchange the original notes for registered notes, the Company has prepared the following condensed consolidating financial statements, which set forth consolidated financial information of the Issuer, the Company as parent guarantor and the non-guarantor subsidiaries of the Company, as well as intercompany elimination adjustments relating to intercompany transactions. The information in these financial statements has been prepared in accordance with the requirements of Rule 3-10 of Regulation S-X, “Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered.” Investments in subsidiaries have been accounted for using the equity method.

 

 

F-67


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

31. Guarantor financial information (continued)

 

Condensed Consolidating Balance Sheet

 

 

As of December 31,  2017

 

 

 

Issuer/

Subsidiary

 

 

 

Parent/

Guarantor

 

 

 

Non-

Guarantor

Subsidiaries

 

 

 

 

Eliminations

 

 

 

 

Consolidated

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

4,507

 

 

$

2,136

 

 

$

497,825

 

 

 

 

 

 

 

 

 

$

504,468

 

Accounts receivable intercompany, net

 

 

82,935

 

 

 

 

 

 

 

 

 

 

 

(82,935

)

 

 

 

 

 

Accounts receivable, net

 

 

 

 

 

 

 

 

693,085

 

 

 

 

 

 

 

 

 

 

693,085

 

Intercompany loans

 

 

194,854

 

 

 

 

 

 

1,620,537

 

 

 

 

 

(1,815,391

)

 

 

 

 

 

Intercompany other receivable

 

 

25,343

 

 

 

82,631

 

 

 

89,189

 

 

 

 

 

(197,163

)

 

 

 

 

 

Prepaid expenses and other current assets

 

 

311

 

 

 

1,276

 

 

 

234,755

 

 

 

 

 

 

 

 

 

 

236,342

 

Total current assets

 

$

307,950

 

 

$

86,043

 

 

$

3,135,391

 

 

 

 

$

(2,095,489

)

 

 

 

$

1,433,895

 

Property, plant and equipment, net

 

 

391

 

 

 

 

 

 

206,639

 

 

 

 

 

 

 

 

 

 

207,030

 

Intercompany loans

 

 

 

 

 

 

 

 

500,000

 

 

 

 

 

(500,000

)

 

 

 

 

 

Deferred tax assets

 

 

 

 

 

 

 

 

76,929

 

 

 

 

 

 

 

 

 

 

76,929

 

Investment in subsidiaries

 

 

426,410

 

 

 

2,864,386

 

 

 

529,179

 

 

 

 

 

(3,819,975

)

 

 

 

 

 

Investment in equity affiliates

 

 

 

 

 

 

 

 

886

 

 

 

 

 

 

 

 

 

 

886

 

Investment in debentures, intercompany

 

 

717,909

 

 

 

 

 

 

 

 

 

 

 

(717,909

)

 

 

 

 

 

Intercompany other receivable

 

 

 

 

 

49,761

 

 

 

 

 

 

 

 

(49,761

)

 

 

 

 

 

Intangible assets, net

 

 

 

 

 

 

 

 

131,590

 

 

 

 

 

 

 

 

 

 

131,590

 

Goodwill

 

 

 

 

 

 

 

 

1,337,122

 

 

 

 

 

 

 

 

 

 

1,337,122

 

Other assets

 

 

 

 

 

 

 

 

262,169

 

 

 

 

 

 

 

 

 

 

262,169

 

Total assets

 

$

1,452,660

 

 

$

3,000,190

 

 

$

6,179,905

 

 

 

 

$

(7,183,134

)

 

 

 

$

3,449,621

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities and equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term borrowings

 

$

 

 

$

 

 

$

170,000

 

 

 

 

$

 

 

 

 

$

170,000

 

Intercompany loans

 

 

38,000

 

 

 

1,597,537

 

 

 

179,854

 

 

 

 

 

(1,815,391

)

 

 

 

 

 

        Current portion of long-term debt

 

 

 

 

 

 

 

 

39,226

 

 

 

 

 

 

 

 

 

 

39,226

 

Accounts payable

 

 

103

 

 

 

58

 

 

 

14,889

 

 

 

 

 

 

 

 

 

 

15,050

 

Intercompany accounts payable

 

 

 

 

 

 

 

 

82,935

 

 

 

 

 

(82,935

)

 

 

 

 

 

Income taxes payable

 

 

885

 

 

 

 

 

 

29,141

 

 

 

 

 

 

 

 

 

 

30,026

 

Intercompany other payable

 

 

29,526

 

 

 

59,266

 

 

 

108,371

 

 

 

 

 

(197,163

)

 

 

 

 

 

Accrued expenses and other current liabilities

 

 

5,995

 

 

 

2,390

 

 

 

576,097

 

 

 

 

 

 

 

 

 

 

584,482

 

Total current liabilities

 

$

74,509

 

 

$

1,659,251

 

 

$

1,200,513

 

 

 

 

$

(2,095,489

)

 

 

 

$

838,784

 

Long-term debt, less current portion

 

 

347,761

 

 

 

 

 

 

658,926

 

 

 

 

 

 

 

 

 

 

1,006,687

 

Deferred tax liabilities

 

 

 

 

 

 

 

 

6,747

 

 

 

 

 

 

 

 

 

 

6,747

 

Intercompany other payable

 

 

 

 

 

 

 

 

49,761

 

 

 

 

 

(49,761

)

 

 

 

 

 

Non-current intercompany loans payable

 

 

500,000

 

 

 

 

 

 

717,909

 

 

 

 

 

(1,217,909

)

 

 

 

 

 

Other liabilities

 

 

1,211

 

 

 

153

 

 

 

167,245

 

 

 

 

 

 

 

 

 

 

168,609

 

Total liabilities

 

$

923,481

 

 

$

1,659,404

 

 

$

2,801,101

 

 

 

 

$

(3,363,159

)

 

 

 

$

2,020,827

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Redeemable non-controlling interest

 

 

 

 

 

 

 

 

4,750

 

 

 

 

 

 

 

 

 

 

4,750

 

Shareholders' equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common stock

 

 

28

 

 

 

1,924

 

 

 

189,649

 

 

 

 

 

(189,677

)

 

 

 

 

1,924

 

Additional paid-in capital

 

 

575,862

 

 

 

1,421,354

 

 

 

1,107,383

 

 

 

 

 

(1,683,231

)

 

 

 

 

1,421,368

 

Retained earnings

 

 

(12,277

)

 

 

272,738

 

 

 

2,504,580

 

 

 

 

 

(2,409,059

)

 

 

 

 

355,982

 

Accumulated other comprehensive income (loss)

 

 

(34,434

)

 

 

(355,230

)

 

 

(427,558

)

 

 

 

 

461,992

 

 

 

 

 

(355,230

)

Total equity

 

 

529,179

 

 

 

1,340,786

 

 

 

3,374,054

 

 

 

 

 

(3,819,975

)

 

 

 

 

1,424,044

 

Commitments and contingencies

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total liabilities, redeemable non-controlling interest and equity

 

$

1,452,660

 

 

$

3,000,190

 

 

$

6,179,905

 

 

 

 

$

(7,183,134

)

 

 

 

$

3,449,621

 

 

 

 

F-68


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

 

31. Guarantor financial information (continued)

 

Condensed Consolidating Balance Sheet

 

 

 

As of December 31,  2016

 

 

 

Issuer/ Subsidiary

 

 

 

Parent/ Guarantor

 

 

 

Non-Guarantor

Subsidiaries

 

 

 

 

Eliminations

 

 

 

 

Consolidated

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

11,215

 

 

$

7,849

 

 

$

403,559

 

 

 

 

$

 

 

 

 

$

422,623

 

Accounts receivable intercompany, net

 

 

55,618

 

 

 

 

 

 

 

 

 

 

 

(55,618

)

 

 

 

 

 

Accounts receivable, net

 

 

 

 

 

 

 

 

615,265

 

 

 

 

 

 

 

 

 

 

615,265

 

Intercompany loans

 

 

396,682

 

 

 

 

 

 

1,270,150

 

 

 

 

 

(1,666,832

)

 

 

 

 

 

Intercompany other receivable

 

 

26,985

 

 

 

72,883

 

 

 

57,475

 

 

 

 

 

(157,343

)

 

 

 

 

 

Prepaid expenses and other current assets

 

 

151

 

 

 

131

 

 

 

188,867

 

 

 

 

 

 

 

 

 

 

189,149

 

Total current assets

 

$

490,651

 

 

$

80,863

 

 

$

2,535,316

 

 

 

 

$

(1,879,793

)

 

 

 

$

1,227,037

 

Property, plant and equipment, net

 

 

547

 

 

 

 

 

 

192,671

 

 

 

 

 

 

 

 

 

 

193,218

 

Intangible assets, net

 

 

 

 

 

 

 

 

78,946

 

 

 

 

 

 

 

 

 

 

78,946

 

Intercompany loans

 

 

 

 

 

 

 

 

500,000

 

 

 

 

 

(500,000

)

 

 

 

 

 

Deferred tax assets

 

 

 

 

 

 

 

 

70,143

 

 

 

 

 

 

 

 

 

 

70,143

 

Investment in subsidiaries

 

 

423,530

 

 

 

2,470,680

 

 

 

1,005,396

 

 

 

 

 

(3,899,606

)

 

 

 

 

 

Investment in equity affiliates

 

 

4,121

 

 

 

 

 

 

679

 

 

 

 

 

 

 

 

 

 

4,800

 

Investment in debentures, intercompany

 

 

675,180

 

 

 

 

 

 

 

 

 

 

 

(675,180

)

 

 

 

 

 

Intercompany other receivable

 

 

 

 

 

47,954

 

 

 

 

 

 

 

 

(47,954

)

 

 

 

 

 

Goodwill

 

 

 

 

 

 

 

 

1,069,408

 

 

 

 

 

 

 

 

 

 

1,069,408

 

Other assets

 

 

 

 

 

 

 

 

242,328

 

 

 

 

 

 

 

 

 

 

242,328

 

Total assets

 

$

1,594,029

 

 

$

2,599,497

 

 

$

5,694,887

 

 

 

 

$

(7,002,533

)

 

 

 

$

2,885,880

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities and equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term borrowings

 

$

 

 

$

 

 

$

160,000

 

 

 

 

$

 

 

 

 

$

160,000

 

Current portion of long-term debt

 

 

 

 

 

 

 

 

39,181

 

 

 

 

 

 

 

 

 

 

39,181

 

Intercompany loan

 

 

73,000

 

 

 

1,333,650

 

 

 

260,182

 

 

 

 

 

(1,666,832

)

 

 

 

 

 

Accounts payable

 

 

168

 

 

 

1

 

 

 

9,599

 

 

 

 

 

 

 

 

 

 

9,768

 

Intercompany accounts payable

 

 

 

 

 

 

 

 

55,618

 

 

 

 

 

(55,618

)

 

 

 

 

 

Income taxes payable

 

 

777

 

 

 

 

 

 

23,382

 

 

 

 

 

 

 

 

 

 

24,159

 

Intercompany other payable

 

 

2,612

 

 

 

58,440

 

 

 

96,291

 

 

 

 

 

(157,343

)

 

 

 

 

 

Accrued expenses and other current liabilities

 

 

7,148

 

 

 

3,695

 

 

 

487,404

 

 

 

 

 

 

 

 

 

 

498,247

 

Total current liabilities

 

$

83,705

 

 

$

1,395,786

 

 

$

1,131,657

 

 

 

 

$

(1,879,793

)

 

 

 

$

731,355

 

Long-term debt, less current portion

 

 

 

 

 

 

 

 

698,152

 

 

 

 

 

 

 

 

 

 

698,152

 

Intercompany other payable

 

 

 

 

 

 

 

 

47,954

 

 

 

 

 

(47,954

)

 

 

 

 

 

Deferred tax liabilities

 

 

231

 

 

 

 

 

 

2,184

 

 

 

 

 

 

 

 

 

 

2,415

 

Non-current intercompany loans payable

 

 

500,000

 

 

 

 

 

 

675,180

 

 

 

 

 

(1,175,180

)

 

 

 

 

 

Other liabilities

 

 

4,697

 

 

 

307

 

 

 

157,786

 

 

 

 

 

 

 

 

 

 

162,790

 

Total liabilities

 

$

588,633

 

 

$

1,396,093

 

 

$

2,712,913

 

 

 

 

$

(3,102,927

)

 

 

 

$

1,594,712

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Redeemable non-controlling interest

 

 

 

 

 

 

 

 

4,520

 

 

 

 

 

 

 

 

 

 

4,520

 

Shareholders’ equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common stock

 

 

28

 

 

 

1,984

 

 

 

189,649

 

 

 

 

 

(189,677

)

 

 

 

 

1,984

 

Additional paid-in capital

 

 

1,211,108

 

 

 

1,384,468

 

 

 

1,107,348

 

 

 

 

 

(2,318,456

)

 

 

 

 

1,384,468

 

Retained earnings

 

 

(85,093

)

 

 

274,877

 

 

 

2,076,761

 

 

 

 

 

(1,908,424

)

 

 

 

 

358,121

 

Accumulated other comprehensive income (loss)

 

 

(120,647

)

 

 

(457,925

)

 

 

(396,304

)

 

 

 

 

516,951

 

 

 

 

 

(457,925

)

Total equity

 

$

1,005,396

 

 

$

1,203,404

 

 

$

2,977,454

 

 

 

 

$

(3,899,606

)

 

 

 

$

1,286,648

 

Commitments and contingencies

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total liabilities, redeemable non-controlling interest and equity

 

$

1,594,029

 

 

$

2,599,497

 

 

$

5,694,887

 

 

 

 

$

(7,002,533

)

 

 

 

$

2,885,880

 

 

F-69


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

31. Guarantor financial information (continued)

 

 

Condensed Consolidating Statement of Income (Loss)

 

 

 

Year ended December 31,  2017

 

 

 

Issuer/

Subsidiary

 

 

 

Parent/

Guarantor

 

 

 

 

 

Non-

Guarantor

Subsidiaries

 

 

 

 

Eliminations

 

 

 

 

Consolidated

 

Net revenues

 

$

46,722

 

 

$

 

 

 

 

$

2,736,929

 

 

 

 

$

(46,722

)

 

 

 

$

2,736,929

 

Cost of revenue

 

 

 

 

 

 

 

 

 

 

1,683,704

 

 

 

 

 

 

 

 

 

 

1,683,704

 

Gross profit

 

$

46,722

 

 

$

 

 

 

 

$

1,053,225

 

 

 

 

$

(46,722

)

 

 

 

$

1,053,225

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative expenses

 

 

9,859

 

 

 

21,076

 

 

 

 

 

728,531

 

 

 

 

 

(69,619

)

 

 

 

 

689,847

 

Amortization of acquired intangible assets

 

 

 

 

 

 

 

 

 

 

36,412

 

 

 

 

 

 

 

 

 

 

36,412

 

Other operating (income) expense, net

 

 

(3,412

)

 

 

 

 

 

 

 

1,751

 

 

 

 

 

 

 

 

 

 

(1,661

)

Income (loss) from operations

 

$

40,275

 

 

$

(21,076

)

 

 

 

$

286,531

 

 

 

 

$

22,897

 

 

 

 

$

328,627

 

Foreign exchange gains (losses), net

 

 

3,312

 

 

 

2

 

 

 

 

 

(1,318

)

 

 

 

 

 

 

 

 

 

1,996

 

Interest income (expense), net

 

 

(11,375

)

 

 

 

 

 

 

 

(20,360

)

 

 

 

 

 

 

 

 

 

(31,735

)

Intercompany interest income (expense), net

 

 

47,547

 

 

 

(10,148

)

 

 

 

 

(37,399

)

 

 

 

 

 

 

 

 

 

 

Other income (expense), net

 

 

18,391

 

 

 

 

 

 

 

 

7,847

 

 

 

 

 

 

 

 

 

 

26,238

 

Income (loss) before equity-method investment activity,

net and income tax expense

 

$

98,150

 

 

$

(31,222

)

 

 

 

$

235,301

 

 

 

 

$

22,897

 

 

 

 

$

325,126

 

Gain (loss) on equity-method investment activity, net

 

 

(15,058

)

 

 

294,333

 

 

 

 

 

75,657

 

 

 

 

 

(359,475

)

 

 

 

 

(4,543

)

Income before income tax expense

 

$

83,092

 

 

$

263,111

 

 

 

 

$

310,958

 

 

 

 

$

(336,578

)

 

 

 

$

320,583

 

Income tax expense

 

 

7,435

 

 

 

 

 

 

 

 

52,307

 

 

 

 

 

 

 

 

 

 

59,742

 

Net income

 

$

75,657

 

 

$

263,111

 

 

 

 

$

258,651

 

 

 

 

$

(336,578

)

 

 

 

$

260,841

 

Net loss attributable to redeemable non-controlling interest

 

 

 

 

 

 

 

 

 

 

(2,270

)

 

 

 

 

 

 

 

 

 

(2,270

)

Net income attributable to Genpact Limited shareholders

 

$

75,657

 

 

$

263,111

 

 

 

 

$

260,921

 

 

 

 

$

(336,578

)

 

 

 

$

263,111

 

 

F-70


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

31. Guarantor financial information (continued)

 

Condensed Consolidating Statement of Income (Loss)

 

 

 

Year ended December 31,  2016

 

 

 

Issuer/

Subsidiary

 

 

 

Parent/

Guarantor

 

 

 

 

 

Non-

Guarantor

Subsidiaries

 

 

 

 

Eliminations

 

 

 

 

Consolidated

 

Net revenues

 

$

39,518

 

 

$

 

 

 

 

$

2,570,756

 

 

 

 

$

(39,518

)

 

 

 

$

2,570,756

 

Cost of revenue

 

 

 

 

 

 

 

 

 

 

1,554,707

 

 

 

 

 

 

 

 

 

 

1,554,707

 

Gross profit

 

$

39,518

 

 

$

 

 

 

 

$

1,016,049

 

 

 

 

$

(39,518

)

 

 

 

$

1,016,049

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative expenses

 

 

9,499

 

 

 

12,772

 

 

 

 

 

672,742

 

 

 

 

 

(41,984

)

 

 

 

 

653,029

 

Amortization of acquired intangible assets

 

 

 

 

 

 

 

 

 

 

27,183

 

 

 

 

 

 

 

 

 

 

27,183

 

Other operating (income) expense, net

 

 

(4,043

)

 

 

(500

)

 

 

 

 

(397

)

 

 

 

 

 

 

 

 

 

(4,940

)

Income (loss) from operations

 

$

34,062

 

 

$

(12,272

)

 

 

 

$

316,521

 

 

 

 

$

2,466

 

 

 

 

$

340,777

 

Foreign exchange gains (losses), net

 

 

(1,633

)

 

 

57

 

 

 

 

 

4,206

 

 

 

 

 

 

 

 

 

 

2,630

 

Interest income (expense), net

 

 

(1,358

)

 

 

 

 

 

 

 

(14,826

)

 

 

 

 

 

 

 

 

 

(16,184

)

Intercompany interest income (expense), net

 

 

81,359

 

 

 

 

 

 

 

 

(81,359

)

 

 

 

 

 

 

 

 

 

 

Other income (expense), net

 

 

(829

)

 

 

(3,390

)

 

 

 

 

14,339

 

 

 

 

 

 

 

 

 

 

10,120

 

Income (loss) before equity-method investment

activity, net and income tax expense

 

$

111,601

 

 

$

(15,605

)

 

 

 

$

238,881

 

 

 

 

$

2,466

 

 

 

 

$

337,343

 

Gain (loss) on equity-method investment activity, net

 

 

29,969

 

 

 

285,289

 

 

 

 

 

133,186

 

 

 

 

 

(456,142

)

 

 

 

 

(7,698

)

Income before income tax expense

 

$

141,570

 

 

$

269,684

 

 

 

 

$

372,067

 

 

 

 

$

(453,676

)

 

 

 

$

329,645

 

Income tax expense

 

 

8,384

 

 

 

 

 

 

 

 

53,714

 

 

 

 

 

 

 

 

 

 

62,098

 

Net income

 

$

133,186

 

 

$

269,684

 

 

 

 

$

318,353

 

 

 

 

$

(453,676

)

 

 

 

$

267,547

 

Net loss attributable to redeemable non-controlling interest

 

 

 

 

 

 

 

 

 

 

(2,137

)

 

 

 

 

 

 

 

 

 

(2,137

)

Net income attributable to Genpact Limited shareholders

 

$

133,186

 

 

$

269,684

 

 

 

 

$

320,490

 

 

 

 

$

(453,676

)

 

 

 

$

269,684

 

 

F-71


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

31. Guarantor financial information (continued)

 

 

Condensed Consolidating Statement of Income (Loss)

 

 

 

Year ended December 31,  2015

 

 

 

Issuer/

Subsidiary

 

 

 

Parent/

Guarantor

 

 

 

 

 

Non-

Guarantor

Subsidiaries

 

 

 

 

Eliminations

 

 

 

 

Consolidated

 

Net revenues

 

$

34,250

 

 

$

 

 

 

 

$

2,461,044

 

 

 

 

$

(34,250

)

 

 

 

$

2,461,044

 

Cost of revenue

 

 

 

 

 

 

 

 

 

 

1,493,547

 

 

 

 

 

 

 

 

 

 

1,493,547

 

Gross profit

 

$

34,250

 

 

$

 

 

 

 

$

967,497

 

 

 

 

$

(34,250

)

 

 

 

$

967,497

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative expenses

 

 

4,594

 

 

 

21,298

 

 

 

 

 

616,472

 

 

 

 

 

(34,250

)

 

 

 

 

608,114

 

Amortization of acquired intangible assets

 

 

 

 

 

 

 

 

 

 

28,513

 

 

 

 

 

 

 

 

 

 

28,513

 

Other operating (income) expense, net

 

 

22,149

 

 

 

 

 

 

 

 

(3,203

)

 

 

 

 

(22,268

)

 

 

 

 

(3,322

)

Income (loss) from operations

 

$

7,507

 

 

$

(21,298

)

 

 

 

$

325,715

 

 

 

 

$

22,268

 

 

 

 

$

334,192

 

Foreign exchange gains (losses), net

 

 

(3,574

)

 

 

(219

)

 

 

 

 

9,062

 

 

 

 

 

 

 

 

 

 

5,269

 

Interest income (expense), net, intercompany

 

 

42,417

 

 

 

2,027

 

 

 

 

 

(44,444

)

 

 

 

 

 

 

 

 

 

 

Interest income (expense), net

 

 

(531

)

 

 

 

 

 

 

 

(30,736

)

 

 

 

 

 

 

 

 

 

(31,267

)

Other income (expense), net

 

 

 

 

 

 

 

 

 

 

4,360

 

 

 

 

 

 

 

 

 

 

4,360

 

Income (loss) before equity-method investment

activity, net and income tax expense

 

$

45,819

 

 

$

(19,490

)

 

 

 

$

263,957

 

 

 

 

$

22,268

 

 

 

 

$

312,554

 

Gain (loss) on equity-method investment activity, net

 

 

17,757

 

 

 

237,040

 

 

 

 

 

56,416

 

 

 

 

 

(322,013

)

 

 

 

 

(10,800

)

Income before income tax expense

 

$

63,576

 

 

$

217,550

 

 

 

 

$

320,373

 

 

 

 

$

(299,745

)

 

 

 

$

301,754

 

Income tax expense

 

 

7,160

 

 

 

 

 

 

 

 

54,777

 

 

 

 

 

 

 

 

 

 

61,937

 

Net income

 

$

56,416

 

 

$

217,550

 

 

 

 

$

265,596

 

 

 

 

$

(299,745

)

 

 

 

$

239,817

 

Net loss (income) attributable to redeemable non-controlling interest

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income attributable to Genpact Limited shareholders

 

$

56,416

 

 

$

217,550

 

 

 

 

$

265,596

 

 

 

 

$

(299,745

)

 

 

 

$

239,817

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

F-72


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

 

 

 

31. Guarantor financial information (continued)

 

Condensed Consolidating Statement of Comprehensive Income (Loss)

 

 

Year ended December 31,  2017

 

 

Issuer/ Subsidiary

 

 

Parent/ Guarantor

 

 

Non-Guarantor Subsidiaries

 

 

Eliminations

 

 

Genpact

Limited

Shareholders

 

 

Redeemable Non-controlling interest

 

Net income (loss)

$

75,657

 

 

$

263,111

 

 

$

260,921

 

 

$

(336,578

)

 

$

263,111

 

 

$

(2,270

)

Other comprehensive income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Currency translation adjustments

 

74,716

 

 

 

93,871

 

 

 

93,871

 

 

 

(168,587

)

 

 

93,871

 

 

 

(341

)

Net income (loss) on cash flow hedging derivatives, net of taxes (Note 7)

 

9,788

 

 

 

12,611

 

 

 

12,611

 

 

 

(22,399

)

 

 

12,611

 

 

 

 

Retirement benefits, net of taxes

 

475

 

 

 

(3,787

)

 

 

(3,787

)

 

 

3,312

 

 

 

(3,787

)

 

 

 

Other comprehensive income (loss)

$

84,979

 

 

$

102,695

 

 

$

102,695

 

 

$

(187,674

)

 

$

102,695

 

 

$

(341

)

Comprehensive income (loss)

$

160,636

 

 

$

365,806

 

 

$

363,616

 

 

$

(524,252

)

 

$

365,806

 

 

$

(2,611

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year ended  December 31,  2016

 

 

Issuer/ Subsidiary

 

 

Parent/ Guarantor

 

 

Non-Guarantor Subsidiaries

 

 

Eliminations

 

 

Genpact

Limited

Shareholders

 

 

Redeemable Non-controlling interest

 

Net income (loss)

$

133,186

 

 

$

269,684

 

 

$

320,490

 

 

$

(453,676

)

 

$

269,684

 

 

$

(2,137

)

Other comprehensive income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Currency translation adjustments

 

(31,679

)

 

 

(46,340

)

 

 

(46,340

)

 

 

78,019

 

 

 

(46,340

)

 

 

104

 

Net income (loss) on cash flow hedging derivatives, net of taxes (Note 7)

 

42,016

 

 

 

43,742

 

 

 

43,742

 

 

 

(85,758

)

 

 

43,742

 

 

 

 

Retirement benefits, net of taxes

 

(717

)

 

 

(4,042

)

 

 

(4,042

)

 

 

4,759

 

 

 

(4,042

)

 

 

 

Other comprehensive income (loss)

$

9,620

 

 

$

(6,640

)

 

$

(6,640

)

 

$

(2,980

)

 

$

(6,640

)

 

$

104

 

Comprehensive income (loss)

$

142,806

 

 

$

263,044

 

 

$

313,850

 

 

$

(456,656

)

 

$

263,044

 

 

$

(2,033

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31,  2015

 

 

Issuer/ Subsidiary

 

 

Parent/ Guarantor

 

 

Non-Guarantor Subsidiaries

 

 

Eliminations

 

 

Genpact

Limited

Shareholders

 

 

Redeemable Non-controlling interest

 

Net income (loss)

$

56,416

 

 

$

217,550

 

 

$

265,596

 

 

$

(299,745

)

 

$

239,817

 

 

$

 

Other comprehensive income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Currency translation adjustments

 

(67,173

)

 

 

(64,504

)

 

 

(64,504

)

 

 

131,677

 

 

 

(64,504

)

 

 

 

Net income (loss) on cash flow hedging derivatives, net of taxes (Note 7)

 

27,247

 

 

 

22,880

 

 

 

22,880

 

 

 

(50,127

)

 

 

22,880

 

 

 

 

Retirement benefits, net of taxes

 

554

 

 

 

2,823

 

 

 

2,823

 

 

 

(3,377

)

 

 

2,823

 

 

 

 

Other comprehensive income (loss)

$

(39,372

)

 

$

(38,801

)

 

$

(38,801

)

 

$

78,173

 

 

$

(38,801

)

 

$

 

Comprehensive income (loss)

$

17,044

 

 

$

178,749

 

 

$

226,795

 

 

$

(221,572

)

 

$

201,016

 

 

$

 

 

F-73


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

31. Guarantor financial information (continued)

 

Condensed Consolidating Statement of Cash Flows

 

 

 

Year ended December 31,  2017

 

 

 

Issuer/

Subsidiary

 

 

 

Parent/

Guarantor

 

 

 

Non-

Guarantor

Subsidiaries

 

 

Eliminations

 

 

Consolidated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating activities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net cash (used for) provided by operating activities

 

$

(315,877

)

 

$

(8,345

)

 

$

511,847

 

 

$

171,453

 

 

$

359,078

 

Investing activities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Purchase of property, plant and equipment

 

 

 

 

 

 

 

 

(57,231

)

 

 

 

 

 

(57,231

)

Payment for internally generated intangible assets

 

 

 

 

 

 

 

 

(16,441

)

 

 

 

 

 

(16,441

)

Proceeds from sale of property, plant and equipment

 

 

 

 

 

 

 

 

1,738

 

 

 

 

 

 

1,738

 

Investment in equity affiliates

 

 

(523

)

 

 

 

 

 

27

 

 

 

 

 

 

(496

)

Investment in subsidiaries

 

 

(3,638

)

 

 

 

 

 

51,127

 

 

 

(47,489

)

 

 

 

Payment for business acquisitions, net of cash acquired

 

 

 

 

 

 

 

 

(284,822

)

 

 

 

 

 

(284,822

)

Proceeds from divestiture of business, net of cash divested

 

 

 

 

 

 

 

 

(4,738

)

 

 

 

 

 

(4,738

)

Net cash (used for)  provided by investing activities

 

$

(4,161

)

 

$

 

 

$

(310,340

)

 

$

(47,489

)

 

$

(361,990

)

Financing activities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Repayment of capital lease obligations

 

 

 

 

 

 

 

 

(2,708

)

 

 

 

 

 

(2,708

)

Payment of debt issuance costs

 

 

(2,630

)

 

 

 

 

 

 

 

 

 

 

 

(2,630

)

Proceeds from long-term debt

 

 

350,000

 

 

 

 

 

 

 

 

 

 

 

 

350,000

 

Repayment of long-term debt

 

 

 

 

 

 

 

 

(40,000

)

 

 

 

 

 

(40,000

)

Proceeds from short-term borrowings

 

 

 

 

 

 

 

 

295,000

 

 

 

 

 

 

295,000

 

Repayment of short-term borrowings

 

 

 

 

 

 

 

 

(285,000

)

 

 

 

 

 

(285,000

)

Proceeds from intercompany loans

 

 

 

 

 

263,886

 

 

 

 

 

 

(263,886

)

 

 

 

Repayment of intercompany loans

 

 

(35,000

)

 

 

 

 

 

(80,328

)

 

 

115,328

 

 

 

 

Proceeds from issuance of  common shares under stock-based compensation plans

 

 

 

 

 

15,528

 

 

 

 

 

 

 

 

 

15,528

 

Payment for net settlement of stock-based awards

 

 

 

 

 

(10,296

)

 

 

 

 

 

 

 

 

(10,296

)

Payment of earn-out/deferred consideration

 

 

 

 

 

 

 

 

(6,219

)

 

 

 

 

 

(6,219

)

Dividend paid

 

 

 

 

 

(46,686

)

 

 

 

 

 

 

 

 

(46,686

)

Payment for stock purchased and retired

 

 

 

 

 

(219,784

)

 

 

 

 

 

 

 

 

(219,784

)

Payment for expenses related to stock purchase

 

 

 

 

 

(16

)

 

 

 

 

 

 

 

 

(16

)

Change in amounts due from/to consolidated affiliates

 

 

 

 

 

 

 

 

(24,594

)

 

 

24,594

 

 

 

 

Excess tax benefit on stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net cash (used for) provided by financing activities

 

$

312,370

 

 

$

2,632

 

 

$

(143,849

)

 

$

(123,964

)

 

$

47,189

 

Effect of exchange rate changes

 

 

960

 

 

 

 

 

 

36,608

 

 

 

 

 

 

37,568

 

Net increase (decrease) in cash and cash equivalents

 

 

(7,668

)

 

 

(5,713

)

 

 

57,658

 

 

 

 

 

 

44,277

 

Cash and cash equivalents at the beginning of the period

 

 

11,215

 

 

 

7,849

 

 

 

403,559

 

 

 

 

 

 

422,623

 

Cash and cash equivalents at the end of the period

 

$

4,507

 

 

$

2,136

 

 

$

497,825

 

 

$

 

 

$

504,468

 

 

F-74


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

31. Guarantor financial information (continued)

 

Condensed Consolidating Statement of Cash Flows

 

 

 

Year ended December 31,  2016

 

 

 

Issuer/

Subsidiary

 

 

 

Parent/

Guarantor

 

 

 

Non-

Guarantor

Subsidiaries

 

 

Eliminations

 

 

Consolidated

 

Operating activities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net cash (used for) provided by operating activities

 

$

(42,212

)

 

$

25,592

 

 

$

(66,519

)

 

$

428,911

 

 

$

345,772

 

Investing activities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Purchase of property, plant and equipment

 

 

(625

)

 

 

 

 

 

(81,301

)

 

 

 

 

 

(81,926

)

Payment for internally generated intangible assets

 

 

 

 

 

 

 

 

(6,846

)

 

 

 

 

 

(6,846

)

Proceeds from sale of property, plant and equipment

 

 

 

 

 

 

 

 

547

 

 

 

 

 

 

547

 

Investment in equity affiliates

 

 

(5,884

)

 

 

 

 

 

(3,736

)

 

 

 

 

 

(9,620

)

Investment in subsidiaries

 

 

(53,619

)

 

 

 

 

 

(8,101

)

 

 

61,720

 

 

 

-

 

Payment for business acquisitions, net of cash acquired

 

 

 

 

 

 

 

 

(45,162

)

 

 

 

 

 

(45,162

)

Proceeds from divestiture of business, net of cash divested

 

 

 

 

 

 

 

 

17,242

 

 

 

 

 

 

17,242

 

Net cash (used for) provided by investing activities

 

$

(60,128

)

 

$

 

 

$

(127,357

)

 

$

61,720

 

 

$

(125,765

)

Financing activities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Repayment of capital lease obligations

 

 

 

 

 

 

 

 

(1,793

)

 

 

 

 

 

(1,793

)

Repayment of long-term debt

 

 

 

 

 

 

 

 

(40,000

)

 

 

 

 

 

(40,000

)

Proceeds from short-term borrowings

 

 

 

 

 

 

 

 

200,000

 

 

 

 

 

 

200,000

 

Repayment of short-term borrowings

 

 

 

 

 

 

 

 

(61,500

)

 

 

 

 

 

(61,500

)

Proceeds from intercompany loans

 

 

73,000

 

 

 

303,000

 

 

 

50,445

 

 

 

(426,445

)

 

 

 

Repayment of intercompany loans

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Proceeds from issuance of  common shares under stock-based compensation plans

 

 

 

 

 

18,228

 

 

 

 

 

 

 

 

 

18,228

 

Proceeds from issuance of  common shares

 

 

40,000

 

 

 

 

 

 

 

 

 

(40,000

)

 

 

 

Payment for net settlement of stock-based awards

 

 

 

 

 

(769

)

 

 

 

 

 

 

 

 

(769

)

Payment of earn-out/deferred consideration

 

 

 

 

 

 

 

 

(1,485

)

 

 

 

 

 

(1,485

)

Payment for stock purchased and retired

 

 

 

 

 

(345,200

)

 

 

24,186

 

 

 

(24,186

)

 

 

(345,200

)

Payment for expenses related to stock purchase

 

 

 

 

 

(279

)

 

 

 

 

 

 

 

 

(279

)

Net cash (used for) provided by financing activities

 

$

113,000

 

 

$

(25,020

)

 

$

169,853

 

 

$

(490,631

)

 

$

(232,798

)

Effect of exchange rate changes

 

 

(361

)

 

 

 

 

 

(15,132

)

 

 

 

 

 

(15,493

)

Net increase (decrease) in cash and cash equivalents

 

 

10,660

 

 

 

572

 

 

 

(24,023

)

 

 

 

 

 

(12,791

)

Cash and cash equivalents at the beginning of the period

 

 

916

 

 

 

7,277

 

 

 

442,714

 

 

 

 

 

 

450,907

 

Cash and cash equivalents at the end of the period

 

$

11,215

 

 

$

7,849

 

 

$

403,559

 

 

$

 

 

$

422,623

 

 

F-75


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

31. Guarantor financial information (continued)

 

Condensed Consolidating Statement of Cash Flows

 

 

 

Year ended December 31,  2015

 

 

 

Issuer/

Subsidiary

 

 

 

Parent/

Guarantor

 

 

 

Non-

Guarantor

Subsidiaries

 

 

Eliminations

 

 

Consolidated

 

Operating activities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net cash (used for) provided by operating activities

 

$

(9,868

)

 

$

183,510

 

 

$

347,114

 

 

$

(193,315

)

 

$

327,441

 

Investing activities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Purchase of property, plant and equipment

 

 

 

 

 

 

 

 

(62,173

)

 

 

 

 

 

(62,173

)

Proceeds from sale of property, plant and equipment

 

 

 

 

 

 

 

 

1,486

 

 

 

 

 

 

1,486

 

Investment in equity affiliates

 

 

(6,084

)

 

 

 

 

 

(12,339

)

 

 

 

 

 

(18,423

)

Investment in subsidiaries

 

 

(21,670

)

 

 

 

 

 

(687,455

)

 

 

709,125

 

 

 

 

Payment for business acquisitions, net of cash acquired

 

 

 

 

 

 

 

 

(21,363

)

 

 

 

 

 

(21,363

)

Payment for investment in debentures, intercompany

 

 

(736,692

)

 

 

 

 

 

 

 

 

736,692

 

 

 

 

Net cash (used for) provided by investing activities

 

$

(764,446

)

 

$

 

 

$

(781,844

)

 

$

1,445,817

 

 

$

(100,473

)

Financing activities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Repayment of capital lease obligations

 

 

 

 

 

 

 

 

(2,035

)

 

 

 

 

 

(2,035

)

Payment of debt issuance and refinancing costs

 

 

 

 

 

 

 

 

(6,584

)

 

 

 

 

 

(6,584

)

Proceeds from long-term debt

 

 

 

 

 

 

 

 

800,000

 

 

 

 

 

 

800,000

 

Repayment of long-term debt

 

 

 

 

 

 

 

 

(684,875

)

 

 

 

 

 

(684,875

)

Proceeds from short-term borrowings

 

 

 

 

 

 

 

 

1,451,500

 

 

 

 

 

 

1,451,500

 

Repayment of short-term borrowings

 

 

 

 

 

 

 

 

(1,565,000

)

 

 

 

 

 

(1,565,000

)

Proceeds from intercompany loans

 

 

 

 

 

28,500

 

 

 

-

 

 

 

(28,500

)

 

 

 

Repayment of intercompany loans

 

 

 

 

 

 

 

 

(228,375

)

 

 

228,375

 

 

 

 

Proceeds from issuance of  common shares under stock-based compensation plans

 

 

 

 

 

16,088

 

 

 

 

 

 

 

 

 

16,088

 

Proceeds from issuance of  common shares

 

 

747,656

 

 

 

 

 

 

(6,556

)

 

 

(741,100

)

 

 

 

Payment for net settlement of stock-based awards

 

 

 

 

 

(7,194

)

 

 

 

 

 

 

 

 

(7,194

)

Payment of earn-out/deferred consideration

 

 

 

 

 

 

 

 

(230

)

 

 

 

 

 

(230

)

Proceeds from issuance of debentures, intercompany

 

 

 

 

 

 

 

 

736,692

 

 

 

(736,692

)

 

 

 

Payment for stock purchased and retired

 

 

 

 

 

(226,917

)

 

 

 

 

 

 

 

 

(226,917

)

Payment for expenses related to stock purchase

 

 

 

 

 

(197

)

 

 

(31,975

)

 

 

31,975

 

 

 

(197

)

Excess tax benefit on stock-based compensation

 

 

 

 

 

6,560

 

 

 

6,560

 

 

 

(6,560

)

 

 

6,560

 

Net cash (used for)  provided by financing activities

 

$

747,656

 

 

$

(183,160

)

 

$

469,122

 

 

$

(1,252,502

)

 

$

(218,884

)

Effect of exchange rate changes

 

 

(159

)

 

 

 

 

 

(18,806

)

 

 

 

 

 

(18,965

)

Net increase (decrease) in cash and cash equivalents

 

 

(26,658

)

 

 

350

 

 

 

34,392

 

 

 

 

 

 

8,084

 

Cash and cash equivalents at the beginning of the period

 

 

27,733

 

 

 

6,927

 

 

 

427,128

 

 

 

 

 

 

461,788

 

Cash and cash equivalents at the end of the period

 

$

916

 

 

$

7,277

 

 

$

442,714

 

 

$

 

 

$

450,907

 

 

 

 

 

F-76

g-ex992_481.htm

 

Exhibit 99.2

GENPACT LIMITED AND ITS SUBSIDIARIES

Consolidated Balance Sheets

(Unaudited)

(In thousands, except per share data and share count)

 

 

 

Notes

 

As of December 31,

2017

 

 

As of March 31,

2018

 

Assets

 

 

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

4

 

$

504,468

 

 

$

424,226

 

Accounts receivable, net

 

5

 

 

693,085

 

 

 

703,066

 

Prepaid expenses and other current assets

 

8

 

 

236,342

 

 

 

199,208

 

Total current assets

 

 

 

$

1,433,895

 

 

$

1,326,500

 

 

 

 

 

 

 

 

 

 

 

 

Property, plant and equipment, net

 

9

 

 

207,030

 

 

 

205,035

 

Deferred tax assets

 

24

 

 

76,929

 

 

 

81,734

 

Investment in equity affiliates

 

25

 

 

886

 

 

 

919

 

Intangible assets, net

 

10

 

 

131,590

 

 

 

125,781

 

Goodwill

 

10

 

 

1,337,122

 

 

 

1,337,051

 

Contract cost assets

 

19

 

 

-

 

 

 

162,435

 

Other assets

 

 

 

 

262,169

 

 

 

157,672

 

Total assets

 

 

 

$

3,449,621

 

 

$

3,397,127

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities and equity

 

 

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

 

 

Short-term borrowings

 

11

 

$

170,000

 

 

$

275,000

 

Current portion of long-term debt

 

12

 

 

39,226

 

 

 

39,237

 

Accounts payable

 

 

 

 

15,050

 

 

 

13,811

 

Income taxes payable

 

24

 

 

30,026

 

 

 

40,026

 

           Accrued expenses and other current liabilities

 

13

 

 

584,482

 

 

 

503,116

 

Total current liabilities

 

 

 

$

838,784

 

 

$

871,190

 

 

 

 

 

 

 

 

 

 

 

 

Long-term debt, less current portion

 

12

 

 

1,006,687

 

 

 

996,999

 

Deferred tax liabilities

 

24

 

 

6,747

 

 

 

7,083

 

      Other liabilities

 

14

 

 

168,609

 

 

 

155,858

 

Total liabilities

 

 

 

$

2,020,827

 

 

$

2,031,130

 

 

 

 

 

 

 

 

 

 

 

 

Redeemable non-controlling interest

 

 

 

 

4,750

 

 

 

 

Shareholders' equity

 

 

 

 

 

 

 

 

 

 

Preferred shares, $0.01 par value, 250,000,000 authorized, none issued

 

 

 

 

 

 

 

 

Common shares, $0.01 par value, 500,000,000 authorized, 192,825,207

and 190,613,135 issued and outstanding as of December 31, 2017

and March 31, 2018, respectively

 

 

 

 

1,924

 

 

 

1,903

 

Additional paid-in capital

 

 

 

 

1,421,368

 

 

 

1,422,897

 

Retained earnings

 

 

 

 

355,982

 

 

 

321,916

 

Accumulated other comprehensive income (loss)

 

 

 

 

(355,230

)

 

 

(380,719

)

Total equity

 

 

 

$

1,424,044

 

 

$

1,365,997

 

Commitments and contingencies

 

27

 

 

 

 

 

 

 

 

Total liabilities, redeemable non-controlling interest and equity

 

 

 

$

3,449,621

 

 

$

3,397,127

 

 

See accompanying notes to the Consolidated Financial Statements.

1


 

GENPACT LIMITED AND ITS SUBSIDIARIES

Consolidated Statements of Income

(Unaudited)

(In thousands, except per share data and share count)

 

 

 

 

 

Three months ended March 31,

 

 

 

Notes

 

2017

 

 

2018

 

Net revenues

 

19

 

$

622,995

 

 

$

688,912

 

Cost of revenue

 

20, 25

 

 

383,337

 

 

 

444,324

 

Gross profit

 

 

 

$

239,658

 

 

$

244,588

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative expenses

 

21, 25

 

 

160,858

 

 

 

171,109

 

Amortization of acquired intangible assets

 

10

 

 

7,242

 

 

 

9,936

 

Other operating (income) expense, net

 

22

 

 

(7,538

)

 

 

(218

)

Income from operations

 

 

 

$

79,096

 

 

$

63,761

 

Foreign exchange gains (losses), net

 

 

 

 

(4,913

)

 

 

4,798

 

Interest income (expense), net

 

23

 

 

(5,493

)

 

 

(8,100

)

Other income (expense), net

 

26

 

 

553

 

 

 

15,550

 

Income before equity-method investment activity, net and income tax expense

 

 

 

$

69,243

 

 

$

76,009

 

Equity-method investment activity, net

 

 

 

 

(4,558

)

 

 

 

Income before income tax expense

 

 

 

$

64,685

 

 

$

76,009

 

Income tax expense

 

24

 

 

12,245

 

 

 

12,075

 

Net income

 

 

 

$

52,440

 

 

$

63,934

 

Net loss attributable to redeemable non-controlling interest

 

 

 

 

898

 

 

 

761

 

Net income attributable to Genpact Limited shareholders

 

 

 

$

53,338

 

 

$

64,695

 

Net income available to Genpact Limited common shareholders

 

18

 

$

53,338

 

 

$

64,695

 

Earnings per common share attributable to Genpact Limited

   common shareholders

 

18

 

 

 

 

 

 

 

 

Basic

 

 

 

$

0.27

 

 

$

0.34

 

Diluted

 

 

 

$

0.26

 

 

$

0.33

 

Weighted average number of common shares used  in computing earnings per common share attributable to Genpact Limited common shareholders

 

 

 

 

 

 

 

 

 

 

Basic

 

 

 

 

199,069,528

 

 

 

192,816,626

 

Diluted

 

 

 

 

202,655,937

 

 

 

196,288,569

 

 

See accompanying notes to the Consolidated Financial Statements.

2


 

GENPACT LIMITED AND ITS SUBSIDIARIES

Consolidated Statements of Comprehensive Income (Loss)

(Unaudited)

(In thousands, except per share data and share count)

 

 

 

Three months ended March 31,

 

 

 

2017

 

 

2018

 

 

 

Genpact

Limited

Shareholders

 

 

Redeemable

Non-

controlling

interest

 

 

Genpact

Limited

Shareholders

 

 

Redeemable

Non-

controlling

interest

 

Net income (loss)

 

$

53,338

 

 

$

(898

)

 

$

64,695

 

 

$

(761

)

Other comprehensive income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Currency translation  adjustments

 

 

51,627

 

 

 

(12

)

 

 

(9,335

)

 

 

(424

)

Net income (loss) on cash flow hedging derivatives, net of taxes (Note 7)

 

 

18,858

 

 

 

 

 

 

(18,932

)

 

 

 

Retirement benefits, net of taxes

 

 

119

 

 

 

 

 

 

513

 

 

 

 

Other comprehensive income (loss)

 

 

70,604

 

 

 

(12

)

 

 

(27,754

)

 

 

(424

)

Comprehensive income (loss)

 

$

123,942

 

 

$

(910

)

 

$

36,941

 

 

$

(1,185

)

 

See accompanying notes to the Consolidated Financial Statements.

3


 

GENPACT LIMITED AND ITS SUBSIDIARIES

Consolidated Statements of Equity and Redeemable Non-controlling Interest

(Unaudited)

(In thousands, except share count)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

Common shares

 

 

 

 

 

 

 

 

 

 

Other

 

 

 

 

 

 

Redeemable

 

 

 

No. of Shares

 

 

Amount

 

 

Additional Paid-

in Capital

 

 

Retained

Earnings

 

 

Comprehensive

Income (Loss)

 

 

Total

Equity

 

 

non-controlling

interest.

 

Balance as of January 1, 2017

 

 

198,794,052

 

 

$

1,984

 

 

$

1,384,468

 

 

$

358,121

 

 

$

(457,925

)

 

$

1,286,648

 

 

$

4,520

 

Issuance of common shares on exercise of options (Note 16)

 

 

455,835

 

 

 

5

 

 

 

6,540

 

 

 

 

 

 

 

 

6,545

 

 

 

 

Issuance of common shares under the

employee stock purchase plan (Note 16)

 

 

55,788

 

 

 

1

 

 

 

1,217

 

 

 

 

 

 

 

 

 

1,218

 

 

 

 

Net settlement on vesting of restricted share units (Note 16)

 

 

76,865

 

 

 

1

 

 

 

(1

)

 

 

 

 

 

 

 

 

 

 

 

 

Net settlement on vesting of performance units (Note 16)

 

 

731,701

 

 

 

7

 

 

 

(9,946

)

 

 

 

 

 

 

 

 

(9,939

)

 

 

 

Stock repurchased and retired (Note 17)

 

 

(7,387,240

)

 

 

(74

)

 

 

(40,000

)

 

 

(179,710

)

 

 

 

 

 

(219,784

)

 

 

 

Expenses related to stock purchase (Note 17)

 

 

 

 

 

 

 

 

 

 

 

 

(16

)

 

 

 

 

 

(16

)

 

 

 

Stock-based compensation expense (Note 16)

 

 

 

 

 

 

 

 

4,986

 

 

 

 

 

 

 

 

 

4,986

 

 

 

 

Comprehensive income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income

 

 

 

 

 

 

 

 

 

 

 

53,338

 

 

 

 

 

 

53,338

 

 

 

(898

)

Other comprehensive    income

 

-

 

 

 

 

 

 

 

 

 

 

 

 

70,604

 

 

 

70,604

 

 

 

(12

)

Dividend (Note 17 )

 

 

 

 

 

 

 

 

 

 

 

(11,957

)

 

 

 

 

 

(11,957

)

 

 

 

Balance as of March 31, 2017

 

 

192,727,001

 

 

$

1,924

 

 

$

1,347,265

 

 

$

219,776

 

 

$

(387,321

)

 

$

1,181,644

 

 

$

3,610

 

 

See accompanying notes to the Consolidated Financial Statements.

4


 

GENPACT LIMITED AND ITS SUBSIDIARIES

Consolidated Statements of Equity and Redeemable Non-controlling Interest

(Unaudited)

(In thousands, except share count)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

Common shares

 

 

 

 

 

 

 

 

 

 

Other

 

 

 

 

 

 

Redeemable

 

 

 

No. of

Shares

 

 

Amount

 

 

Additional Paid-

in Capital

 

 

Retained

Earnings

 

 

Comprehensive

Income (Loss)

 

 

Total

Equity

 

 

non-controlling

interest.

 

Balance as of January 1, 2018, as previously reported

 

 

192,825,207

 

 

$

1,924

 

 

$

1,421,368

 

 

$

355,982

 

 

$

(355,230

)

 

$

1,424,044

 

 

$

4,750

 

Adoption of ASU 2014-09 (Note 2(f))

 

 

 

 

 

 

 

 

 

 

 

17,924

 

 

 

 

 

 

17,924

 

 

 

 

 

Adjusted balance as of January 1, 2018

 

 

192,825,207

 

 

$

1,924

 

 

$

1,421,368

 

 

$

373,906

 

 

$

(355,230

)

 

$

1,441,968

 

 

$

4,750

 

Adoption of ASU 2018-02 (Note 7, 24)

 

 

 

 

 

 

 

 

 

 

 

(2,265

)

 

 

2,265

 

 

 

 

 

 

 

Issuance of common shares on exercise of options (Note 16)

 

 

161,837

 

 

 

2

 

 

 

2,549

 

 

 

 

 

 

 

 

2,551

 

 

 

 

Issuance of common shares under the employee stock purchase plan (Note 16)

 

 

58,476

 

 

 

1

 

 

 

1,650

 

 

 

 

 

 

 

 

 

1,651

 

 

 

 

Net settlement on vesting of restricted share units (Note 16)

 

 

55,631

 

 

 

1

 

 

 

(1

)

 

 

 

 

 

 

 

 

 

 

 

 

Net settlement on vesting of performance units (Note 16)

 

 

691,958

 

 

 

7

 

 

 

(13,291

)

 

 

 

 

 

 

 

 

(13,284

)

 

 

 

Stock repurchased and retired (Note 17)

 

 

(3,179,974

)

 

 

(32

)

 

 

4,000

 

 

 

(99,952

)

 

 

 

 

 

(95,984

)

 

 

 

Expenses related to stock purchase (Note 17)

 

 

 

 

 

 

 

 

 

 

 

(60

)

 

 

 

 

 

(60

)

 

 

 

Stock-based compensation expense (Note 16)

 

 

 

 

 

 

 

 

7,787

 

 

 

 

 

 

 

 

 

7,787

 

 

 

 

Payment for purchase of redeemable non-controlling interest

 

 

 

 

 

 

 

 

(1,165

)

 

 

 

 

 

 

 

 

(1,165

)

 

 

(3,565

)

Comprehensive income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income

 

 

 

 

 

 

 

 

 

 

 

64,695

 

 

 

 

 

 

64,695

 

 

 

(761

)

Other comprehensive income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(27,754

)

 

 

(27,754

)

 

 

(424

)

Dividend (Note 17)

 

 

 

 

 

 

 

 

 

 

 

(14,408

)

 

 

 

 

 

(14,408

)

 

 

 

Balance as of  March 31, 2018

 

 

190,613,135

 

 

$

1,903

 

 

$

1,422,897

 

 

$

321,916

 

 

$

(380,719

)

 

$

1,365,997

 

 

$

 

 

See accompanying notes to the Consolidated Financial Statements.

5


 

GENPACT LIMITED AND ITS SUBSIDIARIES

Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

 

 

Three months ended March 31,

 

 

 

 

2017

 

 

 

2018

 

Operating activities

 

 

 

 

 

 

 

 

Net income attributable to Genpact Limited shareholders

 

$

53,338

 

 

$

64,695

 

Net loss attributable to redeemable non-controlling interest

 

 

(898

)

 

 

(761

)

Net income

 

$

52,440

 

 

$

63,934

 

Adjustments to reconcile net income to net cash provided by (used for) operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

14,139

 

 

 

15,836

 

Amortization of debt issuance costs

 

 

375

 

 

 

488

 

Amortization of acquired intangible assets

 

 

7,242

 

 

 

9,936

 

Reserve for doubtful receivables

 

 

 

 

 

(103

)

Unrealized loss (gain) on revaluation of foreign currency asset/liability

 

 

8,757

 

 

 

(8,525

)

Equity-method investment activity, net

 

 

4,558

 

 

 

 

Stock-based compensation expense

 

 

4,986

 

 

 

7,787

 

Deferred income taxes

 

 

(2,890

)

 

 

(4,625

)

Others, net

 

 

(4,301

)

 

 

(28

)

Change in operating assets and liabilities:

 

 

 

 

 

 

 

 

Decrease (increase) in accounts receivable

 

 

19,649

 

 

 

(6,025

)

Increase in prepaid expenses, other current assets, contract cost assets and other assets

 

 

(12,025

)

 

 

(37,008

)

Decrease in accounts payable

 

 

(928

)

 

 

(1,224

)

Decrease in accrued expenses, other current liabilities and other liabilities

 

 

(69,131

)

 

 

(77,734

)

Increase in income taxes payable

 

 

8,157

 

 

 

9,969

 

Net cash provided by/(used for) operating activities

 

$

31,028

 

 

$

(27,322

)

Investing activities

 

 

 

 

 

 

 

 

Purchase of property, plant and equipment

 

 

(17,084

)

 

 

(18,706

)

Payment for internally generated intangible assets

 

 

(2,614

)

 

 

(4,365

)

Proceeds from sale of property, plant and equipment

 

 

389

 

 

 

144

 

Investment in equity affiliates

 

 

(467

)

 

 

 

Payment for business acquisitions, net of cash acquired

 

 

(9,237

)

 

 

 

Payment for purchase of redeemable non-controlling interest

 

 

 

 

 

(4,730

)

Net cash used for investing activities

 

$

(29,013

)

 

$

(27,657

)

Financing activities

 

 

 

 

 

 

 

 

Repayment of capital lease obligations

 

 

(494

)

 

 

(537

)

Payment of debt issuance costs

 

 

(1,481

)

 

 

 

Proceeds from long-term debt

 

 

350,000

 

 

 

 

Repayment of long-term debt

 

 

(10,000

)

 

 

(10,000

)

Proceeds from short-term borrowings

 

 

40,000

 

 

 

105,000

 

Repayment of short-term borrowings

 

 

(185,000

)

 

 

 

Proceeds from issuance of common shares under stock-based compensation plans

 

 

7,761

 

 

 

4,202

 

Payment for net settlement of stock-based awards

 

 

(9,939

)

 

 

(13,284

)

Payment of earn-out/deferred consideration

 

 

(1,097

)

 

 

(1,476

)

Dividend paid

 

 

(11,957

)

 

 

(14,408

)

Payment for stock purchased and retired

 

 

(219,784

)

 

 

(95,984

)

Payment for expenses related to stock purchase

 

 

(16

)

 

 

(60

)

Net cash used for financing activities

 

$

(42,007

)

 

$

(26,547

)

Effect of exchange rate changes

 

 

5,555

 

 

 

1,284

 

Net increase (decrease) in cash and cash equivalents

 

 

(39,992

)

 

 

(81,526

)

Cash and cash equivalents at the beginning of the period

 

 

422,623

 

 

 

504,468

 

Cash and cash equivalents at the end of the period

 

$

388,186

 

 

$

424,226

 

Supplementary information

 

 

 

 

 

 

 

 

Cash paid during the period for interest

 

$

5,324

 

 

$

13,194

 

Cash paid during the period for income taxes

 

$

16,426

 

 

$

24,157

 

Property, plant and equipment acquired under capital lease obligations

 

$

576

 

 

$

297

 

 

See accompanying notes to the Consolidated Financial Statements

 

 

6


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

 

 

1. Organization

The Company is a global professional services firm that drives digitally-led innovation and runs digitally-enabled intelligent operations for its clients, guided by its experience running thousands of processes for hundreds of Fortune Global 500 clients.  The Company has over 78,000 employees serving clients in key industry verticals from more than 20 countries.  

 The business of the Company was initially conducted through various entities and divisions of GE. The Company began operating independently in 2004 when GE spun off the Company’s operations. In August 2007, the Company completed an initial public offering of its common shares. In 2012, affiliates of Bain Capital Investors, LLC, or Bain Capital, and their co-investors acquired the majority of the remaining interests held by the Company’s initial investors. On each of August 18, 2017 and November 20, 2017, affiliates of Bain Capital and their co-investors sold 10,000,000 common shares of the Company in underwritten public offerings. The Company did not receive any proceeds from these offerings.

 

2. Summary of significant accounting policies

 

(a) Basis of preparation and principles of consolidation

 

The unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and the rules and regulations of the Securities and Exchange Commission for reporting on Form 10-Q. Accordingly, they do not include certain information and note disclosures required by generally accepted accounting principles for annual financial reporting and should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

 

The unaudited interim consolidated financial statements reflect all adjustments that management considers necessary for a fair presentation of the results of operations for these periods. The results of operations for interim periods are not necessarily indicative of results for the full year.

 

The accompanying unaudited interim consolidated financial statements have been prepared on a consolidated basis and reflect the financial statements of Genpact Limited, a Bermuda company, and all of its subsidiaries that are more than 50% owned and controlled. When the Company does not have a controlling interest in an entity but exerts significant influence on the entity, the Company applies the equity method of accounting. All intercompany transactions and balances are eliminated in consolidation.

 

Non-controlling interest in subsidiaries that is redeemable outside of the Company’s control for cash or other assets is reflected in the mezzanine section between liabilities and equity in the consolidated balance sheets at the redeemable value, which approximates fair value. Redeemable non-controlling interest is adjusted to its fair value at each balance sheet date. Any resulting increases or decreases in the estimated redemption amount are affected by corresponding changes to additional paid in capital. The share of non-controlling interest in subsidiary earnings is reflected in net loss (income) attributable to redeemable non-controlling interest in the consolidated statements of income.

 

(b) Use of estimates

 

The preparation of consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements. Significant items subject to such estimates and assumptions include the useful lives of property, plant and equipment, intangibles and goodwill, revenue recognition, reserves for doubtful receivables, valuation allowances for deferred tax assets, the valuation of derivative financial instruments, measurements of stock-based compensation, assets and obligations related to employee benefits, determining the nature and timing of satisfaction of performance obligations, determining the standalone selling price of performance obligations, variable consideration, and other obligations for revenue recognition

7


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

2. Summary of significant accounting policies (Continued)

 

and income tax uncertainties and other contingencies. Management believes that the estimates used in the preparation of the consolidated financial statements are reasonable. Although these estimates are based upon management’s best knowledge of current events and actions, actual results could differ from these estimates. Any changes in estimates are adjusted prospectively in the Company’s consolidated financial statements.

 

(c) Business combinations, goodwill and other intangible assets

 

The Company accounts for its business combinations using the acquisition method of accounting in accordance with ASC 805, Business Combinations, by recognizing the identifiable tangible and intangible assets acquired and liabilities assumed, and any non-controlling interest in the acquired business, measured at their acquisition date fair values. Contingent consideration is included within the acquisition cost and is recognized at its fair value on the acquisition date. A liability resulting from contingent consideration is remeasured to fair value as of each reporting date until the contingency is resolved. Changes in fair value are recognized in earnings. All assets and liabilities of the acquired businesses, including goodwill, are assigned to reporting units. Acquisition-related costs are expensed as incurred under Selling, General and Administrative Expenses.

 

Goodwill represents the cost of acquired businesses in excess of the fair value of identifiable tangible and intangible net assets purchased. Goodwill is not amortized but is tested for impairment at least on an annual basis on December 31, based on a number of factors, including operating results, business plans and future cash flows. The Company performs an assessment of qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Based on the assessment of events or circumstances, the Company performs a quantitative assessment of goodwill impairment if it determines that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, based on the quantitative impairment analysis, the carrying value of the goodwill of a reporting unit exceeds the fair value of such goodwill, an impairment loss is recognized in an amount equal to the excess. In addition, the Company performs a qualitative assessment of goodwill impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. See Note 10 for information and related disclosures.

 

Intangible assets acquired individually or with a group of other assets or in a business combination and developed internally are carried at cost less accumulated amortization based on their estimated useful lives as follows:

 

Customer-related intangible assets

 

1-14 years

Marketing-related intangible assets

 

1-10 years

Other intangible assets

 

2-9 years

 

 

8


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

2. Summary of significant accounting policies (Continued)

Intangible assets acquired individually or with a group of other assets or in a business combination and developed internally are carried at cost less accumulated amortization based on their estimated useful lives as follows:

 

Customer-related intangible assets

 

1-14 years

Marketing-related intangible assets

 

1-10 years

Other intangible assets

 

2-9 years

 

Intangible assets are amortized over their estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are consumed or otherwise realized.

In business combinations where the fair value of identifiable tangible and intangible net assets purchased exceeds the cost of the acquired business, the Company recognizes the resulting gain under “Other operating (income) expense, net” in the consolidated statements of income.

 

(d) Financial instruments and concentration of credit risk

 

Financial instruments that potentially subject the Company to concentration of credit risk are reflected principally in cash and cash equivalents, derivative financial instruments and accounts receivable. The Company places its cash and cash equivalents and derivative financial instruments with corporations and banks with high investment grade ratings, limits the amount of credit exposure with any one corporation or bank and conducts ongoing evaluations of the creditworthiness of the corporations and banks with which it does business. To reduce its credit risk on accounts receivable, the Company conducts ongoing credit evaluations of its clients. GE accounted for 11% and 10% of receivables as of December 31, 2017 and March 31, 2018, respectively. GE accounted for 11% and 8% of total revenue for the three months ended March 31, 2017 and 2018, respectively.   

 

(e) Accounts receivable

 

Accounts receivable are recorded at the invoiced or to be invoiced amount and do not bear interest. Amounts collected on trade accounts receivable are included in net cash provided by operating activities in the consolidated statements of cash flows. The Company maintains an allowance for doubtful accounts for estimated losses inherent in its accounts receivable portfolio. In establishing the required allowance, management considers historical losses adjusted to take into account current market conditions and clients’ financial condition, the amount of receivables in dispute, and the current receivables’ aging and current payment patterns. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company does not have any off-balance-sheet credit exposure related to its clients.

 

(f) Changes in accounting policies

 

Except as described below, the Company has applied accounting policies consistently to all periods presented in these consolidated financial statements. The Company adopted Topic 606, Revenue from Contracts with Customers, effective January 1, 2018. As a result, the Company has changed its accounting policy for revenue recognition as detailed below. The Company applied Topic 606 using the modified retrospective method, which involves recognizing the cumulative effect of initially applying Topic 606 as an adjustment to the Company’s opening equity balance as of January 1, 2018. Therefore, comparative information has not been adjusted and continues to be reported under Topic 605. As a result of the Company’s adoption of this new standard, certain sales incentive programs meet the requirements for capitalization. Such costs are amortized over the period of expected benefit rather than expensed as incurred per the Company’s prior practice. The cumulative impact of the adoption of this standard resulted in an increase in retained earnings of $17,924 as of January 1, 2018 with a corresponding impact on contract cost assets of $23,227 and deferred tax liability of $5,303. As of January 1, 2018, contract assets and contract liabilities relating to the same customer contract amounting to $21,348 have been offset.

9


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

2. Summary of significant accounting policies (Continued)

 

Revenue Recognition

 

The Company derives its revenue primarily from business process outsourcing and information technology services, which primarily are provided on a time-and-material, transaction or fixed-price basis. The Company recognizes revenue when the promised services are delivered to customers for an amount that reflects the consideration to which the entity expects to be entitled in exchange for those services. Revenues from services rendered under time-and materials and transaction-based contracts are recognized as the services are provided. The Company’s fixed-price contracts include contracts for application development, maintenance and support services. Revenues from these contracts are recognized ratably over the term of the agreement. The Company accrues for revenue and unbilled receivables for the services rendered between the last billing date and the balance sheet date.

 

Customer contracts can also include incentive payments received for discrete benefits delivered or promised to be delivered to clients or service level agreements that could result in credits or refunds to the customer. Revenues relating to such arrangements are accounted for as variable consideration when the amount of revenue to be recognized can be estimated to the extent that it is probable that a significant reversal of any incremental revenue will not occur.

 

The Company has deferred revenue attributable to certain process transition activities, with respect to its customers where such activities do not represent separate performance obligation. Revenues relating to such transition activities are classified under contract liabilities and subsequently recognized ratably over the period in which the related services are performed. Costs relating to such transition activities are fulfillment costs which are directly related to the contract and result in generation or enhancement of resources and are expected to be recoverable under the contract and thereby classified as contract cost assets and are recognized ratably over the estimated expected period of benefit, under Cost of Revenue.

 

Revenues are reported net of value-added tax, business tax and applicable discounts and allowances. Reimbursements of out-of-pocket expenses received from clients have been included as part of revenues.

 

Revenue for performance obligations that are satisfied over time is recognized in accordance with the methods prescribed for measuring progress. The input (effort or cost expended) method has been used to measure progress towards completion as there is a direct relationship between input and productivity. Provisions for estimated losses, if any, on uncompleted contracts are recorded in the period in which such losses become probable based on the current contract estimates.

 

The Company enters into multiple-element revenue arrangements in which a client may purchase a combination of products or services. Revenue from multiple-element arrangements is recognized, for each element, based on allocation of the transaction price to each performance obligation on a relative standalone basis.

 

Certain contracts may include offerings such as sale of licenses, which may be perpetual or subscription based. Revenue from distinct perpetual licenses is recognized upfront at the point in time when the software is made available to the customer. Revenue from subscription based licenses is recognized as ratably over the subscription term.

 

All incremental and direct costs incurred for acquiring contracts, such as certain sales commission, are classified as contract cost asset. Such costs are amortized over the expected period of benefit and recorded under Selling, General and Administrative Expenses.

 

Other upfront fees paid to customers are classified as contract asset. Such costs are amortized over the expected period of benefit and recorded as an adjustment to the transaction price and reduced from revenue.

 

Timing of revenue recognition may differ from the timing of invoicing to customers. If payment is received in respect of services prior to the delivery of services, the payment is recognized as an advance from customers and classified as contract liabilities. Contract assets and contract liabilities relating to the same customer contract have been offset and presented on a net basis in the consolidated financial statements. See note 19 for information and related disclosures regarding contract balances.

 

10


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

2. Summary of significant accounting policies (Continued)

 

For a description of the Company’s revenue recognition accounting policy in effect before the Company’s adoption of ASC 606, see Note 3—“Summary of significant accounting policies” under Item 1 —“Financial Statements” and Part II, Item 7—“Management’s Discussion and Analysis of Financial Condition and Results of Operations”—“Critical Accounting Policies and Estimates” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

 

Significant judgements

 

The Company has contracts with customers which often include promises to transfer multiple products and services to the customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment.

 

Judgment is also required to determine the standalone selling price for each distinct performance obligation. In instances where the standalone selling price is not directly observable, it is determined using information that may include market conditions and other observable inputs.

 

Customer contracts can include incentive payments received for discrete benefits delivered to clients or service level agreements that could result in credits or refunds to the customer. Such amounts are estimated at contract inception and are adjusted at the end of each reporting period as additional information becomes available only to the extent that it is probable that a significant reversal of any incremental revenue will not occur.

 

11


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

Impacts on consolidated financial statements

 

The following tables summarize the impacts of adopting Topic 606 on the Company’s consolidated financial statements for the three months ended March 31, 2018.

 

Consolidated Balance sheet

As of March 31, 2018

As reported

Adjustments

Balances without adoption of Topic 606

Assets

 

 

 

Current assets

 

 

 

Cash and cash equivalents

$                 424,226

 

$                         424,226

Accounts receivable, net

703,066

 

703,066

Prepaid expenses and other current assets (a, c)

                     199,208

              74,092

                            273,300

Total current assets

$          1,326,500

74,092

$                  1,400,592

 

 

 

 

Property, plant and equipment, net

205,035

 

205,035

Deferred tax assets

                       81,734

 

                               81,734

Investment in equity affiliates

919

 

919

Intangible assets, net

                      125,781

 

                             125,781

Goodwill

1,337,051

 

1,337,051

Contract cost assets (a, b)

                      162,435

          (162,435)

                                          —  

Other assets (a, c)

157,672

89,499

247,171

Total assets

$          3,397,127

               1,156

    $                3,398,283

 

 

 

 

Liabilities and equity

 

 

 

Current liabilities

 

 

 

Short-term borrowings

$               275,000

 

$                       275,000

Current portion of long-term debt

39,237

 

39,237

Accounts payable

13,811

 

13,811

Income taxes payable

40,026

 

40,026

Accrued expenses and other current liabilities (c)

503,116

8,429

511,545

Total current liabilities

$             871,190

      8,429.00

$                    879,619

 

 

 

 

  Long-term debt, less current portion

            996,999

 

            996,999

  Deferred tax liabilities (b)

                 7,083

        (5,303)

                  1,780

  Other liabilities (c)

             155,858

               15,998

             171,856

Total liabilities

$         2,031,130

19,124

$               2,050,254

 

 

 

 

  Redeemable non-controlling interest

                                  -  

 

                                          -  

Shareholders' equity

 

 

 

Preferred shares, $0.01 par value, 250,000,000 authorized, none  issued

 

 

 

Common shares, $0.01 par value, 500,000,000 authorized,        

 

 

 

  192,825,207 and 190,613,135 issued and outstanding as of  

 

 

 

  December 31, 2017 and March 31, 2018, respectively

1,903

 

1,903

Additional paid-in capital

1,422,897

 

1,422,897

Retained earnings (b)

321,916

(17,968)

303,948

Accumulated other comprehensive income (loss)

(380,719)

 

(380,719)

Total equity

$     1,365,997

(17,968)

$              1,348,029

Commitments and contingencies

 

 

 

Total liabilities, redeemable non-controlling interest and equity  

$     3,397,127

1,156

$             3,398,283

(a) The Company has reclassified the deferred transition cost from “Prepaid expenses and other current assets” amounting to $65,663 and “Other assets” amounting to $73,501 to “Contract cost assets” amounting to $139,164 as a result of its adoption of ASC 606.               (b) The cumulative impact of the adoption of ASC 606 resulted in an increase of $23,227 in the contract cost asset related to sales incentive programs

12


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

(excluding the effect of the current period – refer to note d to the table below) as of January 1, 2018 with a corresponding impact of $17,924 on retained earnings (excluding the effect of the current period – refer to note d to the table below) and on deferred tax liability of $5,303. (c) As a result of its adoption of ASC 606 the Company has offset (i) contract assets amounting to $8,429 under “Prepaid expenses and other current assets” against contract liabilities under “Accrued expenses and other current liabilities” related to the same customer contract and (ii) contract assets amounting to $15,998 under “Other assets” against contract liabilities under “Other liabilities” related to the same customer contract.

13


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

Consolidated Statement of Income

 

Three months ended March 31, 2018

As reported

Adjustments

Balances without adoption of Topic 606

Net revenues

$         688,912

 

$       688,912

Cost of revenue

444,324

 

444,324

Gross profit

$       244,588

                        

$     244,588

Operating expenses:

 

 

 

Selling, general and administrative expenses (d)

171,109

44

171,153

Amortization of acquired intangible assets

9,936

 

9,936

Other operating (income) expense, net

(218)

 

(218)

Income from operations

$          63,761

(44)

$       63,717

Foreign exchange gains (losses), net

4,798

 

4,798

Interest income (expense), net

(8,100)

 

(8,100)

Other income (expense), net

15,550

 

15,550

Income before equity-method investment activity, net and income tax expense

$        76,009

(44)

$     75,965

Equity-method investment activity, net

                           —  

                        —  

                                   —  

Income before income tax expense

$        76,009

(44)

$     75,965

Income tax expense

12,075

                       —  

12,075

Net income

$        63,934

(44)

$    63,890

Net loss  attributable to non-controlling interest

761

                       —  

761

Net income attributable to Genpact Limited shareholders

$        64,695

(44)

$    64,651

 

(d) During the three months ended March 31, 2018, the Company amortized $3,239 in contract costs related to obtaining a contract. Upon the adoption of ASC 606 the Company capitalized such costs in an amount of $3,283, resulting in a net adjustment of $44.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

14


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

 

Consolidated Statement of Cash flow

Three months ended March 31, 2018

As reported

Adjustments

Balances without adoption of Topic 606

Operating activities

 

 

 

Net income attributable to Genpact Limited shareholders (e)

$   64,695

(44)

$   64,651

Net loss attributable to redeemable non-controlling interest

(761)

 

(761)

Net income (e)

$   63,934

(44)

$   63,890

Adjustments to reconcile net income to net cash used for operating activities:

 

 

 

Depreciation and amortization

15,836

 

15,836

Amortization of debt issuance costs

488

 

488

Amortization of acquired intangible assets

9,936

 

9,936

Reserve for doubtful receivables

(103)

 

(103)

Unrealized gain on revaluation of foreign currency asset/liability

(8,525)

 

(8,525)

Stock-based compensation expense

7,787

 

7,787

Deferred income taxes

(4,625)

 

(4,625)

Other net

(28)

 

(28)

Change in operating assets and liabilities:

 

 

 

Increase in accounts receivable

(6,025)

 

(6,025)

Increase in prepaid expenses, other current assets, contract cost assets and other                 assets (e, f)

(37,008)

(3,035)

(40,043)

Decrease in accounts payable

(1,224)

 

(1,224)

Decrease in accrued expenses, other current liabilities and other liabilities (f)

(77,734)

3,079

(74,655)

Decrease in income taxes payable

9,969

 

9,969

Net cash provided used for operating activities

$   (27,322)

           

$   (27,322)

Investing activities

 

 

 

Purchase of property, plant and equipment

(18,706)

 

(18,706)

Payment for internally generated intangible assets

(4,365)

 

(4,365)

Proceeds from sale of property, plant and equipment

144

 

144

Payment for redeemable non-controlling interest

(4,730)

 

(4,730)

Net cash used for investing activities

$   (27,657)

           

$   (27,657)

Financing activities

 

 

 

Repayment of capital lease obligations

(537)

 

(537)

Repayment of long-term debt

(10,000)

 

(10,000)

Proceeds from short-term borrowings

105,000

 

105,000

Proceeds from issuance of common shares under stock-based compensation plans

4,202

 

4,202

Payment for net settlement of stock-based awards

(13,284)

 

(13,284)

Payment of earn-out/deferred consideration

(1,476)

 

(1,476)

Dividend paid

(14,408)

 

(14,408)

Payment for stock purchased and retired

(95,984)

 

(95,984)

Payment for expenses related to stock purchase

(60)

 

(60)

Net cash used for financing activities

$   (26,547)

           

$   (26,547)

Effect of exchange rate changes

1,284

 

1,284

Net increase (decrease) in cash and cash equivalents

(81,526)

 

(81,526)

Cash and cash equivalents at the beginning of the period

504,468

 

504,468

Cash and cash equivalents at the end of the period

$   424,226

           

$   424,226

(e) During the three months ended March 31, 2018, the Company amortized $3,239 in contract costs related to obtaining a contract. Upon adoption of ASC 606 the Company capitalized such costs in an amount of $3,283, resulting in net adjustment of $44.                                        (f) Upon the adoption of ASC 606 the Company offset certain contract assets against contract liabilities related to the same contract in an amount of $3,079.

15


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

2. Summary of significant accounting policies (Continued)

 

(g) Recently issued and adopted accounting pronouncements

 

The authoritative bodies release standards and guidance which are assessed by management for impact on the Company’s consolidated financial statements.

 

The Company has adopted the following recently released accounting standards:

 

The Company adopted Topic 606, Revenue from Contracts with Customers, with a date of initial application of January 1, 2018 using the modified retrospective method. The cumulative impact of the adoption of this standard has been described in section (f) above.

 

In February 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-02, “Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income.” The new standard provides guidance to “allow a reclassification from accumulated other comprehensive income (“AOCI”) to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act.” The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those years, and the guidance may be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal income tax rate in the Tax Cuts and Jobs Act is recognized. Early adoption is permitted. On January 1, 2018, the Company elected the early adoption of ASU 2018-02, which was adopted at the beginning of the period and no prior periods have been adjusted.

 

In addition, the Company has adopted the following recently released accounting standards. Adoption of these standards did not have a material impact on the Company’s consolidated results of operations, cash flows, financial position or disclosures:

 

Effective January 1, 2017, the Company adopted FASB ASU 2016-06, Derivatives and Hedging (Topic 815). The amendments in this update clarify the requirements for assessing whether contingent call (put) options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts. An entity performing the assessment under the amendments in this update is required to assess the embedded call (put) options solely in accordance with a four-step decision sequence.

 

Effective January 1, 2018, the Company adopted FASB ASU 2017-01, “Business Combinations (Topic 805): Clarifying the Definition of a Business.” The new guidance revises the definition of a business. The definition of a business affects many areas of accounting (e.g., acquisitions, disposals, goodwill impairment, consolidation).

 

Effective January 1, 2018, the Company adopted FASB ASU 2016-16, “Intra-Entity Transfers of Assets Other Than Inventory.” The new guidance eliminates the exception for deferment of tax recognition until the transferred asset is sold to a third party or otherwise recovered through use for all intra-entity sales of assets other than inventory.

 

Effective January 1, 2018, the Company adopted FASB ASU 2017-07, “Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost.” The ASU requires entities to (1) disaggregate the current-service-cost component from the other components of net benefit cost (the “other components”) and present it with other current compensation costs for related employees in the income statement and (2) present the other components elsewhere in the income statement and outside of income from operations if that subtotal is presented. In addition, the

16


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

2. Summary of significant accounting policies (Continued)

 

ASU requires entities to disclose the income statement lines that contain the other components if they are not presented on appropriately described separate lines.

 

Effective January 1, 2017, the Company early adopted FASB ASU 2016-15, "Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments." The new guidance is intended to reduce diversity in how certain transactions are classified in the statement of cash flows.

 

The following recently released accounting standards have not yet been adopted by the Company:

 

In February 2016, the FASB issued ASU No. 2016-02, “Leases.” The core principle of the ASU is that a lessee should recognize the assets and liabilities that arise from its leases other than those that meet the definition of a short-term lease. The ASU requires extensive qualitative and quantitative disclosures, including with respect to significant judgments made by management. Subsequently, the FASB issued ASU No. 2017-13, in September 2017, which amends and clarifies ASU 2016-02. The ASU will be effective for the Company beginning January 1, 2019, including interim periods in the fiscal year 2019. Early adoption is permitted. The Company expects to complete its assessment of adopting ASU No. 2016-02 in the third quarter of 2018. The Company continues to evaluate the impact of its pending adoption of ASU 2016-02 on its consolidated results of operations, cash flows, financial position and disclosures, and the Company’s preliminary assessments are subject to change.

 

In August 2017, the FASB issued ASU 2017-12, “Derivatives and Hedging.” The amendment expands an entity’s ability to hedge accounting to non-financial and financial risk components and requires changes in fair value of hedging instruments to be presented in the same income statement line as the hedged item. The ASU also amends the presentation and disclosure requirements for the effect of hedge accounting. The ASU must be adopted using a modified retrospective approach with a cumulative effect adjustment recorded to the opening balance of retained earnings as of the initial application date. The ASU is effective for the Company beginning January 1, 2019, including interim periods in the fiscal year 2019. Early adoption is permitted. The Company is in the process of assessing the impact of this ASU on its consolidated results of operations, cash flows, financial position and disclosures.

 

(h) Reclassification

 

Certain reclassifications have been made in the consolidated financial statements of prior periods to conform to the classification used in the current period. The impact of such reclassifications on the consolidated financial statements is not material.

 

 

17


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

3. Business acquisitions

 

A. Certain acquisitions

 

(a) Strategic Sourcing Excellence Limited

 

On January 8, 2016, the Company acquired 51% of the outstanding equity interest in Strategic Sourcing Excellence LLC (“SSE”), a Delaware limited liability company. The total consideration paid by the Company to the selling equity holders for the acquired interest in SSE was $14,541. This amount includes the fair value of earn-out consideration, cash consideration of $2,550, and an adjustment for working capital, transaction expenses and indebtedness. During the quarter ended December 31, 2016, the Company recorded certain measurement period adjustments. These measurement period adjustments did not have a significant impact on the Company’s consolidated statements of income, balance sheets or cash flows in any period. The equity purchase agreement between the Company and the selling equity holders of SSE also provided for contingent earn-out consideration of up to $20,000, payable by the Company to the selling equity holders based on the future performance of the acquired business relative to the thresholds specified in the earn-out calculation. Up to $9,800 of the total potential earn-out consideration, representing the selling equity holders’ 49% interest in SSE, was payable only if either the put or call option, each as described below, was exercised. This acquisition enhances the Company’s sourcing and procurement consulting domain expertise.

 

The equity purchase agreement granted the Company a call option to purchase the remaining 49% equity interest in SSE, which option the Company had the right to exercise between January 1, 2018 and January 31, 2018. Since the Company did not exercise its call option during such period, the selling equity holders exercised their put option on March 1, 2018 in accordance with the terms of the equity purchase agreement to require the Company to purchase their 49% interest in SSE for $2,950. The Company also paid $1,780 in earn-out consideration to the selling equity shareholders during the three months ended March 31, 2018. The amount paid in excess of carrying amount has been recorded in additional paid-in capital.

 

Acquisition-related costs of $164 have been included in selling, general and administrative expenses as incurred. Through this transaction, the Company acquired assets with a value of $412 and assumed liabilities amounting to $617. The results of operations of the acquired business, the fair value of the acquired assets and assumed liabilities, and redeemable non-controlling interest are included in the Company’s Consolidated Financial Statements with effect from the date of the acquisition.

 

In connection with the transaction, the Company recorded $300 in customer-related intangible assets with an amortization period of five years. Goodwill arising from the acquisition amounted to $14,445, which has been allocated to the Company’s India reporting unit and is deductible for tax purposes. The goodwill represents future economic benefits the Company expects to derive from its expanded presence in the sourcing and procurement consulting domains, operating synergies and other anticipated benefits of combining the acquired operations with those of the Company.

 

(b) TandemSeven, Inc.

 

On September 5, 2017, the Company acquired 100% of the outstanding equity interest in TandemSeven, Inc. (“TandemSeven”), a Massachusetts corporation, for total purchase consideration of $35,637. This amount includes cash consideration of $31,784, net of cash acquired of $3,853, and an adjustment for working capital and indebtedness. During the quarter ended March 31, 2018, the Company recorded certain measurement period adjustments. These adjustments did not have a significant impact on the Company’s consolidated statements of income, balance sheets or cash flows. TandemSeven’s focus on improving the design of customer experiences complements the Company’s existing capabilities aimed at transforming clients’ processes end-to-end.

 

In connection with the acquisition of TandemSeven, the Company recorded $2,000 in customer-related intangibles, $1,700 in marketing-related intangibles and $800 in technology-related intangible assets, which have a weighted average amortization period of two years. Goodwill arising from the acquisition amounted to $25,227, which has been allocated to the Company’s India reporting unit and is deductible for tax purposes. The goodwill represents primarily the acquired design expertise, operating synergies and other benefits expected to result from combining the acquired operations with those of the Company.

18


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

3. Business acquisitions (Continued)

 

Acquisition-related costs of $932 have been included in selling, general and administrative expenses as incurred. In connection with the transaction, the Company also acquired certain assets with a value of $7,378, assumed certain liabilities amounting to $1,207 and recognized a net deferred tax liability of $260. The results of operations of the acquired business and the fair value of the acquired assets and assumed liabilities are included in the Company’s consolidated financial statements with effect from the date of the acquisition.

 

(c) BrightClaim LLC and associated companies

 

On May 3, 2017, the Company acquired 100% of the outstanding equity interest in each of BrightClaim LLC, a Delaware limited liability company, BrightServe LLC, a Georgia limited liability company, National Vendor LLC, a Delaware limited liability company, and BrightClaim Blocker, Inc., a Delaware corporation (collectively referred to as “BrightClaim”) for total purchase consideration of $56,461, subject to adjustment for certain transaction expenses incurred by BrightClaim in connection with closing. This amount includes cash consideration of $52,395, net of cash acquired of $4,002, and an adjustment for working capital and net debt. The Company paid the sellers total consideration of$56,496. During the quarter ended September 30, 2017, the Company recorded certain measurement period adjustments resulting in a receivable of $35, which had been collected as of March 31, 2018. These measurement period adjustments did not have a significant impact on the Company’s consolidated statements of income, balance sheets or cash flows. This acquisition enhances the Company’s breadth and depth of service offerings for clients in the insurance industry.

 

In connection with the acquisition of BrightClaim, the Company recorded $8,000 in customer-related intangibles, $3,200 in marketing related intangibles, $2,200 in technology-related intangibles and $200 in other intangibles, which have a weighted average amortization period of four years. Goodwill arising from the acquisition amounted to $42,638, which has been allocated to the Company’s India reporting unit and is partially deductible for tax purposes. The goodwill represents primarily the capabilities, operating synergies and other benefits expected to result from combining the acquired operations with those of the Company.

 

Acquisition-related costs of $1,563 have been included in selling, general and administrative expenses as incurred. In connection with the transaction, the Company also acquired certain assets with a value of $10,367, assumed certain liabilities amounting to $7,415, and recognized a net deferred tax liability of $2,728. The results of operations of the acquired business and the fair value of the acquired assets and assumed liabilities are included in the Company’s consolidated financial statements with effect from the date of the acquisition.

 

(d) RAGE Frameworks, Inc.

 

On April 13, 2017, the Company acquired 100% of the outstanding equity interest in RAGE Frameworks, Inc. (“RAGE”), a Delaware corporation, for total consideration of $125,089. This amount includes cash consideration of $124,149, net of cash acquired of $1,605, and an adjustment for working capital and indebtedness. During the quarter ended December 31, 2017, the Company recorded certain measurement period adjustments. These measurement period adjustments did not have a significant impact on the Company’s consolidated statements of income, balance sheets or cash flows. This acquisition enhances the Company’s digital and artificial intelligence capabilities by adding knowledge-based automation technology and services.

 

In connection with the acquisition of RAGE, the Company recorded $1,600 in customer-related intangibles, $600 in marketing-related intangibles, $12,400 in technology-related intangible assets and $100 in other intangible assets, which have a weighted average amortization period of seven years. Goodwill arising from the acquisition amounted to $105,114, which has been allocated to the Company’s India reporting unit and is not deductible for tax purposes. The goodwill represents primarily the acquired digital and artificial intelligence capabilities, operating synergies and other benefits expected to result from combining the acquired operations with those of the Company.

 

 

 

 

19


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

3. Business acquisitions (Continued)

 

Acquisition-related costs of $881 have been included in selling, general and administrative expenses as incurred. In connection with the transaction, the Company also acquired certain assets with a value of $13,836 and assumed certain liabilities amounting to $9,654. The Company also recognized a net deferred tax asset of $1,094. The results of operations

of the acquired business and the fair value of the acquired assets and assumed liabilities are included in the Company’s consolidated financial statements with effect from the date of the acquisition.

 

(e) Other acquisitions in 2017

 

In 2017, the Company also completed five individually immaterial business acquisition transactions, namely the acquisition of a supply chain management delivery center in the U.S. from Kraft Foods Group Brands LLC (“U.S. Delivery Center”), the purchase of all of the outstanding equity interest in OnSource, LLC (“OnSource”), the purchase of the IT business of Birlasoft (“Birlasoft”), the purchase of the image processing business of Fiserv Solutions of Australia Pty Ltd. (“Fiserv”) and the purchase of all of the outstanding equity interest in Lease Dimensions, Inc. (“Lease Dimensions”). The aggregate total estimated consideration the Company paid to consummate these acquisitions was $87,586. This aggregate amount includes the estimated fair value of contingent earn-out consideration, cash consideration of $76,612, net of cash acquired of $254, and preliminary adjustments for closing date working capital, indebtedness, value transfer, seller transaction expenses and certain employee-related liabilities.

 

The U.S. Delivery Center acquisition enhances the Company’s supply chain management capabilities for its clients in the consumer packaged goods industry. The OnSource acquisition brings incremental digital capabilities to the Company’s insurance service offerings. The Birlasoft transaction expands the Company’s end-to-end capabilities for its clients in the healthcare and aviation industries. The Fiserv transaction strengthens the Company’s financial services portfolio and expands its Australia footprint. The Lease Dimensions acquisition enhances the Company’s capabilities in commercial lending and leasing.

 

During the quarter ended December 31, 2017, the Company recorded certain measurement period adjustments with respect to the Birlasoft and Fiserv transactions. These measurement period adjustments did not have a significant impact on the Company’s consolidated statements of income, balance sheets or cash flows.

 

The purchase agreement for the acquisition of the U.S. Delivery Center provides for contingent earn-out consideration ranging from $0 to $10,000, payable by the Company to the seller based on the achievement of certain milestones relative to the thresholds specified in the earn-out calculation. The purchase agreement for the Lease Dimensions acquisition provides for contingent earn-out consideration ranging from $0 to $3,000, payable by the Company to the sellers based on the future performance of the business relative to the thresholds specified in the earn-out calculation.

 

In connection with these transactions, the Company recorded $33,494 in customer-related intangibles, $1,936 in marketing-related intangibles, $2,956 in technology-related intangibles and $100 in other intangibles, which have a weighted average amortization period of five years. Goodwill arising from these acquisitions amounted to $56,521. The goodwill represents primarily the capabilities, operating synergies and other benefits expected to result from combining the acquired operations with those of the Company.

 

 

 

 

 

 

 

 

 

 

 

 

20


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

3. Business acquisitions (Continued)

 

The following table sets forth, with respect to each of the five acquisitions, the acquisition date, goodwill reporting unit and the tax deductibility of the goodwill:

 

Acquisition

Acquisition date

Goodwill reporting unit

Tax deductibility - goodwill

U.S. Delivery Center

October 16, 2017

India

Deductible

OnSource

July 18, 2017

India

Deductible

Birlasoft

July 18, 2017

IT Services

Deductible

Fiserv

May 11, 2017

India

Non-deductible

Lease Dimensions

February 15, 2017

Americas

Non-deductible

 

Acquisition-related costs for these acquisitions, amounting to $2,369 in the aggregate, have been included in selling, general and administrative expenses as incurred. Through these transactions, the Company acquired assets with a value of $10,387, assumed liabilities amounting to $11,239, and recognized a net deferred tax liability of $6,570. The results of operations of the acquired businesses and the fair value of the acquired assets and assumed liabilities are included in the Company’s consolidated financial statements with effect from the respective dates of the acquisitions.

 

B. Divestiture

 

(a) A portion of IT support business in Europe

 

In November 2017, the Company completed the sale of a portion of its legacy IT support business in Europe (the “Business”). Sale proceeds were $0. During the year ended December 31, 2017, the Business recorded net revenues of $4,546 and a net loss of $9,706.

 

The Company recorded a loss of $5,668 in its consolidated statement of income in connection with the sale of the Business, calculated as follows:

 

Net sale proceeds

 

$

               —

Net assets of the business, including the translation impact thereof

 

 

5,569

Selling expenses

 

 

99

Loss on divestiture included in other income (expense), net

 

$

        5,668

 

21


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

4. Cash and cash equivalents

Cash and cash equivalents as of December 31, 2017 and March 31, 2018 are set out in the table below:

 

 

 

As of December 31,

 

 

As of March 31,

 

 

 

2017

 

 

2018

 

Cash and other bank balances

 

 

504,468

 

 

 

424,226

 

Total

 

$

504,468

 

 

$

424,226

 

 

5. Accounts receivable, net of reserve for doubtful receivables

The following table provides details of the Company’s reserve for doubtful receivables:

 

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 2017

 

 

Three months

ended March 31, 2018

 

Opening balance as of January 1

 

$

15,519

 

 

$

23,660

 

Additions due to acquisitions

 

 

235

 

 

 

-

 

Additions charged/reversal released to cost and expense

 

 

9,819

 

 

 

(103

)

Deductions/effect of exchange rate fluctuations

 

 

(1,913

)

 

 

1

 

Closing balance

 

$

23,660

 

 

$

23,558

 

 

Accounts receivable were $716,745 and $726,624, and the reserves for doubtful receivables were $23,660 and $23,558, resulting in net accounts receivable balances of $693,085 and $703,066 as of December 31, 2017 and March 31, 2018, respectively. In addition, accounts receivable due after one year amounting to $1,624 and $1,407 as of December 31, 2017 and March 31, 2018, respectively, are included under other assets in the consolidated balance sheets.

 

Accounts receivable from related parties were $36 and $239 as of December 31, 2017 and March 31, 2018, respectively.  There are no doubtful receivables in amounts due from related parties.

 

6. Fair value measurements

 

The Company measures certain financial assets and liabilities, including derivative instruments, at fair value on a recurring basis. The fair value measurements of these financial assets and liabilities were determined using the following inputs as of December 31, 2017 and March 31, 2018:

 

 

 

As of December 31, 2017

 

 

 

Fair Value Measurements at Reporting Date Using

 

 

 

 

 

 

 

Quoted Prices in

Active Markets for

Identical Assets

 

 

Significant Other

Observable Inputs

 

 

Significant Other

Unobservable

Inputs

 

 

 

Total

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Derivative instruments (Note a,c)

 

$

73,098

 

 

$

 

 

$

73,098

 

 

$

 

Total

 

$

     73,098

 

 

$

 

 

$

73,098

 

 

$

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnout consideration (Note b, d)

 

$

24,732

 

 

$

 

 

$

 

 

$

24,732

 

Derivative instruments (Note b,c)

 

$

18,188

 

 

$

 

 

$

18,188

 

 

$

 

Total

 

$

42,920

 

 

$

 

 

$

18,188

 

 

$

24,732

 

Redeemable non-controlling interest (Note e)

 

$

4,750

 

 

$

 

 

$

 

 

$

4,750

 

22


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

 

6. Fair value measurements (Continued)

 

 

 

As of March 31, 2018

 

 

 

Fair Value Measurements at Reporting Date Using

 

 

 

 

 

 

 

Quoted Prices in

Active Markets for

Identical Assets

 

 

Significant Other

Observable Inputs

 

 

Significant Other

Unobservable

Inputs

 

 

 

Total

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Derivative instruments (Note a, c)

 

$

53,587

 

 

$

 

 

$

53,587

 

 

$

 

Total

 

$

53,587

 

 

$

 

 

$

53,587

 

 

$

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnout consideration (Note b, d)

 

$

23,900

 

 

 

 

 

 

 

 

$

23,900

 

Derivative instruments (Note b, c)

 

$

28,243

 

 

$

 

 

$

28,243

 

 

$

 

Total

 

$

52,143

 

 

$

 

 

$

28,243

 

 

$

23,900

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(a)Included in prepaid expenses and other current assets and other assets in the consolidated balance sheets.

(b)

Included in accrued expenses and other current liabilities and other liabilities in the consolidated balance sheets.

(c)

The Company values its derivative instruments based on market observable inputs, including both forward and spot prices for the relevant currencies and interest rate indices for relevant interest rates. The quotes are taken from an independent market database.

(d)

The fair value of earn-out consideration, calculated as the present value of expected future payments to be made to the sellers of acquired businesses, was derived by estimating the future financial performance of the acquired businesses using the earn-out formula and performance targets specified in each purchase agreement and adjusting the result to reflect the Company’s estimate of the likelihood of achievement of such targets. Given the significance of the unobservable inputs, the valuations are classified in level 3 of the fair value hierarchy.

(e)

The Company’s estimate of the fair value of redeemable non-controlling interest is based on unobservable inputs considering the assumptions that market participants would make in pricing the obligation. Given the significance of the unobservable inputs, the valuation is classified in level 3 of the fair value hierarchy. See Note 3—Business Acquisitions.

 

The following table provides a roll-forward of the fair value of earn-out consideration categorized as level 3 in the fair value hierarchy for the three months ended March 31, 2017 and 2018:

 

 

 

Three months ended

 

 

 

March 31,

 

 

 

2017

 

 

2018

 

Opening balance

 

$

22,435

 

 

$

24,732

 

Earn-out consideration payable in connection with

Acquisitions

 

 

2,320

 

 

 

 

Payments made on earn-out consideration

 

 

(1,206

)

 

 

(1,476

)

Change in fair value of earn-out consideration (Note a)

 

 

(3,138

)

 

 

17

 

Others (Note b)

 

 

852

 

 

 

627

 

Ending balance

 

$

21,263

 

 

$

23,900

 

(a) Changes in the fair value of earn-out consideration are reported in other operating (income) expense, net in the consolidated statements of income.

(b) Interest expense is included in interest income (expense), net and the impact of changes in foreign exchange is reported in foreign exchange gains (losses), net in the consolidated statements of income. The cumulative translation adjustment is reported as a component of other comprehensive income (loss).

 

23


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

7. Derivative financial instruments

 

The Company is exposed to the risk of rate fluctuations on its foreign currency assets and liabilities and on foreign currency denominated forecasted cash flows. The Company has established risk management policies, including the use of derivative financial instruments to hedge foreign currency assets and liabilities, foreign currency denominated forecasted cash flows and interest rate risk. These derivative financial instruments are largely deliverable and non-deliverable forward foreign exchange contracts and interest rate swaps. The Company enters into these contracts with counterparties that are banks or other financial institutions, and the Company considers the risk of non-performance by such counterparties not to be material. The forward foreign exchange contracts and interest rate swaps mature during a period of up to 57 months and the forecasted transactions are expected to occur during the same period.

 

The following table presents the aggregate notional principal amounts of outstanding derivative financial instruments together with the related balance sheet exposure: 

 

 

 

Notional principal amounts

(note a)

 

 

Balance sheet exposure asset

(liability)  (note b)

 

 

 

As of December 31,

2017

 

 

As of March 31,

2018

 

 

As of December 31,

2017

 

 

As of March 31,

2018

 

Foreign exchange forward contracts denominated in:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

United States Dollars (sell) Indian Rupees (buy)

 

$

1,289,400

 

 

$

1,376,800

 

 

$

54,398

 

 

$

30,002

 

United States Dollars (sell) Mexican Peso (buy)

 

 

9,000

 

 

 

9,000

 

 

 

(441

)

 

 

417

 

United States Dollars (sell) Philippines Peso (buy)

 

 

76,650

 

 

 

66,300

 

 

 

69

 

 

 

(2,858

)

Euro (sell) United States Dollars (buy)

 

 

170,542

 

 

 

153,516

 

 

 

(2,069

)

 

 

(5,810

)

Pound Sterling (buy) United States Dollars (sell)

 

 

24,041

 

 

 

22,150

 

 

 

253

 

 

 

479

 

Euro (sell) Romanian Leu (buy)

 

 

35,826

 

 

 

33,296

 

 

 

(892

)

 

 

(448

)

Japanese Yen (sell) Chinese Renminbi (buy)

 

 

60,768

 

 

 

54,781

 

 

 

1,918

 

 

 

491

 

Pound Sterling (sell) United States Dollars (buy)

 

 

80,871

 

 

 

67,532

 

 

 

(2,478

)

 

 

(5,317

)

Australian Dollars (sell) United States Dollars (buy)

 

 

136,092

 

 

 

114,932

 

 

 

(5,180

)

 

 

(3,180

)

Interest rate swaps (floating to fixed)

 

 

432,117

 

 

 

425,945

 

 

 

9,332

 

 

 

11,568

 

 

 

 

 

 

 

 

 

 

 

 

54,910

 

 

 

25,344

 

 

(a)

Notional amounts are key elements of derivative financial instrument agreements but do not represent the amount exchanged by counterparties and do not measure the Company’s exposure to credit foreign exchange, interest rate or market risks. However, the amounts exchanged are based on the notional amounts and other provisions of the underlying derivative financial instrument agreements.

(b)

Balance sheet exposure is denominated in U.S. dollars and denotes the mark-to-market impact of the derivative financial instruments on the reporting date.

 

FASB guidance on derivatives and hedging requires companies to recognize all derivative instruments as either assets or liabilities at fair value in the balance sheet. In accordance with the FASB guidance on derivatives and hedging, the Company designates foreign exchange forward contracts and interest rate swaps as cash flow hedges. Foreign exchange forward contracts are entered into to cover the effects of future exchange rate variability on forecasted revenues and purchases of services, and interest rate swaps are entered into to cover interest rate fluctuation risk. In addition to this program, the Company uses derivative instruments that are not accounted for as hedges under the FASB guidance in order to hedge foreign exchange risks related to balance sheet items, such as receivables and intercompany borrowings, that are denominated in currencies other than the Company’s underlying functional currency.

24


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

7. Derivative financial instruments (Continued)

 

The fair value of the Company’s derivative instruments and their location in the Company’s financial statements are summarized in the table below:

 

 

 

Cash flow hedges

 

 

Non-designated

 

 

 

As of December 31,

2017

 

 

As of March 31,

2018

 

 

As of December 31,

2017

 

 

As of March 31,

2018

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Prepaid expenses and other current assets

 

$

43,557

 

 

$

32,750

 

 

$

4,635

 

 

$

973

 

Other assets

 

$

24,906

 

 

$

19,864

 

 

$

 

 

$

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accrued expenses and other current liabilities

 

$

10,092

 

 

$

13,326

 

 

$

254

 

 

$

1,986

 

Other liabilities

 

$

7,842

 

 

$

12,931

 

 

$

 

 

$

 

 

Cash flow hedges

 

For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of the gain (loss) on the derivative instrument is reported as a component of other comprehensive income (loss) and reclassified into earnings in the same period or periods during which the hedged transaction is recognized in the consolidated statements of income. Gains (losses) on the derivatives, representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness, are recognized in earnings as incurred.

 

In connection with cash flow hedges, the gains (losses) recorded as a component of other comprehensive income (loss), or OCI, and the related tax effects are summarized below:

 

 

 

Three months ended March 31,

 

 

 

2017

 

 

2018

 

 

 

Before-Tax

amount

 

 

Tax (Expense) or

Benefit

 

 

 

Net of tax

Amount

 

 

Before-Tax

amount

 

 

Tax (Expense) or

Benefit

 

 

Net of tax

Amount

 

Opening balance

 

$

37,461

 

 

$

(13,979

)

 

 

$

23,482

 

 

$

50,529

 

 

$

(14,436

)

 

$

36,093

 

Adoption of ASU 2018-02 (note 24)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2,265

 

 

 

2,265

 

Net gains (losses) reclassified into statement of income on completion of hedged transactions

 

 

9,295

 

 

 

(3,432

)

 

 

 

5,863

 

 

 

8,279

 

 

 

(1,616

)

 

 

6,663

 

Changes in fair value of effective portion of outstanding derivatives, net

 

 

39,508

 

 

 

(14,787

)

 

 

 

24,721

 

 

 

(15,893

)

 

 

3,625

 

 

 

(12,269

)

Gain (loss) on cash flow hedging derivatives, net

 

 

30,213

 

 

 

(11,355

)

 

 

 

18,858

 

 

 

(24,172

)

 

 

5,240

 

 

 

(18,932

)

Closing balance

 

$

67,674

 

 

$

(25,334

)

 

 

$

42,340

 

 

$

26,357

 

 

$

(6,931

)

 

$

19,426

 

 

25


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

7. Derivative financial instruments (Continued)

 

The gains or losses recognized in other comprehensive income (loss) and their effects on financial performance are summarized below: 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amount of Gain (Loss)

 

 

 

 

Amount of Gain (Loss)

 

 

 

 

reclassified from OCI into

 

 

 

 

recognized in OCI on

 

 

Location of Gain (Loss)

 

Statement of Income

 

 

Derivatives in

 

Derivatives (Effective Portion)

 

 

reclassified

 

(Effective Portion)

 

 

Cash Flow

 

Three months ended

 

 

from OCI into

 

Three months ended

 

 

Hedging

 

March 31,

 

 

Statement of Income

 

March 31,

 

 

Relationships

 

2017

 

 

2018

 

 

(Effective Portion)

 

2017

 

 

2018

 

 

Forward foreign

exchange contracts

 

$

39,296

 

 

$

(18,679

)

 

Revenue

 

$

3,760

 

 

$

(1,474

)

 

Interest rate swaps

 

 

212

 

 

 

2,786

 

 

Cost of revenue

 

 

4,570

 

 

 

7,270

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and

administrative expenses

 

 

1,248

 

 

 

1,934

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

 

(283

)

 

 

549

 

 

 

 

$

39,508

 

 

$

(15,893

)

 

 

 

$

9,295

 

 

$

8,279

 

 

 

Gain (loss) recognized in income on the ineffective portion of derivatives and the amount excluded from effectiveness testing is $0 for the three months ended March 31, 2017 and 2018, respectively.

 

Non-designated Hedges

 

 

 

 

 

 

 

 

 

 

Amount of Gain (Loss) recognized in Statement of Income on Derivatives

 

 

 

 

 

Three months ended March 31,

 

Derivatives not designated as hedging instruments

 

Location of Gain (Loss)  recognized in Statement of Income on Derivatives

 

2017

 

 

2018

 

Forward foreign exchange

   contracts (Note a)

 

Foreign exchange gains

   (losses), net

 

$

8,910

 

 

$

(4,288

)

 

 

 

 

$

8,910

 

 

$

(4,288

)

 

(a)

These forward foreign exchange contracts were entered into to hedge fluctuations in foreign exchange rates for recognized balance sheet items such as receivables and intercompany borrowings, and were not originally designated as hedges under FASB guidance on derivatives and hedging. Realized gains (losses) and changes in the fair value of these derivatives are recorded in foreign exchange gains (losses), net in the consolidated statements of income.

26


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

8. Prepaid expenses and other current assets

 

Prepaid expenses and other current assets consist of the following:

 

 

 

As of December 31,

 

 

As of March 31,

 

 

 

2017

 

 

2018

 

Advance income and non-income taxes

 

$

51,832

 

 

$

65,493

 

Deferred transition costs (Note 19)

 

 

62,029

 

 

 

-

 

Contract asset (Note 19)

 

 

 

 

 

15,886

 

Customer acquisition cost (Note 19)

 

 

19,327

 

 

 

 

Prepaid expenses

 

 

16,944

 

 

 

19,638

 

Derivative instruments

 

 

48,192

 

 

 

33,723

 

Employee advances

 

 

5,014

 

 

 

3,764

 

Deposits

 

 

4,719

 

 

 

7,331

 

Advances to suppliers

 

 

2,705

 

 

 

5,502

 

Others

 

 

25,580

 

 

 

47,871

 

 

 

$

236,342

 

 

$

199,208

 

 

9. Property, plant and equipment, net

 

The following table provides the gross and net amount of property, plant and equipment:

 

 

 

As of December 31,

 

 

As of March 31,

 

 

 

2017

 

 

2018

 

Property, plant and equipment, gross

 

$

666,031

 

 

$

673,901

 

Less: accumulated depreciation and amortization

 

 

(459,001

)

 

 

(468,866

)

Property, plant and equipment, net

 

$

207,030

 

 

$

205,035

 

 

Depreciation expense on property, plant and equipment for the three months ended March 31, 2017 and 2018 was $11,230 and $12,275, respectively.  Computer software amortization for the three months ended March 31, 2017 and 2018 amounted to $2,679 and $3,212, respectively.  

 

The depreciation and amortization expenses set forth above include the effect of the reclassification of foreign exchange (gains) losses related to the effective portion of foreign currency derivative contracts, amounting to $(228) and $(349) for the three months ended March 31, 2017 and 2018, respectively.

 

10. Goodwill and intangible assets

 

The following table presents the changes in goodwill for the year ended December 31, 2017 and three months ended March 31, 2018:

 

 

 

As of December 31,

 

 

As of March 31,

 

 

 

2017

 

 

2018

 

Opening balance

 

$

1,069,408

 

 

$

1,337,122

 

Goodwill relating to acquisitions consummated during

the period

 

 

229,745

 

 

 

 

Impact of measurement period adjustments

 

 

(106

)

 

 

(83

)

Effect of exchange rate fluctuations

 

 

38,075

 

 

 

12

 

Closing balance

 

$

1,337,122

 

 

$

1,337,051

 

 

The total amount of goodwill deductible for tax purposes was $120,617 and $121,774 as of December 31, 2017 and March 31, 2018, respectively.

 

27


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

The Company’s intangible assets are as follows:

 

 

 

As of December 31, 2017

 

 

As of March 31, 2018

 

 

 

Gross carrying amount

 

 

Accumulated amortization & Impairment

 

 

Net

 

 

Gross carrying amount

 

 

Accumulated amortization & Impairment

 

 

Net

 

Customer-related intangible assets

 

$

369,173

 

 

$

293,029

 

 

$

76,144

 

 

$

367,640

 

 

$

298,048

 

 

$

69,592

 

Marketing-related intangible assets

 

 

52,443

 

 

$

39,212

 

 

 

13,231

 

 

 

52,165

 

 

 

39,538

 

 

 

12,627

 

Technology-related intangible assets

 

 

54,189

 

 

 

28,278

 

 

 

25,911

 

 

 

55,101

 

 

 

32,135

 

 

 

22,966

 

Other intangible assets

 

 

3,081

 

 

 

2,314

 

 

$

767

 

 

 

2,460

 

 

 

1,710

 

 

 

750

 

Intangible assets under development

 

 

15,537

 

 

 

 

 

$

15,537

 

 

 

19,846

 

 

 

 

 

 

19,846

 

 

 

 

494,423

 

 

 

362,833

 

 

$

131,590

 

 

$

497,212

 

 

$

371,431

 

 

$

125,781

 

 

Amortization expenses for intangible assets disclosed in the Consolidated Statements of Income under amortization of intangible assets for the three months ended March 31, 2017 and 2018 were $7,242 and $9,936, respectively.  

 

Amortization expenses for technology-related, internally-developed intangible assets disclosed in the Consolidated Statements of Income under cost of revenue and selling, general and administrative expense for the three months ended March 31, 2017, and 2018 were $0, and $400 respectively.  

 

11. Short-term borrowings

 

The Company has the following borrowing facilities:

 

 

(a)

Fund-based and non-fund-based credit facilities with banks, which are available for operational requirements in the form of overdrafts, letters of credit, guarantees and short-term loans. As of December 31, 2017 and March 31, 2018, the limits available were $15,064 and $14,311, respectively, of which $7,900 and $7,312 was utilized, constituting non-funded drawdown.

 

 

(b)

A fund-based and non-fund based revolving credit facility of $350,000, which the Company obtained in June 2015 as described in note 12. As of December 31, 2017 and March 31, 2018, a total of $170,978 and $276,073 respectively, was utilized, of which $170,000 and $275,000 respectively, constituted funded drawdown and $978 and $1,073, respectively, constituted non-funded drawdown. The revolving facility expires in June 2020. The funded drawdown amount bore interest at a rate equal to LIBOR plus a margin of 1.50% per annum as of December 31, 2017 and March 31, 2018. The unutilized amount on the revolving facility bore a commitment fee of 0.25% as of December 31, 2017 and March 31, 2018. The credit agreement contains certain customary covenants, including a maximum leverage covenant and a minimum interest coverage ratio. During the three months ended March 31, 2018, the Company was in compliance with the financial covenants.      

12. Long-term debt

 

In June 2015, the Company refinanced its 2012 credit facility through a new credit facility comprised of an $800,000 term loan and a $350,000 revolving credit facility. Borrowings under the new facility bear interest at a rate equal to, at the election of the Company, either LIBOR plus an applicable margin equal to 1.50% per annum or a base rate plus an applicable margin equal to 0.50% per annum, in each case subject to adjustment based on the Company’s debt ratings provided by Standard & Poor’s Rating Services and Moody’s Investors Service, Inc. Based on the Company’s election and then current credit rating, the applicable interest rate is equal to LIBOR plus 1.50% per annum. The credit agreement contains certain customary covenants, and during the three months ended March 31, 2018, the Company was in compliance with the financial covenants of the credit agreement.

 

As of December 31, 2017 and March 31, 2018, the amount outstanding under the term loan, net of debt amortization expense of $1,848 and $1,654, was $698,152 and $688,346, respectively. As of December 31, 2017 and March 31, 2018, the term loan bore interest at a rate equal to LIBOR plus a margin of 1.50% per annum based on the Company’s election and current credit rating. Indebtedness under the refinanced facility is unsecured. The amount outstanding on the term loan as of March 31, 2018 will be repaid through quarterly payments of $10,000, and the balance will be repaid upon the maturity of the term loan on June 30, 2020.

28


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

 

The maturity profile of the term loan outstanding as of March 31, 2018, net of debt amortization expense, is as follows:

 

Year ended

 

Amount

 

2018

 

 

29,421

 

2019

 

 

39,272

 

2020

 

 

619,653

 

Total

 

$

688,346

 

 

29


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

12. Long-term debt (Continued)

 

In March 2017, the Company issued $350,000 aggregate principal amount of 3.70% senior notes in a private offering, resulting in cash proceeds of approximately $348,519, net of an underwriting fee of $1,481. In connection with the offering, the Company incurred other debt issuance costs of $1,161. The total debt issuance cost of $2,642 is being amortized over the life of the notes as additional interest expense. As of December 31, 2017 and March 31, 2018, the amount outstanding under the notes, net of debt amortization expense of $2,239 and $2,110, was $347,761 and $347,890 respectively, which is payable on April 1, 2022. The Company will pay interest on the notes semi-annually in arrears on April 1 and October 1 of each year, ending on the maturity date of April 1, 2022. The Company, at its option, may redeem the notes at any time in whole or in part, at a redemption price equal to (i) 100% of the principal amount of the notes redeemed, together with accrued and unpaid interest on the redeemed amount, and (ii) if the notes are redeemed prior to March 1, 2022, a specified “make-whole” premium. The notes are subject to certain customary covenants, including limitations on the ability of the Company and certain of its subsidiaries to incur debt secured by liens, engage in certain sale and leaseback transactions and consolidate, merge, convey or transfer their assets and during the three months ended March 31, 2018, the Company was in compliance with the covenants. Upon certain change of control transactions, the Company will be required to make an offer to repurchase the notes at a price equal to 101% of the aggregate principal amount of such notes, plus accrued and unpaid interest.  The interest rate payable on the notes is subject to adjustment if the credit rating of the notes is downgraded up to a maximum increase of 2.0%. The Company is required to offer to exchange the notes for registered notes or have one or more shelf registration statements declared effective within 455 days after the issue date of the notes and, if such exchange offer fails to be consummated or such registration statement fails to be effective by June 25, 2018, then the interest payable on the notes will increase by 0.25% per annum during the 90-day period immediately following such date and will further increase by 0.25% per annum at the end of each subsequent 90-day period up to a maximum increase of 0.50%. The notes are senior unsecured obligations of the Company and will rank equally with all other senior unsecured indebtedness of the Company outstanding from time to time.

13. Accrued expenses and other current liabilities

 

Accrued expenses and other current liabilities consist of the following:

 

 

 

As of December 31,

 

 

As of March 31,

 

 

 

2017

 

 

2018

 

Accrued expenses

 

$

204,997

 

 

$

183,777

 

Accrued employee cost

 

 

204,506

 

 

 

123,076

 

Earn-out consideration

 

 

14,928

 

 

 

18,161

 

Statutory liabilities

 

 

36,283

 

 

 

48,371

 

Retirement benefits

 

 

21,074

 

 

 

21,455

 

Derivative instruments

 

 

10,346

 

 

 

15,312

 

Advance from customers (note 19)

 

 

25,476

 

 

 

 

Contract liabilities (note 19)

 

 

 

 

 

81,515

 

Deferred transition revenue (note 19)

 

 

52,233

 

 

 

 

Other liabilities

 

 

13,093

 

 

 

9,953

 

Capital lease obligations

 

 

1,546

 

 

 

1,496

 

 

 

$

584,482

 

 

$

503,116

 

 

30


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

14. Other liabilities

 

Other liabilities consist of the following:

 

 

 

As of December 31,

 

 

As of March 31,

 

 

 

2017

 

 

2018

 

Accrued employee cost

 

$

14,020

 

 

$

14,877

 

Earn-out consideration

 

 

9,804

 

 

 

5,739

 

Retirement benefits

 

 

40,520

 

 

 

43,235

 

Derivative instruments

 

 

7,842

 

 

 

12,931

 

Advance from customers (note 19)

 

 

790

 

 

 

 

Contract liabilities (note 19)

 

 

 

 

 

55,484

 

Deferred transition revenue (note 19)

 

 

70,900

 

 

 

 

Others

 

 

22,069

 

 

 

21,187

 

Capital lease obligations

 

 

2,664

 

 

 

2,405

 

 

 

$

168,609

 

 

$

155,858

 

 

31


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

15. Employee benefit plans

 

The Company has employee benefit plans in the form of certain statutory and other schemes covering its employees.

 

Defined benefit plans

 

In accordance with Indian law, the Company maintains a defined benefit retirement plan covering substantially all of its Indian employees. In accordance with Mexican law, the Company provides termination benefits to all of its Mexican employees. In addition, certain of the Company’s subsidiaries in the Philippines and Japan sponsor defined benefit retirement programs.

 

Net defined benefit plan costs for the three months ended March 31, 2017 and 2018 include the following components:

 

 

 

Three months ended March 31,

 

 

 

2017

 

 

2018

 

Service costs

 

$

1,720

 

 

$

1,995

 

Interest costs

 

 

734

 

 

 

995

 

Amortization of actuarial loss

 

 

205

 

 

 

320

 

Expected return on plan assets

 

 

(492

)

 

 

(736

)

Net defined benefit plan costs

 

$

2,167

 

 

$

2,574

 

 

For the three months ended March 31, 2017 and 2018, all of the components of net defined benefit plan costs other than service costs were recorded in “cost of revenue” and “selling, general and administrative expenses” in the Consolidated Statement of Income.

 

Defined contribution plans

 

During the three months ended March 31, 2017 and 2018, the Company contributed the following amounts to defined contribution plans in various jurisdictions:

 

 

 

Three months ended March 31,

 

 

 

2017

 

 

2018

 

India

 

$

5,217

 

 

$

5,944

 

U.S.

 

 

4,280

 

 

 

4,599

 

U.K.

 

 

1,720

 

 

 

2,137

 

China

 

 

3,828

 

 

 

4,394

 

Other regions

 

 

1,130

 

 

 

1,160

 

Total

 

$

16,175

 

 

$

18,234

 

 

32


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

16. Stock-based compensation

The Company has issued options under the Genpact Limited 2007 Omnibus Incentive Compensation Plan (the “2007 Omnibus Plan”) and the Genpact Limited 2017 Omnibus Incentive Compensation Plan (the “2017 Omnibus Plan”) to eligible persons, including employees, directors and certain other persons associated with the Company.

Under the 2007 Omnibus Plan, shares underlying options forfeited, expired, terminated or cancelled under any of the Company’s predecessor plans were added to the number of shares otherwise available for grant under the 2007 Omnibus Plan. The 2007 Omnibus Plan was amended and restated on April 11, 2012 to increase the number of common shares authorized for issuance by 5,593,200 shares to 15,000,000 shares.

On May 9, 2017, the Company’s shareholders approved the adoption of the Genpact Limited 2017 Omnibus Incentive Compensation Plan (the “2017 Omnibus Plan”), pursuant to which 15,000,000 Company common shares are available for issuance. No grants may be made under the 2007 Omnibus Plan after the date of adoption of the 2017 Omnibus Plan.  Grants that were outstanding under the 2007 Omnibus Plan as of the Company’s adoption of the 2017 Omnibus Plan remain subject to the terms of the 2007 Omnibus Plan.

Stock-based compensation costs relating to the foregoing plans during the three months ended March 31, 2017 and 2018 were $4,845 and $7,597, respectively. These costs have been allocated to cost of revenue and selling, general, and administrative expenses.

 

Stock options

 

All options granted under the 2007 and 2017 Omnibus Plans are exercisable into common shares of the Company, have a contractual period of ten years and vest over four to five years unless specified otherwise in the applicable award agreement. The Company recognizes compensation cost over the vesting period of the option.

 

Compensation cost is determined at the date of grant by estimating the fair value of an option using the Black-Scholes option-pricing model.

 

The following table shows the significant assumptions used in determining the fair value of options granted in the three months ended March 31, 2017. No options were granted in the three months ended March 31, 2018.

 

 

 

 

Three months ended

March 31, 2017

 

Dividend yield

 

 

 

 

0.97%

 

Expected life (in months)

 

 

 

 

84

 

Risk-free rate of interest

 

 

 

2.25%

 

Volatility

 

 

 

24.28%

 

 

33


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

16. Stock-based compensation (Continued)

 

A summary of stock option activity during the three months ended March 31, 2018 is set out below:

 

 

 

Three months ended March 31, 2018

 

 

 

Shares arising

out of options

 

 

Weighted average

exercise price

 

 

Weighted average

remaining

contractual life

(years)

 

 

Aggregate

intrinsic

value

 

Outstanding as of January 1, 2018

 

 

5,134,645

 

 

$

19.52

 

 

 

5.6

 

 

$

     —

 

Granted

 

 

 

 

 

 

 

 

 

 

 

 

Forfeited

 

 

 

 

 

 

 

 

 

 

 

 

Expired

 

 

 

 

 

 

 

 

 

 

 

 

Exercised

 

 

(161,837

)

 

 

15.76

 

 

 

 

 

 

2,626

 

Outstanding as of March 31, 2018

 

 

4,972,808

 

 

$

19.64

 

 

 

5.4

 

 

$

61,401

 

Vested as of March 31, 2018 and expected to vest thereafter (Note a)

 

 

4,843,888

 

 

$

19.49

 

 

 

5.4

 

 

$

60,526

 

Vested and exercisable as of March 31, 2018

 

 

3,592,809

 

 

$

17.63

 

 

 

4.4

 

 

$

      51,599

 

Weighted average grant date fair value of grants during the period

 

$

 

 

 

 

 

 

 

 

 

 

 

 

 

  (a) Options expected to vest reflect an estimated forfeiture rate.

 

As of March 31, 2018, the total remaining unrecognized stock-based compensation cost for options expected to vest amounted to $5,708, which will be recognized over the weighted average remaining requisite vesting period of 2.7 years.

Restricted share units

The Company has granted restricted share units, or RSUs, under the 2007 and 2017 Omnibus Plans. Each RSU represents the right to receive one common share. The fair value of each RSU is the market price of one common share of the Company on the date of the grant. The RSUs granted to date have graded vesting schedules of three months to four years. The compensation expense is recognized on a straight-line basis over the vesting term. A summary of RSUs granted during the three months ended March 31, 2018 is set out below:

 

 

 

 

Three months ended March 31, 2018

 

 

 

 

Number of Restricted Share Units

 

 

Weighted Average Grant Date Fair Value

 

Outstanding as of January 1, 2018

 

 

1,605,251

 

 

$

26.17

 

Granted

 

 

 

 

 

 

Vested (Note a)

 

 

(58,875

)

 

 

23.99

 

Forfeited

 

 

  (4,500)

 

 

 

24.59

 

Outstanding as of March 31, 2018

 

 

1,541,876

 

 

$

26.26

 

Expected to vest (Note b)

 

 

1,337,172

 

 

 

 

 

 

(a)

6,000 RSUs that vested during the period were net settled upon vesting by issuing 3,576 shares (net of minimum statutory tax withholding). 52,875 RSUs vested in the year ended December 31, 2017, shares in respect of which will be issuable on December 31, 2018 after withholding shares to the extent of minimum statutory withholding taxes.

(b)

The number of RSUs expected to vest reflects an estimated forfeiture rate.

 

52,482 RSUs vested in the year ended December 31, 2016, in respect of which 52,055 shares were issued during the three months ended March 31, 2018 after withholding shares to the extent of minimum statutory withholding taxes.

34


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

16. Stock-based compensation (Continued)

 

As of March 31, 2018, the total remaining unrecognized stock-based compensation cost related to RSUs amounted to $23,703, which will be recognized over the weighted average remaining requisite vesting period of 2.7 years.

 

Performance units

 

The Company also grants stock awards in the form of performance units, or PUs, and has granted PUs under both the 2007 and 2017 Omnibus Plans.

 

Each PU represents the right to receive one common share at a future date based on the Company’s performance against specified targets. PUs granted to date have vesting schedules of six months to three years. The fair value of each PU is the market price of one common share of the Company on the date of grant and assumes that performance targets will be achieved. PUs granted under the plans are subject to cliff vesting. The compensation expense for such awards is recognized on a straight-line basis over the vesting terms. During the performance period, the Company’s estimate of the number of shares to be issued is adjusted upward or downward based upon the probability of achievement of the performance targets. The ultimate number of shares issued and the related compensation cost recognized is based on a comparison of the final performance metrics to the specified targets.

 

A summary of PU activity during the three months ended March 31, 2018 is set out below:

 

 

 

Three months ended March 31, 2018

 

 

 

Number of

Performance Units

 

 

Weighted

Average Grant

Date Fair Value

 

 

Maximum Shares

Eligible to Receive

 

Outstanding as of January 1, 2018

 

 

2,900,940

 

 

$

24.40

 

 

 

2,900,940

 

Granted

 

 

 

 

 

 

 

 

 

Vested (Note a)

 

 

(1,087,751)

 

 

 

22.73

 

 

 

(1,087,751)

 

Forfeited

 

 

(78,304

)

 

 

24.92

 

 

 

(78,304

)

Adjustment upon final determination of level of

   performance goal achievement (Note b)

 

 

(4,597

)

 

 

25.22

 

 

 

 

 

Adjustment upon final determination of level of

   performance goal achievement (Note b)

 

 

 

 

 

 

 

 

 

 

(4,597

)

Outstanding as of March 31, 2018

 

 

1,730,288

 

 

$

25.43

 

 

 

1,730,288

 

Expected to vest (Note c)

 

 

1,524,101

 

 

 

 

 

 

 

 

 

 

 

(a)

PUs that vested during the period were net settled upon vesting by issuing 691,958 shares (net of minimum statutory tax withholding).

 

(b)

Represents an adjustment made in March 2018 to the number of shares subject to the PUs granted in 2017 upon         certification of the level of achievement of the performance targets underlying such awards.

 

(c)

The number of PUs expected to vest has been adjusted by an estimated forfeiture rate.

 

As of March 31, 2018, the total remaining unrecognized stock-based compensation cost related to PUs amounted to $25,194, which will be recognized over the weighted average remaining requisite vesting period of 1.8 years.

 

 

 

 

35


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

16. Stock-based compensation (Continued)

 

Employee Stock Purchase Plan (ESPP)

 

On May 1, 2008, the Company adopted the Genpact Limited U.S. Employee Stock Purchase Plan and the Genpact Limited International Employee Stock Purchase Plan (together, the “ESPP”). In April 2018, these plans were amended and restated, and their terms were extended to August 31, 2018.  

 

The ESPP allows eligible employees to purchase the Company’s common shares through payroll deductions at 90% of the closing price of the Company’s common shares on the last business day of each purchase interval. The dollar amount of common shares purchased under the ESPP must not exceed 15% of the participating employee’s base salary, subject to a cap of $25 per employee per calendar year. With effect from September 1, 2009, the offering periods commence on the first business day in March, June, September and December of each year and end on the last business day of the subsequent May, August, November and February. 4,200,000 common shares have been reserved for issuance in the aggregate over the term of the ESPP.

 

During the three months ended March 31, 2017 and 2018, 55,788 and 58,476 common shares, respectively, were issued under the ESPP.

 

The ESPP is considered compensatory under the FASB guidance on Compensation-Stock Compensation.

 

The compensation expense for the ESPP is recognized in accordance with the FASB guidance on Compensation-Stock Compensation. The compensation expense for the ESPP during the three months ended March 31, 2017 and 2018 was $141 and $190, respectively, and has been allocated to cost of revenue and selling, general, and administrative expenses.

 

36


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

17. Capital stock

 

Share repurchases

 

As of December 31, 2016, the Company’s board of directors (the “Board”) had authorized the Company to repurchase up to $750,000 in value of the Company’s common shares under its share repurchase program first announced in February 2015. On February 10, 2017 the Board approved up to an additional $500,000 in share repurchases, bringing the total authorization under the Company’s existing program to $1,250,000. The Company’s share repurchase program does not obligate it to acquire any specific number of shares. Under the program, shares may be purchased in privately negotiated and/or open market transactions, including under plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

 

On March 29, 2017, the Company entered into an accelerated share repurchase (“ASR”) agreement with Morgan Stanley & Co. LLC (the “Dealer”) to repurchase Company common shares for an aggregate purchase price of $200,000. Pursuant to the ASR agreement, as amended in November, 2017, the Company paid the aggregate purchase price to the Dealer upfront and received an initial delivery of 6,578,947 common shares on March 30, 2017, an additional delivery of 350,006 common shares on December 29, 2017 and a final delivery of 163,975 common shares on January 17, 2018 upon final settlement of the transaction. The weighted average price per share of the common shares delivered was $28.20. The Company’s purchase of its common shares under the ASR has been recorded as a reduction in retained earnings. All repurchased shares have been retired.

 

The final number of common shares repurchased by the Company under the ASR agreement was based on the volume-weighted average share price of the Company’s common shares during the term of the transaction, less a discount and subject to adjustments pursuant to the terms of the ASR agreement.

 

The ASR agreement contained customary provisions, including, among other things, with respect to mechanisms to determine the number of shares or the amount of cash that will be delivered at settlement, the required timing of delivery upon settlement, specific circumstances under which adjustments may be made to the repurchase transaction, and specific circumstances under which the repurchase transaction may be canceled prior to the scheduled maturity.

 

During the three months ended March 31, 2017 and March 31, 2018, the Company also purchased 808,293 and 3,015,999 of its common shares, respectively, on the open market at a weighted average price of $24.48 and $31.82 per share, respectively, for an aggregate cash amount of $19,784 and $95,984, respectively. All repurchased shares have been retired.

 

The Company records repurchases of its common shares on the settlement date of each transaction. Shares purchased and retired are deducted to the extent of their par value from common stock and from retained earnings for the excess over par value. Direct costs incurred to acquire the shares are included in the total cost of the shares purchased. For the three months ended March 31, 2017 and March 31, 2018, $16 and $60, respectively, was deducted from retained earnings in direct costs related to share repurchases.

 

Dividend

 

In February 2017, the Company’s board of directors approved a dividend program under which the Company paid a regular quarterly cash dividend of $0.06 per share to holders of its common shares, representing an annual dividend of $0.24 per share. On March 28, 2017, the Company paid a dividend of $0.06 per share, amounting to $11,957 in the aggregate, to shareholders of record as of March 10, 2017.

 

On February 12, 2018, the Company announced that its Board of Directors had approved a 25% increase in its quarterly cash dividend to $0.075 per share, up from $0.06 per share in 2017, representing a planned annual dividend of $0.30 per common share, up from $0.24 per share in 2017, payable to holders of the Company’s common shares. On March 21, 2018, the Company paid a dividend of $0.075 per share, amounting to $14,408 in the aggregate, to shareholders of record as of March 9, 2018.

 

37


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

18. Earnings per share

 

The Company calculates earnings per share in accordance with FASB guidance on earnings per share. Basic and diluted earnings per common share give effect to the change in the number of Company common shares outstanding. The calculation of basic earnings per common share is determined by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the respective periods. Potentially dilutive shares, consisting of outstanding options on common shares, restricted share units, performance units and common shares to be issued under the employee stock purchase plan, have been included in the computation of diluted net earnings per share and the weighted average shares outstanding, except where the result would be anti-dilutive.

 

The number of stock awards outstanding but not included in the computation of diluted earnings per common share because their effect was anti-dilutive is 1,003,048 and 660,000 for the three months ended March 31, 2017 and 2018, respectively.

 

 

 

Three months ended March 31,

 

 

 

2017

 

 

2018

 

Net income available to Genpact Limited

   common shareholders

 

$

53,338

 

 

$

64,695

 

Weighted average number of common shares used in

   computing basic earnings per common share

 

 

199,069,528

 

 

 

192,816,626

 

Dilutive effect of stock-based awards

 

 

3,586,409

 

 

 

3,471,943

 

Weighted average number of common shares used in

   computing dilutive earnings per common share

 

 

202,655,937

 

 

 

196,288,569

 

Earnings per common share attributable to Genpact

   Limited common shareholders

 

 

 

 

 

 

 

 

Basic

 

$

0.27

 

 

$

0.34

 

Diluted

 

$

0.26

 

 

$

0.33

 

 

19. Net revenues

 

Disaggregation of revenue

 

In the following tables, revenue is disaggregated by customer classification, service type, major industries serviced and location of service delivery centers.

 

 

Three months ended March 31,

 

 

2017

 

2018

 

GE

$              69,254

 

$              58,049

 

Global Clients

                553,741

 

               630,863

 

Total net revenues

$            622,995

 

$            688,912

 

 

 

Three months ended March 31,

 

 

2017

 

2018

 

Business process outsourcing

$            511,283

 

$             574,061

 

Information technology services

                 111,712

 

                 114,851

 

Total net revenues

$            622,995

 

$            688,912

 

38


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

19. Net revenues (continued)

 

 

Three months ended March 31,

 

 

2017

 

2018

 

Banking, financial services and insurance

$           247,012

 

$            275,627

 

Manufacturing, including pharmaceuticals and

medical equipment manufacturing

                229,214

 

                247,125

 

Technology, healthcare and other services

                146,769

 

                166,160

 

Total net revenues

$            622,995

 

$            688,912

 

 

 

Three months ended  March 31,

 

 

2017

 

2018

 

India

$            411,055

 

$            389,134

 

Asia, other than India

                  66,662

 

                  79,461

 

North and Latin America

                  85,042

 

                152,280

 

Europe

                  60,236

 

                  68,037

 

Total net revenues

$            622,995

 

$            688,912

 

 

Contract balances

 

Accounts receivable include amounts for services that the Company has performed but for which payment has not been received. The Company typically follows a 30-day billing cycle and, as such, at any point in time may have accrued up to 30 days of revenues that have not been billed. The Company has determined in instances where the timing of revenue recognition differs from the timing of invoicing, the contracts generally do not include a significant financing component. Refer to note 4 for details on the Company’s accounts receivable and reserve for doubtful receivables.

 

The following table provides details of the Company’s contract liabilities:

 

Description

 

Three months ended March 31, 2018

 

 

Advances from customers

Deferred transition revenue

Opening balance as of January 1, 2018

$               26,266

$                              101,785

Additions

 

                    11,248

                                     11,083

Revenue recognized

 

                   (2,944)

                                  (10,430)

Currency translation adjustments

 

                             —  

                                         (10)

Closing balance as of March 31, 2018

 

$              34,570

$                            102,428

 

 

 

 

 

 

 

 

39


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

19. Net revenues (continued)

 

The following table includes estimated revenue expected to be recognized in the future related to remaining performance obligations as of March 31, 2018:

 

Description

 

Total

 

Less than 1 year

 

1-3 years

 

3-5 years

 

After 5 years

Transaction price allocated to remaining performance obligations

$  102,428

 

$              47,714

 

$  47,818

 

$   6,676

 

$              220

 

The following table provides details of the Company’s contract assets:

 

Description

 

Three months ended March 31, 2018

 

Opening balance as of January 1, 2018

$                              43,366

Additions

 

                                  10,839

Reduction in revenue recognized

 

                                  (5,902)

Closing balance as of March 31, 2018

 

$                             48,303

 

The following table provides details of the Company’s contract cost assets:

 

Description

 

Three months ended March 31, 2018

 

 

Sales incentive programs

Transition activities

Opening balance as of January 1, 2018

$                 23,227

$                             139,284

Closing balance as of March 31, 2018

 

                     23,271

                                 139,164

Amortization during three months ended March 31, 2018

                        3,239

                                   11,579

 

20. Cost of revenue

 

Cost of revenue consists of the following:

 

 

 

Three months ended March 31,

 

 

 

2017

 

 

2018

 

Personnel expenses

 

$

269,189

 

 

$

310,132

 

Operational expenses

 

 

102,716

 

 

 

121,357

 

Depreciation and amortization

 

 

11,432

 

 

 

12,835

 

 

 

$

383,337

 

 

$

444,324

 

 

21. Selling, general and administrative expenses

 

Selling, general and administrative expenses consist of the following:

 

 

 

Three months ended March 31,

 

 

 

2017

 

 

2018

 

Personnel expenses

 

$

122,569

 

 

$

128,068

 

Operational expenses

 

 

35,813

 

 

 

40,389

 

Depreciation and amortization

 

 

2,476

 

 

 

2,652

 

 

 

$

160,858

 

 

$

171,109

 

 

40


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

22. Other operating (income) expense, net

 

 

 

Three months ended March 31,

 

 

 

2017

 

 

2018

 

Other operating (income) expense

 

$

(4,400

)

 

$

(235

)

Change in fair value of earn out consideration and deferred

consideration (relating to business acquisitions)

 

$

(3,138

)

 

$

17

 

Other operating (income) expense, net

 

$

(7,538

)

 

$

(218

)

 

 

23. Interest income (expense), net

 

 

 

Three months ended March 31,

 

 

 

2017

 

 

2018

 

Interest income

 

$

1,131

 

 

$

3,370

 

Interest expense

 

 

(6,624

)

 

 

(11,470

)

Interest income (expense), net

 

$

(5,493

)

 

$

(8,100

)

 

 

 

 

 

 

 

 

 

 

24. Income taxes

 

The Company determines its tax provision for interim periods using an estimate of its annual effective tax rate adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the Company updates its estimate of the annual effective tax rate, and if its estimated tax rate changes, the Company makes a cumulative adjustment.

 

The Company’s effective tax rate, or ETR, is 15.7% in the first quarter of 2018. The quarterly tax expense includes certain discrete items recorded in the first quarter amounting to $2,746, resulting in lower tax expense. The Company recognized tax benefits, including deductions for equity-based compensation expenses recorded upon vesting of equity awards (“excess tax benefits”) and employment-related tax deductions in India. The tax benefits were partly offset by the partial expiry of tax holidays in India and changes in jurisdictional mix of income. 

 

On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cut and Jobs Act (the “Tax Act”). The Tax Act makes broad and complex changes to the U.S. tax code. The Tax Act also establishes new tax laws that will affect 2018 and subsequent years, including a reduction in the U.S. federal corporate income tax rate from 35% to 21%.

 

On December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118 (“SAB 118”), which provides guidance on accounting for the tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740, Income Taxes. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Tax Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate in the financial statements. 

 

The Company’s estimate of transition tax on mandatory repatriation introduced under the Tax Act was provisional as of December 31, 2017 and remains provisional as of March 31, 2018 based on information available as of March 31, 2018. The Company has not recorded any tax liability for transition tax as of December 31, 2017 and March 31, 2018 pending the calculation of the earnings and profit pool of its controlled foreign corporations. The Company will recognize any changes to provisional amounts as it refines its estimates and interpretations of the application of the Tax Act. The Company expects to complete its analysis of the provisional items during the second half of 2018. The effects of other provisions of the Tax Act are not expected to have a material impact on the Company’s consolidated financial statements for the quarter ended March 31, 2018.

 

 

41


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

24. Income taxes (continued)

 

The Company reports its gain/loss on derivatives designated as cash flow hedges, actuarial gain/loss on retirement benefits and currency translation adjustment, net of taxes to the extent applicable, in accumulated other comprehensive income. The Company follows the specific identification approach for releasing stranded tax effects from accumulated other comprehensive income (loss) (“AOCI”) upon recognition of these AOCI items in the statement of income.

 

As of December 31, 2017, due to a reduction in the U.S. federal corporate income tax rate under the Tax Act, the Company revalued its net deferred tax assets, including deferred tax liabilities recorded through AOCI. Based on this revaluation, the Company recorded a tax gain of $2,265 relating to derivatives, reducing its net deferred tax liability balance, which was recorded as an income tax benefit in the continuing operations for the year ended December 31, 2017.

 

In the quarter ended March 31, 2018, the Company elected to early adopt ASU 2018-02, effective January 1, 2018, and made an election to reclassify the stranded income tax effects of the Tax Act from AOCI to retained earnings for all items of AOCI. The Company has elected to adopt the new guidance at the beginning of the period, and no prior periods have been adjusted. Accordingly, a stranded tax effect in AOCI of $2,265 resulting from the Tax Act has been adjusted through retained earnings.

 

As of December 31, 2017, the Company had unrecognized tax benefits amounting to $26,060, including an amount of $24,877, which, if recognized, would impact the effective tax rate.

 

The following table summarizes activities related to the Company’s unrecognized tax benefits for uncertain tax positions from January 1, 2018 to March 31, 2018: 

 

 

2018

 

Opening balance at January 1

 

$

26,060

 

Increase related to prior year tax positions, including

recorded in acquisition accounting

 

 

229

 

Decrease related to prior year tax positions

 

 

(8

)

Decrease related to prior year tax position due to lapse

of applicable statute of limitation

 

 

(384

)

Effect of exchange rate changes

 

 

(108)

 

Closing balance at March 31

 

$

25,789

 

 

The Company’s unrecognized tax benefits as of March 31, 2018 include an amount of $24,604, which, if recognized, would impact the effective tax rate. As of March 31, 2018 and December 31, 2017, the Company had accrued approximately $4,806 and $4,614, respectively, in interest relating to unrecognized tax benefits. During the year ended December 31, 2017 and the three months ended March 31, 2018, the company recognized approximately $(224) and $285, respectively, excluding the impact of exchange rate differences, in interest on unrecognized tax benefits. As of December 31, 2017 and March 31, 2018, the Company had accrued approximately $1,033 and $1,024, respectively, for penalties.

 

 

42


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

25. Related party transactions

 

The Company has entered into related party transactions with its non-consolidating affiliates. The Company has also entered into related party transactions with a significant shareholder and its affiliates.

 

The Company’s related party transactions can be categorized as follows:

 

Revenue from services

 

During the three months ended March 31, 2017 and 2018, the Company recognized net revenues of $83 and $304, respectively from a client that is a significant shareholder of the Company.

 

During the three months ended March 31, 2017, the Company recognized net revenues of $3,211 from a client that was a non-consolidating affiliate of the Company.

 

Cost of revenue from services

 

The Company purchases certain services from its non-consolidating affiliates, mainly relating to training and recruitment, which are included in cost of revenue. For the three months ended March 31, 2017 and 2018, cost of revenue includes an amount of $575 and $191, respectively, attributable to the cost of services provided by the Company’s non-consolidating affiliates.

 

Selling, general and administrative expenses

 

The Company purchases certain services from its non-consolidating affiliates, mainly relating to training and recruitment, the costs of which are included in selling, general and administrative expenses. For the three months ended March 31, 2017 and 2018, selling, general and administrative expenses include an amount of $94 and $49, respectively, attributable to the cost of services provided by the Company’s non-consolidating affiliates.

 

During the three months ended March 31, 2018, the Company engaged a significant shareholder to provide certain services to the Company amounting to $10, the costs of which are included in selling, general and administrative expenses.    

 

Investment in equity affiliates

 

During the three months ended March 31, 2017, the Company invested $467 in its non-consolidating affiliates.   

 

During the three months ended March 31, 2017, the Company recorded a charge of $2,821 related to an investment in one of its non-consolidating affiliates. This charge was included in equity-method investment activity, net in the Company’s consolidated statement of income.

 

As of December 31, 2017 and March 31, 2018, the Company’s investments in its non-consolidating affiliates amounted to $886 and $919, respectively.

 

Others

 

During the three months ended March 31, 2017, the Company also entered into transactions with one of its non-consolidating affiliates for certain cost reimbursements amounting to $238.  

43


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

25. Related party transactions (Continued)

During the three months ended March 31, 2017, the Company made payments of $1,307 to one of its non-consolidating affiliates under a tax-sharing arrangement in the U.K. This amount represents a portion of the non-consolidated affiliate’s net operating losses surrendered to the Company under the tax sharing arrangement for the years 2015 and 2016. On June 30, 2017, this non-consolidating affiliate ceased to be a related party.

 

26. Other Income (expense), net

 

 

Three months ended March 31,

 

 

2017

 

2018

 

Government incentives

$                         —  

 

$                  15,500

 

Other income/(expense)

                         553

 

                               50

 

Other income (expense), net

$                    553

 

$                 15,550

 

 

27. Commitments and contingencies

 

Capital commitments

 

As of December 31, 2017 and March 31, 2018, the Company has committed to spend $8,314 and $7,221, respectively, under agreements to purchase property, plant and equipment. This amount is net of capital advances paid in respect of these purchases.

 

Bank guarantees

 

The Company has outstanding bank guarantees amounting to $8,879 and $8,385 as of December 31, 2017 and March 31, 2018, respectively. Bank guarantees are generally provided to government agencies and excise and customs authorities for the purpose of maintaining a bonded warehouse. These guarantees may be revoked if the government agencies suffer any losses or damages through the breach of any of the covenants contained in the agreements governing such guarantees.

 

Other commitments

 

The Company’s business process delivery centers in India are 100% export oriented units or Software Technology Parks of India (“STPI”) units under the STPI guidelines issued by the Government of India. These units are exempt from customs, central excise duties and levies on imported and indigenous capital goods, stores and spares. The Company has undertaken to pay custom duties, service taxes, levies and liquidated damages payable, if any, in respect of imported and indigenous capital goods, stores and spares consumed duty-free, in the event that certain terms and conditions are not fulfilled.

 

28. Subsequent Events

 

Share Repurchase

 

Pursuant to its share repurchase program, the Company repurchased 505,520 of its common shares on the open market between April 1, 2018 and May 10, 2018 at a weighted average price of $31.31 per share for an aggregate cash amount of $15,827.

 

 

 

 

 

 

 

 

44


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

 29. Guarantor financial information

 

In March 2017, Genpact Luxembourg S.à r.l. (hereinafter referred to as the “Issuer”), a wholly-owned subsidiary of the Company, issued $350,000 aggregate principal amount of 3.70% senior notes in a private offering. See Note 12 for additional information. The issuance is fully and unconditionally guaranteed by the Company. In connection with the anticipated filing of a registration statement relating to an offer to exchange the original notes for registered notes, the Company has prepared the following condensed consolidating financial statements, which set forth consolidated financial information of the Issuer, the Company as parent guarantor and the non-guarantor subsidiaries of the Company, as well as elimination adjustments relating to intercompany transactions. The information in these financial statements has been prepared in accordance with the requirements of Rule 3-10 Regulation S-X, “Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered.” Investments in subsidiaries have been accounted for using the equity method.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

45


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

29. Guarantor financial information (Continued)

 

Condensed Consolidating Balance Sheet

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

As of March 31, 2018

 

 

 

Issuer/

Subsidiary

 

 

 

Parent/

Guarantor

 

 

 

Non-

Guarantor

Subsidiaries

 

 

Eliminations

 

 

Consolidated

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

8,562

 

 

$

11,206

 

 

$

404,458

 

 

$

 

 

$

424,226

 

Accounts receivable intercompany, net

 

 

76,871

 

 

 

 

 

 

 

 

 

(76,871

)

 

 

 

Accounts receivable, net

 

 

 

 

 

 

 

 

703,066

 

 

 

 

 

 

703,066

 

Intercompany loans

 

 

219,199

 

 

 

 

 

 

1,715,536

 

 

 

(1,934,735

)

 

 

 

Intercompany other receivable

 

 

8,675

 

 

 

79,296

 

 

 

103,293

 

 

 

(191,264

)

 

 

 

Prepaid expenses and other current assets

 

 

355

 

 

 

2,609

 

 

 

196,244

 

 

 

-

 

 

 

199,208

 

Total current assets

 

$

313,662

 

 

$

93,111

 

 

$

3,122,597

 

 

$

(2,202,870

)

 

$

1,326,500

 

Property, plant and equipment, net

 

 

352

 

 

 

 

 

 

204,683

 

 

 

 

 

 

205,035

 

Intercompany loans

 

 

 

 

 

 

 

 

500,000

 

 

 

(500,000

)

 

 

 

Deferred tax assets

 

 

 

 

 

 

 

 

81,734

 

 

 

 

 

 

81,734

 

Investment in subsidiaries

 

 

445,319

 

 

 

2,923,598

 

 

 

559,078

 

 

 

(3,927,995

)

 

 

 

Investment in equity affiliates

 

 

 

 

 

 

 

 

919

 

 

 

 

 

 

919

 

Investment in debentures, intercompany

 

 

704,549

 

 

 

 

 

 

 

 

 

(704,549

)

 

 

 

Intercompany other receivable

 

 

 

 

 

61,503

 

 

 

 

 

 

(61,503

)

 

 

 

Intangible assets, net

 

 

 

 

 

 

 

 

125,781

 

 

 

 

 

 

125,781

 

Goodwill

 

 

 

 

 

 

 

 

1,337,051

 

 

 

 

 

 

1,337,051

 

Contract cost assets

 

 

 

 

 

 

 

 

162,435

 

 

 

 

 

 

162,435

 

Other assets

 

 

 

 

 

 

 

 

157,672

 

 

 

 

 

 

157,672

 

Total assets

 

$

1,463,882

 

 

$

3,078,212

 

 

$

6,251,950

 

 

$

(7,396,917

)

 

$

3,397,127

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities and equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term borrowings

 

$

 

 

$

 

 

$

275,000

 

 

$

 

 

$

275,000

 

Intercompany loans

 

 

22,000

 

 

 

1,716,537

 

 

 

196,199

 

 

 

(1,934,736

)

 

 

 

      Current portion of long-term debt

 

 

 

 

 

 

 

 

39,237

 

 

 

 

 

 

39,237

 

Accounts payable

 

 

166

 

 

 

 

 

 

13,645

 

 

 

 

 

 

13,811

 

Intercompany accounts payable

 

 

 

 

 

 

 

 

76,871

 

 

 

(76,871

)

 

 

 

Income taxes payable

 

 

(972

)

 

 

(377

)

 

 

41,375

 

 

 

-

 

 

 

40,026

 

Intercompany other payable

 

 

31,433

 

 

 

75,492

 

 

 

84,339

 

 

 

(191,264

)

 

 

 

Accrued expenses and other current liabilities

 

 

3,011

 

 

 

2,655

 

 

 

497,450

 

 

 

-

 

 

 

503,116

 

Total current liabilities

 

$

55,638

 

 

$

1,794,307

 

 

$

1,224,116

 

 

$

(2,202,871

)

 

$

871,190

 

Long-term debt, less current portion

 

 

347,890

 

 

 

 

 

 

649,109

 

 

 

 

 

 

996,999

 

Deferred tax liabilities

 

 

 

 

 

 

 

 

7,083

 

 

 

 

 

 

7,083

 

Intercompany other payable

 

 

 

 

 

 

 

 

61,503

 

 

 

(61,503

)

 

 

 

Non-current intercompany loans payable

 

 

500,000

 

 

 

 

 

 

704,549

 

 

 

(1,204,549

)

 

 

 

Other liabilities

 

 

1,276

 

 

 

 

 

 

154,582

 

 

 

 

 

 

155,858

 

Total liabilities

 

$

904,804

 

 

$

1,794,307

 

 

$

2,800,942

 

 

$

(3,468,923

)

 

$

2,031,130

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Redeemable non-controlling interest

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shareholders' equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common stock

 

 

28

 

 

 

1,903

 

 

 

189,649

 

 

 

(189,677

)

 

 

1,903

 

Additional paid-in capital

 

 

575,863

 

 

 

1,424,048

 

 

 

1,108,053

 

 

 

(1,685,067

)

 

 

1,422,897

 

Retained earnings

 

 

37,439

 

 

 

238,673

 

 

 

2,501,881

 

 

 

(2,456,077

)

 

 

321,916

 

Accumulated other comprehensive income (loss)

 

 

(54,252

)

 

 

(380,719

)

 

 

(348,575

)

 

 

402,827

 

 

 

(380,719

)

Total equity

 

 

559,078

 

 

 

1,283,905

 

 

 

3,451,008

 

 

 

(3,927,994

)

 

 

1,365,997

 

Commitments and contingencies

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total liabilities, redeemable non-controlling interest and equity

 

$

1,463,882

 

 

$

3,078,212

 

 

$

6,251,950

 

 

$

(7,396,917

)

 

$

3,397,127

 

 

46


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

29. Guarantor financial information (Continued)

 

Condensed Consolidating Balance Sheet

 

 

 

As of March 31, 2017

 

 

 

Issuer/

Subsidiary

 

 

 

Parent/

Guarantor

 

 

 

Non-

Guarantor

Subsidiaries

 

 

Eliminations

 

 

Consolidated

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

5,839

 

 

$

5,494

 

 

$

376,853

 

 

$

 

 

$

388,186

 

Accounts receivable intercompany, net

 

 

47,230

 

 

 

 

 

 

 

 

 

(47,230

)

 

 

 

Accounts receivable, net

 

 

 

 

 

 

 

 

602,871

 

 

 

 

 

 

602,871

 

Intercompany loans

 

 

773,171

 

 

 

 

 

 

1,449,535

 

 

 

(2,222,706

)

 

 

 

Intercompany other receivable

 

 

12,208

 

 

 

86,632

 

 

 

66,828

 

 

 

(165,668

)

 

 

 

Prepaid expenses and other current assets

 

 

189

 

 

 

514

 

 

 

226,932

 

 

 

 

 

 

227,635

 

Total current assets

 

$

838,637

 

 

$

92,640

 

 

$

2,723,019

 

 

$

(2,435,604

)

 

$

1,218,692

 

Property, plant and equipment, net

 

 

508

 

 

 

 

 

 

212,054

 

 

 

 

 

 

212,562

 

Intercompany loans

 

 

 

 

 

 

 

 

500,000

 

 

 

(500,000

)

 

 

 

Deferred tax assets

 

 

 

 

 

 

 

 

61,029

 

 

 

 

 

 

61,029

 

Investment in subsidiaries

 

 

457,607

 

 

 

2,600,712

 

 

 

1,100,784

 

 

 

(4,159,103

)

 

 

 

Investment in equity affiliates

 

 

 

 

 

 

 

 

769

 

 

 

 

 

 

769

 

Investment in debentures, intercompany

 

 

707,910

 

 

 

 

 

 

 

 

 

(707,910

)

 

 

 

Intercompany other receivable

 

 

 

 

 

36,030

 

 

 

 

 

 

(36,030

)

 

 

 

Intangible assets, net

 

 

 

 

 

 

 

 

69,070

 

 

 

 

 

 

69,070

 

Goodwill

 

 

 

 

 

 

 

 

1,097,329

 

 

 

 

 

 

1,097,329

 

Other assets

 

 

 

 

 

 

 

 

252,279

 

 

 

 

 

 

252,279

 

Total assets

 

$

2,004,662

 

 

$

2,729,382

 

 

$

6,016,333

 

 

$

(7,838,647

)

 

$

2,911,730

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities and equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term borrowings

 

$

 

 

$

 

 

$

15,000

 

 

$

 

 

$

15,000

 

Intercompany loans

 

 

43,385

 

 

 

1,556,150

 

 

 

623,171

 

 

 

(2,222,706

)

 

 

 

       Current portion of long-term debt

 

 

 

 

 

 

 

 

39,192

 

 

 

 

 

 

39,192

 

Accounts payable

 

 

60

 

 

 

31

 

 

 

8,995

 

 

 

 

 

 

9,086

 

Intercompany accounts payable

 

 

 

 

 

 

 

 

47,230

 

 

 

(47,230

)

 

 

 

Income taxes payable

 

 

(210

)

 

 

 

 

 

33,301

 

 

 

 

 

 

33,091

 

Intercompany other payable

 

 

2,622

 

 

 

71,762

 

 

 

91,284

 

 

 

(165,668

)

 

 

 

Accrued expenses and other current liabilities

 

 

7,356

 

 

 

2,749

 

 

 

416,848

 

 

 

 

 

 

426,953

 

Total current liabilities

 

$

53,213

 

 

$

1,630,692

 

 

$

1,275,021

 

 

$

(2,435,604

)

 

$

523,322

 

Long-term debt, less current portion

 

 

347,432

 

 

 

 

 

 

688,346

 

 

 

 

 

 

1,035,778

 

Deferred tax liabilities

 

 

231

 

 

 

 

 

 

1,584

 

 

 

 

 

 

1,815

 

Intercompany other payable

 

 

 

 

 

 

 

 

36,030

 

 

 

(36,030

)

 

 

 

Non-current intercompany loans payable

 

 

500,000

 

 

 

 

 

 

707,910

 

 

 

(1,207,910

)

 

 

 

Other liabilities

 

 

3,002

 

 

 

292

 

 

 

162,267

 

 

 

 

 

 

165,561

 

Total liabilities

 

$

903,878

 

 

$

1,630,984

 

 

$

2,871,158

 

 

$

(3,679,544

)

 

$

1,726,476

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Redeemable non-controlling interest

 

 

 

 

 

 

 

 

3,610

 

 

 

 

 

 

3,610

 

Shareholders' equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common stock

 

 

28

 

 

 

1,924

 

 

 

189,649

 

 

 

(189,677

)

 

 

1,924

 

Additional paid-in capital

 

 

1,211,108

 

 

 

1,347,262

 

 

 

1,109,207

 

 

 

(2,320,312

)

 

 

1,347,265

 

Retained earnings

 

 

(53,239

)

 

 

136,533

 

 

 

2,201,248

 

 

 

(2,064,766

)

 

 

219,776

 

Accumulated other comprehensive income (loss)

 

 

(57,113

)

 

 

(387,321

)

 

 

(358,539

)

 

 

415,652

 

 

 

(387,321

)

Total equity

 

 

1,100,784

 

 

 

1,098,398

 

 

 

3,141,565

 

 

 

(4,159,103

)

 

 

1,181,644

 

Commitments and contingencies

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total liabilities, redeemable non-controlling interest and equity

 

$

2,004,662

 

 

$

2,729,382

 

 

$

6,016,333

 

 

$

(7,838,647

)

 

$

2,911,730

 

47


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

29. Guarantor financial information (Continued)

 

Condensed Consolidating Statement of Income (Loss)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended March 31, 2018

 

 

 

Issuer/

Subsidiary

 

 

 

Parent/

Guarantor

 

 

 

Non-

Guarantor

Subsidiaries

 

 

Eliminations

 

 

Consolidated

 

Net revenues

 

$

11,939

 

 

$

 

 

$

686,449

 

 

$

(9,476

)

 

$

688,912

 

Cost of revenue

 

 

 

 

 

 

 

 

444,324

 

 

 

 

 

 

444,324

 

Gross profit

 

$

11,939

 

 

$

 

 

$

242,125

 

 

$

(9,476

)

 

$

244,588

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative expenses

 

 

1,623

 

 

 

1,492

 

 

 

177,536

 

 

 

(9,542

)

 

 

171,109

 

Amortization of acquired intangible assets

 

 

 

 

 

 

 

 

9,936

 

 

 

 

 

 

9,936

 

Other operating (income) expense, net

 

 

17

 

 

 

 

 

 

(235

)

 

 

 

 

 

(218

)

Income (loss) from operations

 

$

10,299

 

 

$

(1,492

)

 

$

54,888

 

 

$

66

 

 

$

63,761

 

Foreign exchange gains (losses), net

 

 

953

 

 

 

221

 

 

 

3,624

 

 

 

 

 

 

4,798

 

Interest income (expense), net

 

 

(3,489

)

 

 

 

 

 

(4,611

)

 

 

 

 

 

(8,100

)

Intercompany interest income (expense), net

 

 

20,543

 

 

 

(3,235

)

 

 

(17,308

)

 

 

 

 

 

 

Other income (expense), net

 

 

 

 

 

 

 

 

15,550

 

 

 

 

 

 

15,550

 

Income (loss) before equity-method investment activity, net and income tax expense

 

$

28,306

 

 

$

(4,506

)

 

$

52,143

 

 

$

66

 

 

$

76,009

 

Gain (loss) on equity-method investment activity, net

 

 

7,443

 

 

 

69,201

 

 

 

34,058

 

 

 

(110,702

)

 

 

 

Income before income tax expense

 

$

35,749

 

 

$

64,695

 

 

$

86,201

 

 

$

(110,636

)

 

$

76,009

 

Income tax expense

 

 

1,691

 

 

 

 

 

 

10,384

 

 

 

 

 

 

12,075

 

Net income

 

$

34,058

 

 

$

64,695

 

 

$

75,817

 

 

$

(110,636

)

 

$

63,934

 

Net loss attributable to redeemable non-controlling interest

 

 

 

 

 

 

 

 

(761

)

 

 

 

 

 

(761

)

Net income attributable to Genpact Limited shareholders

 

$

34,058

 

 

$

64,695

 

 

$

76,578

 

 

$

(110,636

)

 

$

64,695

 

 

 

 

 

48


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

29. Guarantor financial information (Continued)

 

Condensed Consolidating Statement of Income (Loss)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended March 31,  2017

 

 

 

Issuer/

Subsidiary

 

 

 

Parent/

Guarantor

 

 

 

Non-

Guarantor

Subsidiaries

 

 

Eliminations

 

 

Consolidated

 

Net revenues

 

$

7,562

 

 

$

 

 

$

622,995

 

 

$

(7,562

)

 

$

622,995

 

Cost of revenue

 

 

 

 

 

 

 

 

383,337

 

 

 

 

 

 

383,337

 

Gross profit

 

$

7,562

 

 

$

 

 

$

239,658

 

 

$

(7,562

)

 

$

239,658

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative expenses

 

 

1,141

 

 

 

3,789

 

 

 

163,494

 

 

 

(7,566

)

 

 

160,858

 

Amortization of acquired intangible assets

 

 

 

 

 

 

 

 

7,242

 

 

 

 

 

 

7,242

 

Other operating (income) expense, net

 

 

(3,138

)

 

 

 

 

 

(4,400

)

 

 

 

 

 

(7,538

)

Income (loss) from operations

 

$

9,559

 

 

$

(3,789

)

 

$

73,322

 

 

$

4

 

 

$

79,096

 

Foreign exchange gains (losses), net

 

 

1,616

 

 

 

(5

)

 

 

(6,524

)

 

 

 

 

 

(4,913

)

Interest income (expense), net

 

 

17,937

 

 

 

 

 

 

(23,430

)

 

 

 

 

 

(5,493

)

Intercompany interest income (expense), net

 

 

2,246

 

 

 

(2,296

)

 

 

50

 

 

 

 

 

 

-

 

Other income (expense), net

 

 

 

 

 

 

 

 

553

 

 

 

 

 

 

553

 

Income (loss) before equity-method investment activity, net and income tax expense

 

$

31,358

 

 

$

(6,090

)

 

$

43,971

 

 

$

4

 

 

$

69,243

 

Gain (loss) on equity-method investment activity, net

 

 

1,979

 

 

 

59,428

 

 

 

31,854

 

 

 

(97,819

)

 

 

(4,558

)

Income before income tax expense

 

$

33,337

 

 

$

53,338

 

 

$

75,825

 

 

$

(97,815

)

 

$

64,685

 

Income tax expense

 

 

1,483

 

 

 

-

 

 

 

10,762

 

 

 

 

 

 

12,245

 

Net income

 

$

31,854

 

 

$

53,338

 

 

$

65,063

 

 

$

(97,815

)

 

$

52,440

 

Net loss attributable to redeemable non-controlling interest

 

 

 

 

 

 

 

 

(898

)

 

 

 

 

 

(898

)

Net income attributable to Genpact Limited shareholders

 

$

31,854

 

 

$

53,338

 

 

$

65,961

 

 

$

(97,815

)

 

$

53,338

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

49


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

29. Guarantor financial information (Continued)

 

Condensed Consolidating Statement of Comprehensive Income (Loss)

 

 

  

Three months ended March 31,  2018

 

 

Issuer/ Subsidiary

 

 

Parent/ Guarantor

 

 

Non-Guarantor Subsidiaries

 

 

Eliminations

 

 

Genpact

Limited

Shareholders

 

 

Redeemable Non-controlling interest

 

Net income (loss)

$

34,058

 

 

$

64,695

 

 

$

76,578

 

 

$

(110,636

)

 

$

64,695

 

 

$

(761

)

Other comprehensive income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Currency translation adjustments

 

(6,353

)

 

 

(9,335

)

 

 

(9,335

)

 

 

15,688

 

 

 

(9,335

)

 

 

(424

)

Net income (loss) on cash flow hedging derivatives, net of taxes (Note 7)

 

(15,681

)

 

 

(18,932

)

 

 

(18,932

)

 

 

34,613

 

 

 

(18,932

)

 

 

 

Retirement benefits, net of taxes

 

80

 

 

 

513

 

 

 

513

 

 

 

(593

)

 

 

513

 

 

 

 

Other comprehensive income (loss)

$

(21,954

)

 

$

(27,754

)

 

$

(27,754

)

 

$

49,708

 

 

$

(27,754

)

 

$

(424

)

Comprehensive income (loss)

$

12,104

 

 

$

36,941

 

 

$

48,824

 

 

$

(60,928

)

 

$

36,941

 

 

$

(1,185

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended March 31,  2017

 

 

Issuer/ Subsidiary

 

 

Parent/ Guarantor

 

 

Non-Guarantor Subsidiaries

 

 

Eliminations

 

 

Genpact

Limited

Shareholders

 

 

Redeemable Non-controlling interest

 

Net income (loss)

$

31,854

 

 

$

53,338

 

 

$

65,961

 

 

$

(97,815

)

 

$

53,338

 

 

$

(898

)

Other comprehensive income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Currency translation adjustments

 

43,546

 

 

 

51,627

 

 

 

51,627

 

 

 

(95,173

)

 

 

51,627

 

 

 

(12

)

Net income (loss) on cash flow hedging derivatives, net of taxes (Note 7)

 

20,407

 

 

 

18,858

 

 

 

18,858

 

 

 

(39,265

)

 

 

18,858

 

 

 

 

Retirement benefits, net of taxes

 

70

 

 

 

119

 

 

 

119

 

 

 

(189

)

 

 

119

 

 

 

 

Other comprehensive income (loss)

$

64,023

 

 

$

70,604

 

 

$

70,604

 

 

$

(134,627

)

 

$

70,604

 

 

$

(12

)

Comprehensive income (loss)

$

95,877

 

 

$

123,942

 

 

$

136,565

 

 

$

(232,442

)

 

$

123,942

 

 

$

(910

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

50


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

29. Guarantor financial information (Continued)

 

Condensed Consolidating Statement of Cash Flows

 

 

Three months ended March 31,  2018

 

 

 

Issuer/

Subsidiary

 

 

 

Parent/

Guarantor

 

 

 

Non-

Guarantor

Subsidiaries

 

 

Eliminations

 

 

Consolidated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating activities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net cash (used for) provided by operating activities

 

$

22,190

 

 

$

9,604

 

 

$

(162,656

)

 

$

103,540

 

 

$

(27,322

)

Investing activities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Purchase of property, plant and equipment

 

 

 

 

 

 

 

 

(18,706

)

 

 

 

 

 

(18,706

)

Payment for internally generated intangible assets

 

 

 

 

 

 

 

 

(4,365

)

 

 

 

 

 

(4,365

)

Proceeds from sale of property, plant and equipment

 

 

 

 

 

 

 

 

144

 

 

 

 

 

 

144

 

Investment in subsidiaries

 

 

(2,000

)

 

 

 

 

 

2,066

 

 

 

(66

)

 

 

 

Payment for business acquisitions, net of cash acquired

 

 

 

 

 

 

 

 

(4,730

)

 

 

-

 

 

 

(4,730

)

Net cash (used for) provided by investing activities

 

$

(2,000

)

 

$

 

 

$

(25,591

)

 

$

(66

)

 

$

(27,657

)

Financing activities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Repayment of capital lease obligations

 

 

 

 

 

 

 

 

(537

)

 

 

 

 

 

(537

)

Proceeds from long-term debt

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Repayment of long-term debt

 

 

 

 

 

 

 

 

(10,000

)

 

 

 

 

 

(10,000

)

Proceeds from short-term borrowings

 

 

130

 

 

 

 

 

 

105,000

 

 

 

(130

)

 

 

105,000

 

Proceeds from intercompany loans

 

 

 

 

 

119,000

 

 

 

344

 

 

 

(119,344

)

 

 

 

Repayment of intercompany loans

 

 

(16,000

)

 

 

 

 

 

 

 

 

16,000

 

 

 

 

Proceeds from issuance of common shares under stock-based compensation plans

 

 

 

 

 

4,202

 

 

 

 

 

 

 

 

 

4,202

 

Payment for net settlement of stock-based awards

 

 

 

 

 

(13,284

)

 

 

 

 

 

 

 

 

(13,284

)

Payment of earn-out/deferred consideration

 

 

 

 

 

 

 

 

(1,476

)

 

 

 

 

 

(1,476

)

Dividend paid

 

 

 

 

 

(14,408

)

 

 

 

 

 

 

 

 

(14,408

)

Payment for stock purchased and retired

 

 

 

 

 

(95,984

)

 

 

 

 

 

 

 

 

(95,984

)

Payment for expenses related to stock purchase

 

 

 

 

 

(60

)

 

 

 

 

 

 

 

 

(60

)

Net cash (used for) provided by financing activities

 

$

(15,870

)

 

$

(534

)

 

$

93,331

 

 

$

(103,474

)

 

$

(26,547

)

Effect of exchange rate changes

 

 

(265

)

 

 

 

 

 

1,549

 

 

 

 

 

 

1,284

 

Net increase (decrease) in cash and cash equivalents

 

 

4,320

 

 

 

9,070

 

 

 

(94,916

)

 

 

 

 

 

(81,526

)

Cash and cash equivalents at the beginning of the period

 

 

4,507

 

 

 

2,136

 

 

 

497,825

 

 

 

 

 

 

504,468

 

Cash and cash equivalents at the end of the period

 

$

8,562

 

 

$

11,206

 

 

$

404,458

 

 

$

 

 

$

424,226

 

 

 

 

 

 

51


GENPACT LIMITED AND ITS SUBSIDIARIES

Notes to the Consolidated Financial Statements

(In thousands, except per share data and share count)

 

29. Guarantor financial information (Continued)

 

Condensed Consolidating Statement of Cash Flows

 

 

 

Three months ended March 31,  2017

 

 

 

Issuer/

Subsidiary

 

 

 

Parent/

Guarantor

 

 

 

Non-

Guarantor

Subsidiaries

 

 

Eliminations

 

 

Consolidated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating activities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net cash (used for) provided by operating activities

 

$

(314,439

)

 

$

9,080

 

 

$

(222,607

)

 

$

558,994

 

 

$

31,028

 

Investing activities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Purchase of property, plant and equipment

 

 

 

 

 

 

 

 

(17,084

)

 

 

 

 

 

(17,084

)

Payment for internally generated intangible assets

 

 

 

 

 

 

 

 

(2,614

)

 

 

 

 

 

(2,614

)

Proceeds from sale of property, plant and equipment

 

 

 

 

 

 

 

 

389

 

 

 

 

 

 

389

 

Investment in equity affiliates

 

 

(9,841

)

 

 

 

 

 

9,374

 

 

 

 

 

 

(467

)

Investment in subsidiaries

 

 

 

 

 

 

 

 

4

 

 

 

(4

)

 

 

 

Payment for business acquisitions, net of cash acquired

 

 

 

 

 

 

 

 

(9,237

)

 

 

 

 

 

(9,237

)

Net cash (used for) provided by investing activities

 

$

(9,841

)

 

$

 

 

$

(19,168

)

 

$

(4

)

 

$

(29,013

)

Financing activities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Repayment of capital lease obligations

 

 

 

 

 

 

 

 

(494

)

 

 

 

 

 

(494

)

Payment of debt issuance costs

 

 

(1,481

)

 

 

 

 

 

 

 

 

 

 

 

(1,481

)

Proceeds from long- term debt

 

 

350,000

 

 

 

 

 

 

 

 

 

 

 

 

350,000

 

Repayment of long-term debt

 

 

 

 

 

 

 

 

(10,000

)

 

 

 

 

 

(10,000

)

Proceeds from short-term borrowings

 

 

 

 

 

 

 

 

40,000

 

 

 

 

 

 

40,000

 

Repayment of short-term borrowings

 

 

 

 

 

 

 

 

(185,000

)

 

 

 

 

 

(185,000

)

Proceeds from intercompany loan

 

 

 

 

 

222,500

 

 

 

366,105

 

 

 

(588,605

)

 

 

 

Repayment of intercompany loans

 

 

(29,615

)

 

 

 

 

 

 

 

 

29,615

 

 

 

 

Proceeds from issuance of common shares under stock-based compensation plans

 

 

 

 

 

7,761

 

 

 

 

 

 

 

 

 

7,761

 

Payment for net settlement of stock-based awards

 

 

 

 

 

(9,939

)

 

 

 

 

 

 

 

 

(9,939

)

Payment of earn-out/deferred consideration

 

 

 

 

 

 

 

 

(1,097

)

 

 

 

 

 

(1,097

)

Dividend paid

 

 

 

 

 

(11,957

)

 

 

 

 

 

 

 

 

(11,957

)

Payment for stock purchased and retired

 

 

 

 

 

(219,784

)

 

 

 

 

 

 

 

 

(219,784

)

Payment for expenses related to stock purchase

 

 

 

 

 

(16

)

 

 

 

 

 

 

 

 

(16

)

Net cash (used for)provided by financing activities

 

$

318,904

 

 

$

(11,435

)

 

$

209,514

 

 

$

(558,990

)

 

$

(42,007

)

Effect of exchange rate changes

 

 

 

 

 

 

 

 

5,555

 

 

 

 

 

 

5,555

 

Net increase (decrease) in cash and cash equivalents

 

 

(5,376

)

 

 

(2,355

)

 

 

(32,261

)

 

 

 

 

 

(39,992

)

Cash and cash equivalents at the beginning of the period

 

 

11,215

 

 

 

7,849

 

 

 

403,559

 

 

 

 

 

 

422,623

 

Cash and cash equivalents at the end of the period

 

$

5,839

 

 

$

5,494

 

 

$

376,853

 

 

$

 

 

$

388,186

 

 

 

 

52